phenytoin has been researched along with Absence Status in 381 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The ESETT was a prospective, double-blinded, adaptive trial evaluating levetiracetam, valproate, and fosphenytoin as second-line agents in benzodiazepine-refractory status epilepticus in adults and children." | 9.51 | Treatment of Toxin-Related Status Epilepticus With Levetiracetam, Fosphenytoin, or Valproate in Patients Enrolled in the Established Status Epilepticus Treatment Trial. ( Chamberlain, JM; Coralic, Z; Kapur, J; Olson, KR; Overbeek, D; Silbergleit, R, 2022) |
| "The efficacy and safety of levetiracetam are superior to that of phenytoin in children with status epilepticus." | 9.41 | Comparison of Safety and Effectiveness between Levetiracetam and Phenytoin in the Treatment of Pediatric Status Epilepticus: A Meta- Analysis. ( AlMuhanna, FA; AlMuhanna, MA; AlMulihi, QA; AlSultan, EA, 2023) |
| "Fosphenytoin (FOS) and its active form, phenytoin (PHT), levetiracetam (LEV), and valproic acid (VPA) are commonly used second-line treatments of status epilepticus." | 9.41 | Early Exposure of Fosphenytoin, Levetiracetam, and Valproic Acid After High-Dose Intravenous Administration in Young Children With Benzodiazepine-Refractory Status Epilepticus. ( Babcock, L; Brundage, RC; Chamberlain, JM; Cloyd, JC; Cock, HR; Coles, LD; Elm, JJ; Fountain, NB; Ivaturi, V; Kapur, J; Lowenstein, DH; Mishra, U; Sathe, AG; Shinnar, S; Silbergleit, R, 2021) |
| "To determine whether levetiracetam is an alternative to fosphenytoin to control Benzodiazepine Refractory Status Epilepticus (BRSE) in pediatric population and also to compare the acute drug related side-effects and ventilation requirement among the both arms of anti-epileptic drug therapy." | 9.34 | Clinical Effectiveness of Levetiracetam Compared to Fosphenytoin in the Treatment of Benzodiazepine Refractory Convulsive Status Epilepticus. ( Kandasamy, S; Krishnamoorthi, N; Nalisetty, S; Sangaralingam, T; Sridharan, B; Vijayakumar, V, 2020) |
| "To compare the efficacy of phenytoin, valproate, and levetiracetam in the management of pediatric convulsive status epilepticus." | 9.34 | Comparison of Phenytoin, Valproate and Levetiracetam in Pediatric Convulsive Status Epilepticus: A Randomized Double-blind Controlled Clinical Trial. ( Mahadevan, S; Rameshkumar, R; Vignesh, V, 2020) |
| "Children, adults, and older adults with established status epilepticus respond similarly to levetiracetam, fosphenytoin, and valproate, with treatment success in approximately half of patients." | 9.34 | Efficacy of levetiracetam, fosphenytoin, and valproate for established status epilepticus by age group (ESETT): a double-blind, responsive-adaptive, randomised controlled trial. ( Babcock, L; Barsan, W; Bleck, TP; Chamberlain, JM; Cloyd, J; Cock, H; Connor, JT; Conwit, R; Elm, J; Fountain, NB; Holsti, M; Kapur, J; Lowenstein, D; Meinzer, C; Rogers, A; Shinnar, S; Silbergleit, R; Underwood, E, 2020) |
| "The Established Status Epilepticus Treatment Trial was a blinded, comparative-effectiveness study of fosphenytoin, levetiracetam, and valproic acid in benzodiazepine-refractory status epilepticus." | 9.34 | The association of patient weight and dose of fosphenytoin, levetiracetam, and valproic acid with treatment success in status epilepticus. ( Bleck, TP; Chamberlain, JM; Cloyd, JC; Cock, HR; Coles, LD; Conwit, RA; Elm, JJ; Fountain, NB; Kapur, J; Lowenstein, DH; Sathe, AG; Shinnar, S; Silbergleit, R, 2020) |
| "To determine whether phenytoin or levetiracetam (Keppra, UCB Pharma, Brussels, Belgium) is the more clinically effective intravenous second-line treatment of paediatric convulsive status epilepticus and to help better inform its management." | 9.34 | Levetiracetam as an alternative to phenytoin for second-line emergency treatment of children with convulsive status epilepticus: the EcLiPSE RCT. ( Al Najjar, N; Appleton, RE; Evans, V; Gamble, C; Hickey, H; Humphreys, A; Iyer, A; Lee, E; Lyttle, MD; Messahel, S; Noblet, J; Potter, S; Rainford, NE; Roper, L; Tate, P; Woolfall, K, 2020) |
| "Phenytoin is the current standard of care for second-line treatment of paediatric convulsive status epilepticus after failure of first-line benzodiazepines, but is only effective in 60% of cases and is associated with considerable adverse effects." | 9.30 | Levetiracetam versus phenytoin for second-line treatment of convulsive status epilepticus in children (ConSEPT): an open-label, multicentre, randomised controlled trial. ( Babl, FE; Bonisch, M; Borland, ML; Brabyn, C; Cheng, N; Craig, S; Dalziel, SR; Davidson, A; Donath, S; Francis, KL; Furyk, J; George, S; Harvey, AS; Kochar, A; Neutze, J; Oakley, E; Phillips, N; Rao, A; Sharpe, C; Zhang, M, 2019) |
| "Phenytoin is the recommended second-line intravenous anticonvulsant for treatment of paediatric convulsive status epilepticus in the UK; however, some evidence suggests that levetiracetam could be an effective and safer alternative." | 9.30 | Levetiracetam versus phenytoin for second-line treatment of paediatric convulsive status epilepticus (EcLiPSE): a multicentre, open-label, randomised trial. ( Appleton, RE; Evans, V; Gamble, C; Hickey, H; Humphreys, A; Iyer, A; Lee, ED; Lyttle, MD; Messahel, S; Noblet, J; Potter, S; Rainford, NEA; Roper, L; Tate, P; Woolfall, K, 2019) |
| "IV Levetiracetam controls status epilepticus or cluster seizures with an efficacy comparable to that of phenytoin." | 9.24 | Intravenous levetiracetam vs phenytoin for status epilepticus and cluster seizures: A prospective, randomized study. ( Al-Amrani, K; Al-Asmi, A; Al-Hashim, A; Ganguly, SS; Gujjar, AR; Jacob, PC; Nandhagopal, R, 2017) |
| "The purpose of this study was to compare safety and efficacy of intravenous (IV) levetiracetam (LEV) with IV phenytoin (PHT) in management of status epilepticus (SE)." | 9.20 | Levetiracetam versus phenytoin in management of status epilepticus. ( Bhalla, A; Chakravarthi, S; Goyal, MK; Modi, M; Singh, P, 2015) |
| "To determine whether intravenous lorazepam is as efficacious as diazepam-phenytoin combination in the treatment of convulsive status epilepticus in children." | 9.14 | Lorazepam versus diazepam-phenytoin combination in the treatment of convulsive status epilepticus in children: a randomized controlled trial. ( Gupta, P; Krishnamurthy, S; Sharma, KK; Sreenath, TG, 2010) |
| "To evaluate the efficacy and tolerability of the treatment with valproic acid (VPA) in patients with status epilepticus (SE) or acute repetitive seizures (ARS) comparing it with phenytoin (PHT) treatment." | 9.13 | Treatment of status epilepticus and acute repetitive seizures with i.v. valproic acid vs phenytoin. ( Dabby, R; Gilad, R; Izkovitz, N; Lampl, Y; Rapoport, A; Sadeh, M; Weller, B, 2008) |
| "To synthesize the available evidence examining the efficacy and safety of levetiracetam compared with phenytoin or fosphenytoin in benzodiazepine-refractory pediatric status epilepticus." | 9.12 | Levetiracetam Versus Phenytoin or Fosphenytoin for Second-Line Treatment of Pediatric Status Epilepticus: A Meta-Analysis. ( Catenacci, V; Choong, K; Duffett, M; Hewitt, M; Jones, K; Klowak, JA; Rochwerg, B, 2021) |
| "To systematically evaluate the efficacy and safety of levetiracetam (LEV) versus phenytoin (PHT) as second-line drugs for the treatment of convulsive status epilepticus (CSE) in children." | 9.12 | [Efficacy and safety of levetiracetam versus phenytoin as second-line drugs for the treatment of children with convulsive status epilepticus: a Meta analysis]. ( Shi, R; Wang, ZZ; Yin, HQ, 2021) |
| "To compare the evidence on efficacy, safety, tolerability, and impact on short term/long functional outcome of lacosamide (LCM) and phenytoin (PHT) in patients with status epilepticus." | 9.12 | Efficacy of lacosamide and phenytoin in status epilepticus: A systematic review. ( Dawman, L; Panda, P; Panda, PK; Sharawat, IK, 2021) |
| "To evaluate the efficacy and safety of levetiracetam (LEV) in comparison to phenytoin (PHT) as second line antiseizure medication (ASM) for Pediatric convulsive status epilepticus (SE)." | 9.12 | Efficacy and Safety of Levetiracetam vs. Phenytoin as Second Line Antiseizure Medication for Pediatric Convulsive Status Epilepticus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. ( Angurana, SK; Suthar, R, 2021) |
| "Sixty-eight patients with convulsive status epilepticus (SE) were randomly assigned to two groups to study the efficacy of sodium valproate (VPA) and phenytoin (PHT)." | 9.12 | Sodium valproate vs phenytoin in status epilepticus: a pilot study. ( Kalita, J; Misra, UK; Patel, R, 2006) |
| "The efficacy of a combination of midazolam and phenytoin in treating generalized convulsive status epilepticus in children was studied retrospectively." | 9.11 | Status epilepticus: clinical analysis of a treatment protocol based on midazolam and phenytoin. ( Arts, WF; Brevoord, JC; de Hoog, M; Joosten, KF; van Rooij, RW, 2005) |
| "We compared propofol with high-dose barbiturates in the treatment of refractory status epilepticus (RSE) and propose a protocol for the administration of propofol in RSE in adults, correlating propofol's effect with plasma levels." | 9.08 | Treatment of refractory status epilepticus with propofol: clinical and pharmacokinetic findings. ( Dulaney, E; Kramer, TH; O'Meeghan, R; Raps, EC; Skaar, DJ; Stecker, MM, 1998) |
| "In a randomized, nonblinded clinical trial, 36 consecutive patients with generalized convulsive status epilepticus were treated with either combination diazepam and phenytoin (DZ/DPH) or phenobarbital (PB)." | 9.06 | Treatment of status epilepticus: a prospective comparison of diazepam and phenytoin versus phenobarbital and optional phenytoin. ( Gabor, AJ; Herring, MO; McCurdy, SA; Shaner, DM, 1988) |
| "To compare the efficacy and safety of levetiracetam and phenytoin for the treatment of established status epilepticus." | 9.05 | Levetiracetam versus phenytoin for the treatment of established status epilepticus: A systematic review and meta-analysis of randomized controlled trials. ( Chong, W; Fang, F; Fang, Y; Faramand, A; Jia, D; Jia, L; Li, L; Ma, L; Zhang, Y, 2020) |
| "The objective of the study was to perform a systematic review and meta-analysis to evaluate the efficacy and safety of levetiracetam (LEV) or phenytoin (PHT) as second-line treatment for status epilepticus (SE)." | 9.05 | Levetiracetam vs. phenytoin as 2nd-line treatment for status epilepticus: A systematic review and meta-analysis. ( DeMott, JM; Gottlieb, M; Peksa, GD; Slocum, GW, 2020) |
| "Recent studies have shown conflicting results regarding the effectiveness of levetiracetam for treating benzodiazepine-refractory status epilepticus (SE) compared with phenytoin." | 9.05 | Levetiracetam versus Phenytoin for the Pharmacotherapy of Benzodiazepine-Refractory Status Epilepticus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. ( Chen, Z; Shen, X; Wang, Z; Wei, L; Xue, T, 2020) |
| "Since the 1970s, intravenous (IV) phenytoin (PHT) has traditionally been used as second-stage treatment for convulsive status epilepticus (SE) after failure of benzodiazepines." | 8.98 | A critical appraisal of randomized controlled trials on intravenous phenytoin in convulsive status epilepticus. ( Bragazzi, NL; Brigo, F; Lattanzi, S; Nardone, R; Trinka, E, 2018) |
| "Over last fifty years, intravenous (iv) phenytoin (PHT) loading dose has been the treatment of choice for patients with benzodiazepine-resistant convulsive status epilepticus and several guidelines recommended this treatment regimen with simultaneous iv diazepam." | 8.98 | Why we prefer levetiracetam over phenytoin for treatment of status epilepticus. ( Amantini, A; Campostrini, R; Giannasi, G; Giorgi, FS; Giovannelli, F; Nazerian, P; Paganini, M; Zaccara, G, 2018) |
| "The aim of this study was to conduct a meta-analysis of published studies to directly compare intravenous (IV) levetiracetam (LEV) with IV phenytoin (PHT) or IV valproate (VPA) as second-line treatment of status epilepticus (SE), to indirectly compare intravenous IV LEV with IV VPA using common reference-based indirect comparison meta-analysis, and to verify whether results of indirect comparisons are consistent with results of head-to-head randomized controlled trials (RCTs) directly comparing IV LEV with IV VPA." | 8.93 | Direct and indirect comparison meta-analysis of levetiracetam versus phenytoin or valproate for convulsive status epilepticus. ( Bragazzi, N; Brigo, F; Nardone, R; Trinka, E, 2016) |
| "Our goal was to perform a systematic review of the literature on the use of intravenous lidocaine in pediatrics for status epilepticus (SE) and refractory status epilepticus (RSE) to determine its impact on seizure control." | 8.91 | Lidocaine for Status Epilepticus in Pediatrics. ( Gillman, LM; Kazina, CJ; Teitelbaum, J; West, M; Zeiler, FA; Zeiler, KJ, 2015) |
| "To evaluate the efficacy and tolerability of intravenous fosphenytoin in children with status epilepticus, and resulting serum total phenytoin levels." | 7.96 | Efficacy, Tolerability and Serum Phenytoin Levels after Intravenous Fosphenytoin Loading Dose in Children with Status Epilepticus. ( Bhartiya, S; Gavli, V; Patil, R; Rajadhyaksha, S; Srivastava, K, 2020) |
| "For status epilepticus, the choice of antiepileptic drugs for second-line treatment after benzodiazepine remains controversial: phenytoin or fosphenytoin are recommended, however, it has been unknown which is better." | 7.96 | Phenytoin versus fosphenytoin for second-line treatment of status epilepticus: propensity score matching analysis using a nationwide inpatient database. ( Fushimi, K; Matsui, H; Nakamura, K; Nakano, H; Naraba, H; Ohbe, H; Takahashi, Y; Yasunaga, H, 2020) |
| " Levetiracetam is a relatively newer AED with favorable pharmacokinetics and could be an effective and safer option for the treatment of convulsive status epilepticus (CSE)." | 7.96 | Efficacy and safety profile of intravenous levetiracetam versus phenytoin in convulsive status epilepticus and acute repetitive seizures in children. ( Besli, GE; Yilmaz, S; Yuksel Karatoprak, E, 2020) |
| "Fosphenytoin (fPHT) and continuous intravenous midazolam (cMDL) had commonly been used as second-line treatments for pediatric status epilepticus (SE) in Japan." | 7.88 | Fosphenytoin vs. continuous midazolam for pediatric febrile status epilepticus. ( Fujita, K; Iijima, K; Ishida, Y; Kurosawa, H; Maruyama, A; Morioka, I; Nagase, H; Nishiyama, M; Nozu, K; Takada, S; Tanaka, T; Taniguchi-Ikeda, M; Tomioka, K; Toyoshima, D; Uetani, Y; Yamaguchi, H, 2018) |
| "Purple glove syndrome is a rare and poorly understood complication of phenytoin use, occurring almost always with its intravenous formulation." | 7.81 | Purple glove syndrome occurring after oral administration of phenytoin in therapeutic doses: mechanism still a dilemma. ( Handa, R; Jain, RS; Kumar, S; Nagpal, K; Prakash, S, 2015) |
| "To compare intravenous phenytoin (PHT) and intravenous lacosamide (LCM) for treatment of status epilepticus after failure of the first and second drug." | 7.80 | Intravenous lacosamide or phenytoin for treatment of refractory status epilepticus. ( Berning, S; Kellinghaus, C; Stögbauer, F, 2014) |
| " Approximately 30-40% of brain tumors patients who present with status epilepticus (SE) will not respond to typical therapy consisting of benzodiazepines and phenytoin (PHT), resulting in patients with refractory status epilepticus (RSE)." | 7.78 | Phenytoin, levetiracetam, and pregabalin in the acute management of refractory status epilepticus in patients with brain tumors. ( Doreswamy, M; Gingrich, KJ; Kolls, BJ; Swisher, CB; Vredenburgh, JJ, 2012) |
| "The aim of this study was to determine the efficacy of phenytoin, a sodium channel blocker, in the treatment of febrile status epilepticus in children." | 7.78 | Lack of efficacy of phenytoin in children presenting with febrile status epilepticus. ( Carmant, L; Ismail, S; Lévy, A; Sévère, M; Tikkanen, H; Wolters, FJ, 2012) |
| "Phenytoin (PHT), valproic acid (VPA), or levetiracetam (LEV) are commonly used as second-line treatment of status epilepticus (SE), but comparative studies are not available." | 7.77 | Second-line status epilepticus treatment: comparison of phenytoin, valproate, and levetiracetam. ( Alvarez, V; Burnand, B; Januel, JM; Rossetti, AO, 2011) |
| "To evaluate the effects of high-frequency electrical stimulation (HFS) in both ventral hippocampi, alone and combined with a subeffective dose of antiepileptic drugs, during the status epilepticus (SE) induced by lithium-pilocarpine (LP)." | 7.76 | Antiepileptic drugs combined with high-frequency electrical stimulation in the ventral hippocampus modify pilocarpine-induced status epilepticus in rats. ( Alcantara-Gonzalez, D; Cuellar-Herrera, M; Neri-Bazan, L; Peña, F; Rocha, L, 2010) |
| "Cell damage and spatial localization deficits are often reported as long-term consequences of pilocarpine-induced status epilepticus." | 7.75 | Neuroprotective effects of diazepam, carbamazepine, phenytoin and ketamine after pilocarpine-induced status epilepticus. ( Cunha, AO; dos Santos, WF; Liberato, JL; Mortari, MR, 2009) |
| "A 44-year-old man with treated neurosyphilis presented with subclinical status epilepticus (SE) refractory to intravenous high-dose lorazepam, phenytoin, and valproic acid over 4 days." | 7.72 | Ketamine for refractory status epilepticus: a case of possible ketamine-induced neurotoxicity. ( Lerner, AJ; Maddux, BN; Sagar, SM; Suarez, JI; Ubogu, EE; Werz, MA, 2003) |
| "We investigated the effects of valproate (VPA) on an in vivo model of status epilepticus (SE) induced by intrahippocampal application of 4-aminopyridine (4-AP)." | 7.72 | Valproate suppresses status epilepticus induced by 4-aminopyridine in CA1 hippocampus region. ( Martín, ED; Pozo, MA, 2003) |
| "This study evaluated the effectiveness of fosphenytoin as a single or adjunctive anticonvulsant treatment for nerve agent-induced status epilepticus." | 7.72 | Effects of fosphenytoin on nerve agent-induced status epilepticus. ( Benjamin, A; McDonough, JH; McMonagle, JD; Rowland, T; Shih, TM, 2004) |
| "Status epilepticus is usually initially treated with a benzodiazepine such as diazepam." | 7.71 | Characterization of pharmacoresistance to benzodiazepines in the rat Li-pilocarpine model of status epilepticus. ( Esmaeil, N; Jones, DM; Macdonald, RL; Maren, S, 2002) |
| " It was proposed that the late activity is a model for pharmacoresistant status epilepticus since it was also refractory to phenytoin, carbamazepine, phenobarbital, and midazolam." | 7.70 | Phenytoin, phenobarbital, and midazolam fail to stop status epilepticus-like activity induced by low magnesium in rat entorhinal slices, but can prevent its development. ( Dreier, JP; Heinemann, U; Zhang, CL, 1998) |
| "To examine the putative seizure-protective properties of felbamate in an animal model of self-sustaining status epilepticus (SSSE)." | 7.70 | Felbamate in experimental model of status epilepticus. ( Baldwin, RA; Mazarati, AM; Sofia, RD; Wasterain, CG, 2000) |
| " We compared seizure frequency and mean intravenous benzodiazepine dose required to control absence status epilepticus, intraindividually in subjects on carbamazepine or phenytoin before and after discontinuation of these compounds, and interindividually to subjects without treatment or receiving other drugs." | 7.70 | Refractory idiopathic absence status epilepticus: A probable paradoxical effect of phenytoin and carbamazepine. ( Osorio, I; Peltzer, JN; Reed, RC, 2000) |
| "The effect of nimodipine alone and in combination with diazepam or phenytoin was tested in the electroshock-induced mouse model of status epilepticus." | 7.70 | Anticonvulsant effect of nimodipine alone and in combination with diazepam and phenytoin in a mouse model of status epilepticus. ( Khosla, P; Pandhi, P, 2000) |
| "Four-year-old, 20-kg girl, diagnosed with idiopathic tonic-clonic epilepsy, who developed AHS to phenobarbital and phenytoin and status epilepticus unresponsive to lorazepam." | 7.68 | Diazepam by continuous intravenous infusion for status epilepticus in anticonvulsant hypersensitivity syndrome. ( Bertz, RJ; Howrie, DL, 1993) |
| "Twenty-two patients with partial status epilepticus were treated with phenytoin (DPH) intravenously (mean daily dose: 18,6 +/- 7,3 mg/kg)." | 7.66 | [Use of intravenous phenytoin in treatment of partial status epilepticus (author's transl)]. ( Chauplannaz, G; Courjon, J; Ferry, S; Mauguière, F, 1981) |
| "The treatment of status epilepticus can be improved by using recent developments in the pharmacokinetics and method of intravenous (IV) administration of phenytoin sodium." | 7.66 | Status epilepticus. The role of intravenous phenytoin. ( Cloyd, JC; Gumnit, RJ; McLain, LW, 1980) |
| "Fifteen infants and children were treated with phenytoin for status epilepticus." | 7.65 | An effective dose schedule for phenytoin treatment of status epilepticus in infancy and childhood. ( Albani, M, 1977) |
| "Diazepam was initially administered, followed intravenously by FPHT at 22." | 7.30 | Levetiracetam versus fosphenytoin as a second-line treatment after diazepam for adult convulsive status epilepticus: a multicentre non-inferiority randomised control trial. ( Asami, M; Egawa, S; Fukuda, Y; Hoshiyama, E; Inoue, Y; Ishikawa, E; Kaneko, J; Kimura, A; Kondo, Y; Maruo, K; Marushima, A; Matsumaru, Y; Mochizuki, M; Nakamoto, H; Nakamura, K; Takahashi, Y; Uchida, M; Unemoto, K; Yamada, T; Yonekawa, C, 2023) |
| "Levetiracetam reportedly has similar efficacy and higher safety for SE; however, evidence to support its use for adult SE is lacking." | 7.01 | Levetiracetam versus fosphenytoin as a second-line treatment after diazepam for status epilepticus: study protocol for a multicenter non-inferiority designed randomized control trial. ( Asami, M; Egawa, S; Hoshiyama, E; Inoue, Y; Kaneko, J; Kimura, A; Kondo, Y; Maruo, K; Marushima, A; Nakamura, K; Takahashi, Y; Yamada, T; Yonekawa, C, 2021) |
| "IV phenytoin is an established treatment of SE, but its alkaline aqueous vehicle is associated with dermatologic irritation and systemic complications when rapidly infused." | 6.82 | A critical review of fosphenytoin sodium injection for the treatment of status epilepticus in adults and children. ( Clay, JL; Fountain, NB, 2022) |
| "Phenytoin has traditionally been considered the second-line drug of first choice after failure of first-line treatment using benzodiazepines." | 6.72 | Comparison of the efficacy and safety of levetiracetam and phenytoin in the treatment of established status epilepticus: A systematic review and meta-analysis. ( Cui, XH; Dong, XZ; Liu, JM; Liu, WN; Yang, L; Zhang, L, 2021) |
| "Midazolam was given 0." | 6.70 | Eight-year study of childhood status epilepticus: midazolam infusion in management and outcome. ( Al Riyami, K; Chacko, A; Javed, H; Koul, R, 2002) |
| "How aggressively these seizures should be treated is unclear." | 6.52 | Lacosamide in status epilepticus: Update on the TRENdS study. ( Husain, AM, 2015) |
| "The rates of cessation of seizure and prevention of seizure recurrence for 24 h were 84% for phenytoin and 78." | 5.72 | Efficacy of intravenous levetiracetam versus phenytoin in convulsive status epilepticus and acute repetitive seizures in children. ( Akın, Y; Çağ, Y; Köle, MT; Sager, SG; Zeynel, H, 2022) |
| "The ESETT was a prospective, double-blinded, adaptive trial evaluating levetiracetam, valproate, and fosphenytoin as second-line agents in benzodiazepine-refractory status epilepticus in adults and children." | 5.51 | Treatment of Toxin-Related Status Epilepticus With Levetiracetam, Fosphenytoin, or Valproate in Patients Enrolled in the Established Status Epilepticus Treatment Trial. ( Chamberlain, JM; Coralic, Z; Kapur, J; Olson, KR; Overbeek, D; Silbergleit, R, 2022) |
| "Benzodiazepines are used as first-line treatments for status epilepticus." | 5.46 | Efficacy of levetiracetam versus fosphenytoin for the recurrence of seizures after status epilepticus. ( Daidoji, H; Doi, K; Hashimoto, H; Hiruma, T; Inokuchi, R; Morimura, N; Nakamura, K; Naraba, H; Sonoo, T; Tokunaga, K, 2017) |
| " Adverse effects of fosphenytoin may include: cardiovascular events (hypotension, arrhythmias), paresthesias or pruritus or some central events - somnolence, headache, dizziness, nystagmus and ataxia." | 5.42 | The safety and efficacy of fosphenytoin for the treatment of status epilepticus. ( Borowicz, KK; Czuczwar, SJ; Popławska, M, 2015) |
| "The efficacy and safety of levetiracetam are superior to that of phenytoin in children with status epilepticus." | 5.41 | Comparison of Safety and Effectiveness between Levetiracetam and Phenytoin in the Treatment of Pediatric Status Epilepticus: A Meta- Analysis. ( AlMuhanna, FA; AlMuhanna, MA; AlMulihi, QA; AlSultan, EA, 2023) |
| "Fosphenytoin (FOS) and its active form, phenytoin (PHT), levetiracetam (LEV), and valproic acid (VPA) are commonly used second-line treatments of status epilepticus." | 5.41 | Early Exposure of Fosphenytoin, Levetiracetam, and Valproic Acid After High-Dose Intravenous Administration in Young Children With Benzodiazepine-Refractory Status Epilepticus. ( Babcock, L; Brundage, RC; Chamberlain, JM; Cloyd, JC; Cock, HR; Coles, LD; Elm, JJ; Fountain, NB; Ivaturi, V; Kapur, J; Lowenstein, DH; Mishra, U; Sathe, AG; Shinnar, S; Silbergleit, R, 2021) |
| " Because it was known from the literature that the half-life of midazolam can increase at high dosage, the kinetics of midazolam (MDZ), 1'-hydroxymidazolam, and 4-hydroxymidazolam were assessed at steady state (dosage 1 mg/min) and after stopping treatment." | 5.35 | Pharmacokinetics of midazolam and metabolites in a patient with refractory status epilepticus treated with extraordinary doses of midazolam. ( Bodmer, M; Grignaschi, N; Haschke, M; Krähenbühl, S; Kummer, O; Link, B; Ruegg, S, 2008) |
| "To determine whether levetiracetam is an alternative to fosphenytoin to control Benzodiazepine Refractory Status Epilepticus (BRSE) in pediatric population and also to compare the acute drug related side-effects and ventilation requirement among the both arms of anti-epileptic drug therapy." | 5.34 | Clinical Effectiveness of Levetiracetam Compared to Fosphenytoin in the Treatment of Benzodiazepine Refractory Convulsive Status Epilepticus. ( Kandasamy, S; Krishnamoorthi, N; Nalisetty, S; Sangaralingam, T; Sridharan, B; Vijayakumar, V, 2020) |
| "To compare the efficacy of phenytoin, valproate, and levetiracetam in the management of pediatric convulsive status epilepticus." | 5.34 | Comparison of Phenytoin, Valproate and Levetiracetam in Pediatric Convulsive Status Epilepticus: A Randomized Double-blind Controlled Clinical Trial. ( Mahadevan, S; Rameshkumar, R; Vignesh, V, 2020) |
| "Children, adults, and older adults with established status epilepticus respond similarly to levetiracetam, fosphenytoin, and valproate, with treatment success in approximately half of patients." | 5.34 | Efficacy of levetiracetam, fosphenytoin, and valproate for established status epilepticus by age group (ESETT): a double-blind, responsive-adaptive, randomised controlled trial. ( Babcock, L; Barsan, W; Bleck, TP; Chamberlain, JM; Cloyd, J; Cock, H; Connor, JT; Conwit, R; Elm, J; Fountain, NB; Holsti, M; Kapur, J; Lowenstein, D; Meinzer, C; Rogers, A; Shinnar, S; Silbergleit, R; Underwood, E, 2020) |
| "The Established Status Epilepticus Treatment Trial was a blinded, comparative-effectiveness study of fosphenytoin, levetiracetam, and valproic acid in benzodiazepine-refractory status epilepticus." | 5.34 | The association of patient weight and dose of fosphenytoin, levetiracetam, and valproic acid with treatment success in status epilepticus. ( Bleck, TP; Chamberlain, JM; Cloyd, JC; Cock, HR; Coles, LD; Conwit, RA; Elm, JJ; Fountain, NB; Kapur, J; Lowenstein, DH; Sathe, AG; Shinnar, S; Silbergleit, R, 2020) |
| "To determine whether phenytoin or levetiracetam (Keppra, UCB Pharma, Brussels, Belgium) is the more clinically effective intravenous second-line treatment of paediatric convulsive status epilepticus and to help better inform its management." | 5.34 | Levetiracetam as an alternative to phenytoin for second-line emergency treatment of children with convulsive status epilepticus: the EcLiPSE RCT. ( Al Najjar, N; Appleton, RE; Evans, V; Gamble, C; Hickey, H; Humphreys, A; Iyer, A; Lee, E; Lyttle, MD; Messahel, S; Noblet, J; Potter, S; Rainford, NE; Roper, L; Tate, P; Woolfall, K, 2020) |
| "fosphenytoin, n = 6), and were not statistically different for the three routes of administration." | 5.32 | Pharmacokinetics and clinical effects of phenytoin and fosphenytoin in children with severe malaria and status epilepticus. ( Edwards, G; Kokwaro, GO; Muchohi, SN; Newton, CR; Ogutu, BR; Otieno, GO; Watkins, WM, 2003) |
| "Phenobarbital and MK-801 were superior to phenytoin in suppressing SE and in preventing chronic epilepsy." | 5.31 | Phenobarbital and MK-801, but not phenytoin, improve the long-term outcome of status epilepticus. ( Bertram, EH; Prasad, A; Williamson, JM, 2002) |
| "In a randomized, blinded, adaptive trial, we compared the efficacy and safety of three intravenous anticonvulsive agents - levetiracetam, fosphenytoin, and valproate - in children and adults with convulsive status epilepticus that was unresponsive to treatment with benzodiazepines." | 5.30 | Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus. ( Barsan, W; Chamberlain, JM; Cloyd, J; Cock, H; Connor, JT; Conwit, R; Elm, J; Fountain, N; Kapur, J; Lowenstein, D; Meinzer, C; Shinnar, S; Silbergleit, R, 2019) |
| "EcLiPSE (Emergency treatment with Levetiracetam or Phenytoin in Status Epilepticus in children) is a randomised controlled trial (RCT) in the United Kingdom." | 5.30 | Enhancing practitioners' confidence in recruitment and consent in the EcLiPSE trial: a mixed-method evaluation of site training - a Paediatric Emergency Research in the United Kingdom and Ireland (PERUKI) study. ( Appleton, R; Gamble, C; Hickey, H; Humphreys, A; Iyer, A; Lee, E; Lyttle, MD; Messahel, S; Noblet, J; Rainford, N; Roper, L; Woolfall, K, 2019) |
| "Phenytoin is the current standard of care for second-line treatment of paediatric convulsive status epilepticus after failure of first-line benzodiazepines, but is only effective in 60% of cases and is associated with considerable adverse effects." | 5.30 | Levetiracetam versus phenytoin for second-line treatment of convulsive status epilepticus in children (ConSEPT): an open-label, multicentre, randomised controlled trial. ( Babl, FE; Bonisch, M; Borland, ML; Brabyn, C; Cheng, N; Craig, S; Dalziel, SR; Davidson, A; Donath, S; Francis, KL; Furyk, J; George, S; Harvey, AS; Kochar, A; Neutze, J; Oakley, E; Phillips, N; Rao, A; Sharpe, C; Zhang, M, 2019) |
| "Phenytoin is the recommended second-line intravenous anticonvulsant for treatment of paediatric convulsive status epilepticus in the UK; however, some evidence suggests that levetiracetam could be an effective and safer alternative." | 5.30 | Levetiracetam versus phenytoin for second-line treatment of paediatric convulsive status epilepticus (EcLiPSE): a multicentre, open-label, randomised trial. ( Appleton, RE; Evans, V; Gamble, C; Hickey, H; Humphreys, A; Iyer, A; Lee, ED; Lyttle, MD; Messahel, S; Noblet, J; Potter, S; Rainford, NEA; Roper, L; Tate, P; Woolfall, K, 2019) |
| "Status epilepticus is one of the most frequent neurological emergencies in the intensive care unit." | 5.29 | Propofol in the management of refractory status epilepticus: a case report. ( Borgeat, A; Jallon, P; Suter, PM; Wilder-Smith, OH, 1994) |
| "Status epilepticus was induced in rats with actively epileptogenic cortical cobalt lesions by administration of homocysteine thiolactone." | 5.29 | Lamotrigine vs. phenytoin for treatment of status epilepticus: comparison in an experimental model. ( Hyun, B; Jaing, Q; Treiman, DM; Walton, NY, 1996) |
| "Status epilepticus was induced by injection of homocysteine thiolactone to rats with epileptogenic cortical cobalt lesions." | 5.28 | Efficacy of ACC-9653 (a phenytoin prodrug) in experimental status epilepticus in the rat. ( Treiman, DM; Walton, NY, 1990) |
| " By means of Monte Carlo simulations an optimal dosing scheme for phenytoin loading has been calculated." | 5.27 | Intravenous phenytoin loading in patients after neurosurgery and in status epilepticus. A population pharmacokinetic study. ( Aarons, L; Gratzl, O; Landolt, H; Maitre, P; Uematsu, T; Vozeh, S, 1988) |
| "Most patients had had more than three seizures or were in status epilepticus." | 5.26 | Intravenous phenytoin in acute treatment of seizures. ( Anderson, CB; Cranford, RE; Kostick, B; Leppik, IE; Patrick, B, 1979) |
| "IV Levetiracetam controls status epilepticus or cluster seizures with an efficacy comparable to that of phenytoin." | 5.24 | Intravenous levetiracetam vs phenytoin for status epilepticus and cluster seizures: A prospective, randomized study. ( Al-Amrani, K; Al-Asmi, A; Al-Hashim, A; Ganguly, SS; Gujjar, AR; Jacob, PC; Nandhagopal, R, 2017) |
| "Based on low quality evidence, phenobarbital appears to be the most effective agent for seizure cessation within 60 min of administration in patients with benzodiazepine resistant status epilepticus." | 5.22 | Treatment of benzodiazepine-resistant status epilepticus: Systematic review and network meta-analyses. ( Aneja, S; Arya, R; Cunningham, J; Jain, P; Sharma, S, 2022) |
| "This article will review the different therapeutic options for status, from early treatment at home to the different first-line (benzodiazepines), second-line (phenobarbital, valproic acid, phenytoin, levetiracetam and lacosamide) or third-line treatments, which include both pharmacological (anaesthetics, propofol, ketamine, lidocaine, topiramate, brivaracetam or perampanel) and non-pharmacological (ketogenic diet, immunomodulatory treatments or epilepsy surgery) therapies." | 5.22 | [Paediatric status epilepticus]. ( García-Peñas, JJ; González-Alguacil, E; Soto-Insuga, V, 2022) |
| "We report the efficacy and safety of lorazepam (LOR), phenytoin (PHT), valproate (VPA) and levetiracetam (LEV) as first and second choice antiepileptic drug (AED) in status epilepticus (SE) and their combinations in preventing refractory SE." | 5.22 | A comparison of four antiepileptic drugs in status epilepticus: experience from India. ( Kalita, J; Misra, UK, 2016) |
| "The purpose of this study was to compare safety and efficacy of intravenous (IV) levetiracetam (LEV) with IV phenytoin (PHT) in management of status epilepticus (SE)." | 5.20 | Levetiracetam versus phenytoin in management of status epilepticus. ( Bhalla, A; Chakravarthi, S; Goyal, MK; Modi, M; Singh, P, 2015) |
| "To determine whether intravenous lorazepam is as efficacious as diazepam-phenytoin combination in the treatment of convulsive status epilepticus in children." | 5.14 | Lorazepam versus diazepam-phenytoin combination in the treatment of convulsive status epilepticus in children: a randomized controlled trial. ( Gupta, P; Krishnamurthy, S; Sharma, KK; Sreenath, TG, 2010) |
| "To evaluate the efficacy and tolerability of the treatment with valproic acid (VPA) in patients with status epilepticus (SE) or acute repetitive seizures (ARS) comparing it with phenytoin (PHT) treatment." | 5.13 | Treatment of status epilepticus and acute repetitive seizures with i.v. valproic acid vs phenytoin. ( Dabby, R; Gilad, R; Izkovitz, N; Lampl, Y; Rapoport, A; Sadeh, M; Weller, B, 2008) |
| "To synthesize the available evidence examining the efficacy and safety of levetiracetam compared with phenytoin or fosphenytoin in benzodiazepine-refractory pediatric status epilepticus." | 5.12 | Levetiracetam Versus Phenytoin or Fosphenytoin for Second-Line Treatment of Pediatric Status Epilepticus: A Meta-Analysis. ( Catenacci, V; Choong, K; Duffett, M; Hewitt, M; Jones, K; Klowak, JA; Rochwerg, B, 2021) |
| "To systematically evaluate the efficacy and safety of levetiracetam (LEV) versus phenytoin (PHT) as second-line drugs for the treatment of convulsive status epilepticus (CSE) in children." | 5.12 | [Efficacy and safety of levetiracetam versus phenytoin as second-line drugs for the treatment of children with convulsive status epilepticus: a Meta analysis]. ( Shi, R; Wang, ZZ; Yin, HQ, 2021) |
| "To compare the evidence on efficacy, safety, tolerability, and impact on short term/long functional outcome of lacosamide (LCM) and phenytoin (PHT) in patients with status epilepticus." | 5.12 | Efficacy of lacosamide and phenytoin in status epilepticus: A systematic review. ( Dawman, L; Panda, P; Panda, PK; Sharawat, IK, 2021) |
| "To evaluate the efficacy and safety of levetiracetam (LEV) in comparison to phenytoin (PHT) as second line antiseizure medication (ASM) for Pediatric convulsive status epilepticus (SE)." | 5.12 | Efficacy and Safety of Levetiracetam vs. Phenytoin as Second Line Antiseizure Medication for Pediatric Convulsive Status Epilepticus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. ( Angurana, SK; Suthar, R, 2021) |
| "Levetiracetam was similar to (fos)phenytoin in cessation rate convulsive status epilepticus, and drug resistance, while it was superior (fos)phenytoin in pooled safety outcome." | 5.12 | Efficacy and safety of levetiracetam versus (fos)phenytoin for second-line treatment of epilepticus: a meta-analysis of latest randomized controlled trials. ( Ai, C; Chen, Y; Feng, Y; Jia, Y; Jiang, L; Li, W; Liu, Y; Wang, X; Wang, Z, 2021) |
| "Sixty-eight patients with convulsive status epilepticus (SE) were randomly assigned to two groups to study the efficacy of sodium valproate (VPA) and phenytoin (PHT)." | 5.12 | Sodium valproate vs phenytoin in status epilepticus: a pilot study. ( Kalita, J; Misra, UK; Patel, R, 2006) |
| "The intravenous application of VPA seems to be an easy-to-use, safe and efficient formulation as an alternative to phenytoin in all seizure emergency situations including status epilepticus." | 5.11 | Intravenous valproate as an innovative therapy in seizure emergency situations including status epilepticus--experience in 102 adult patients. ( Peters, CN; Pohlmann-Eden, B, 2005) |
| "The efficacy of a combination of midazolam and phenytoin in treating generalized convulsive status epilepticus in children was studied retrospectively." | 5.11 | Status epilepticus: clinical analysis of a treatment protocol based on midazolam and phenytoin. ( Arts, WF; Brevoord, JC; de Hoog, M; Joosten, KF; van Rooij, RW, 2005) |
| "We compared propofol with high-dose barbiturates in the treatment of refractory status epilepticus (RSE) and propose a protocol for the administration of propofol in RSE in adults, correlating propofol's effect with plasma levels." | 5.08 | Treatment of refractory status epilepticus with propofol: clinical and pharmacokinetic findings. ( Dulaney, E; Kramer, TH; O'Meeghan, R; Raps, EC; Skaar, DJ; Stecker, MM, 1998) |
| "As initial intravenous treatment for overt generalized convulsive status epilepticus, lorazepam is more effective than phenytoin." | 5.08 | A comparison of four treatments for generalized convulsive status epilepticus. Veterans Affairs Status Epilepticus Cooperative Study Group. ( Calabrese, VP; Colling, C; Collins, JF; Faught, E; Handforth, A; Mamdani, MB; Meyers, PD; Ramsay, RE; Rowan, AJ; Treiman, DM; Uthman, BM; Walton, NY, 1998) |
| "In a randomized, nonblinded clinical trial, 36 consecutive patients with generalized convulsive status epilepticus were treated with either combination diazepam and phenytoin (DZ/DPH) or phenobarbital (PB)." | 5.06 | Treatment of status epilepticus: a prospective comparison of diazepam and phenytoin versus phenobarbital and optional phenytoin. ( Gabor, AJ; Herring, MO; McCurdy, SA; Shaner, DM, 1988) |
| "To compare the efficacy and safety of levetiracetam and phenytoin for the treatment of established status epilepticus." | 5.05 | Levetiracetam versus phenytoin for the treatment of established status epilepticus: A systematic review and meta-analysis of randomized controlled trials. ( Chong, W; Fang, F; Fang, Y; Faramand, A; Jia, D; Jia, L; Li, L; Ma, L; Zhang, Y, 2020) |
| "The objective of the study was to perform a systematic review and meta-analysis to evaluate the efficacy and safety of levetiracetam (LEV) or phenytoin (PHT) as second-line treatment for status epilepticus (SE)." | 5.05 | Levetiracetam vs. phenytoin as 2nd-line treatment for status epilepticus: A systematic review and meta-analysis. ( DeMott, JM; Gottlieb, M; Peksa, GD; Slocum, GW, 2020) |
| "Recent studies have shown conflicting results regarding the effectiveness of levetiracetam for treating benzodiazepine-refractory status epilepticus (SE) compared with phenytoin." | 5.05 | Levetiracetam versus Phenytoin for the Pharmacotherapy of Benzodiazepine-Refractory Status Epilepticus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. ( Chen, Z; Shen, X; Wang, Z; Wei, L; Xue, T, 2020) |
| "Since the 1970s, intravenous (IV) phenytoin (PHT) has traditionally been used as second-stage treatment for convulsive status epilepticus (SE) after failure of benzodiazepines." | 4.98 | A critical appraisal of randomized controlled trials on intravenous phenytoin in convulsive status epilepticus. ( Bragazzi, NL; Brigo, F; Lattanzi, S; Nardone, R; Trinka, E, 2018) |
| "Over last fifty years, intravenous (iv) phenytoin (PHT) loading dose has been the treatment of choice for patients with benzodiazepine-resistant convulsive status epilepticus and several guidelines recommended this treatment regimen with simultaneous iv diazepam." | 4.98 | Why we prefer levetiracetam over phenytoin for treatment of status epilepticus. ( Amantini, A; Campostrini, R; Giannasi, G; Giorgi, FS; Giovannelli, F; Nazerian, P; Paganini, M; Zaccara, G, 2018) |
| "The aim of this study was to conduct a meta-analysis of published studies to directly compare intravenous (IV) levetiracetam (LEV) with IV phenytoin (PHT) or IV valproate (VPA) as second-line treatment of status epilepticus (SE), to indirectly compare intravenous IV LEV with IV VPA using common reference-based indirect comparison meta-analysis, and to verify whether results of indirect comparisons are consistent with results of head-to-head randomized controlled trials (RCTs) directly comparing IV LEV with IV VPA." | 4.93 | Direct and indirect comparison meta-analysis of levetiracetam versus phenytoin or valproate for convulsive status epilepticus. ( Bragazzi, N; Brigo, F; Nardone, R; Trinka, E, 2016) |
| "Our goal was to perform a systematic review of the literature on the use of intravenous lidocaine in pediatrics for status epilepticus (SE) and refractory status epilepticus (RSE) to determine its impact on seizure control." | 4.91 | Lidocaine for Status Epilepticus in Pediatrics. ( Gillman, LM; Kazina, CJ; Teitelbaum, J; West, M; Zeiler, FA; Zeiler, KJ, 2015) |
| "Lorazepam is better than diazepam or phenytoin alone for cessation of seizures and carries a lower risk of continuation of status epilepticus requiring a different drug or general anaesthesia." | 4.84 | Anticonvulsant therapy for status epilepticus. ( Al-Roomi, K; Krishnan, PR; Prasad, K; Sequeira, R, 2007) |
| "Lorazepam is better than diazepam or phenytoin alone for cessation of seizures and carries a lower risk of continuation of status epilepticus requiring a different drug or general anaesthesia." | 4.82 | Anticonvulsant therapy for status epilepticus. ( Al-Roomi, K; Krishnan, PR; Prasad, K; Sequeira, R, 2005) |
| " There is, however, considerable debate about the sodium-channel blocker phenytoin, which is often used for status epilepticus, a frequent feature of Dravet syndrome." | 4.12 | Does long-term phenytoin have a place in Dravet syndrome? ( Russ-Hall, SJ; Scheffer, IE; Zographos, GA, 2022) |
| " As part of an embedded study in the 'Emergency treatment with Levetiracetam or Phenytoin in Status Epilepticus in children' (EcLiPSE) trial, we explored how practitioners described the trial and RWPC during recruitment discussions, and how well this information was understood by parents." | 4.02 | Seven-step framework to enhance practitioner explanations and parental understandings of research without prior consent in paediatric emergency and critical care trials. ( Appleton, R; Gamble, C; Hickey, H; Humphreys, A; Iyer, A; Lee, ED; Lyttle, MD; Messahel, S; Noblet, J; Rainford, N; Roper, L; Woolfall, K, 2021) |
| "Key challenges to the successful conduct of The Emergency treatment with Levetiracetam or Phenytoin in Status Epilepticus in children (EcLiPSE) trial were identified at the pre-trial stage." | 4.02 | Planning for success: overcoming challenges to recruitment and conduct of an open-label emergency department-led paediatric trial. ( Appleton, R; Gamble, C; Hickey, H; Humphreys, A; Iyer, A; Lee, ED; Lyttle, MD; Messahel, S; Noblet, J; Rainford, N; Roper, L; Woolfall, K, 2021) |
| " In the early morning of day 3, while midazolam was administered up to the maximum dose, the infant developed status epilepticus, and the anticonvulsant drug was changed to phenytoin." | 4.02 | Rapid infusion of excessive phenytoin: A newborn autopsy case. ( Ichioka, H; Idota, N; Ikegaya, H; Kondou, H; Shintani-Ishida, K, 2021) |
| "To evaluate the efficacy and tolerability of intravenous fosphenytoin in children with status epilepticus, and resulting serum total phenytoin levels." | 3.96 | Efficacy, Tolerability and Serum Phenytoin Levels after Intravenous Fosphenytoin Loading Dose in Children with Status Epilepticus. ( Bhartiya, S; Gavli, V; Patil, R; Rajadhyaksha, S; Srivastava, K, 2020) |
| "For status epilepticus, the choice of antiepileptic drugs for second-line treatment after benzodiazepine remains controversial: phenytoin or fosphenytoin are recommended, however, it has been unknown which is better." | 3.96 | Phenytoin versus fosphenytoin for second-line treatment of status epilepticus: propensity score matching analysis using a nationwide inpatient database. ( Fushimi, K; Matsui, H; Nakamura, K; Nakano, H; Naraba, H; Ohbe, H; Takahashi, Y; Yasunaga, H, 2020) |
| " Levetiracetam is a relatively newer AED with favorable pharmacokinetics and could be an effective and safer option for the treatment of convulsive status epilepticus (CSE)." | 3.96 | Efficacy and safety profile of intravenous levetiracetam versus phenytoin in convulsive status epilepticus and acute repetitive seizures in children. ( Besli, GE; Yilmaz, S; Yuksel Karatoprak, E, 2020) |
| " The aim of the present study was to explore the effect of a selective CB2 receptor agonist β-caryophyllene (BCP) in models of seizures and cognition in mice." | 3.88 | Pharmacological characterization of the cannabinoid receptor 2 agonist, β-caryophyllene on seizure models in mice. ( da Conceição Machado, K; de Carvalho Melo Cavalcante, AA; Gomes Júnior, AL; Momchilova, A; Tchekalarova, J; Tzoneva, R, 2018) |
| "Fosphenytoin (fPHT) and continuous intravenous midazolam (cMDL) had commonly been used as second-line treatments for pediatric status epilepticus (SE) in Japan." | 3.88 | Fosphenytoin vs. continuous midazolam for pediatric febrile status epilepticus. ( Fujita, K; Iijima, K; Ishida, Y; Kurosawa, H; Maruyama, A; Morioka, I; Nagase, H; Nishiyama, M; Nozu, K; Takada, S; Tanaka, T; Taniguchi-Ikeda, M; Tomioka, K; Toyoshima, D; Uetani, Y; Yamaguchi, H, 2018) |
| "Purple glove syndrome is a rare and poorly understood complication of phenytoin use, occurring almost always with its intravenous formulation." | 3.81 | Purple glove syndrome occurring after oral administration of phenytoin in therapeutic doses: mechanism still a dilemma. ( Handa, R; Jain, RS; Kumar, S; Nagpal, K; Prakash, S, 2015) |
| " Diazepam produced a dose-dependent protection against 6-Hz seizures in control and pilocarpine mice, both at 2 weeks and 8 weeks after SE, but with a more pronounced increase in potency in post-SE animals at 2 weeks." | 3.81 | Status epilepticus induction has prolonged effects on the efficacy of antiepileptic drugs in the 6-Hz seizure model. ( Kaminski, RM; Leclercq, K, 2015) |
| " He developed partial complex status epilepticus, requiring benzodiazepines, phenytoin, propofol and intubation." | 3.81 | Medication-induced acute dystonic reaction: the challenge of diagnosing movement disorders in the intensive care unit. ( Digby, G; Jalini, S; Taylor, S, 2015) |
| "To compare intravenous phenytoin (PHT) and intravenous lacosamide (LCM) for treatment of status epilepticus after failure of the first and second drug." | 3.80 | Intravenous lacosamide or phenytoin for treatment of refractory status epilepticus. ( Berning, S; Kellinghaus, C; Stögbauer, F, 2014) |
| " She was diagnosed as having influenza encephalopathy presenting non-convulsive status epilepticus (NCSE), and commenced methylprednisolone pulse therapy followed by prednisolone with gradual tapering." | 3.80 | [Case of non-convulsive status epilepticus after influenza virus B infection]. ( Kira, J; Oyagi, Y; Shigetou, H; Tateishi, T; Uehara, T; Une, H, 2014) |
| " We tested the hypothesis that status epilepticus (SE) or exposure to phenytoin or phenobarbital affects brain expression of the metabolic enzyme CYP2E1." | 3.80 | Effect of status epilepticus and antiepileptic drugs on CYP2E1 brain expression. ( Boussadia, B; de Bock, F; Ghosh, C; Janigro, D; Marchi, N; Pascussi, JM; Plaud, C; Rousset, MC, 2014) |
| " Approximately 30-40% of brain tumors patients who present with status epilepticus (SE) will not respond to typical therapy consisting of benzodiazepines and phenytoin (PHT), resulting in patients with refractory status epilepticus (RSE)." | 3.78 | Phenytoin, levetiracetam, and pregabalin in the acute management of refractory status epilepticus in patients with brain tumors. ( Doreswamy, M; Gingrich, KJ; Kolls, BJ; Swisher, CB; Vredenburgh, JJ, 2012) |
| "The aim of this study was to determine the efficacy of phenytoin, a sodium channel blocker, in the treatment of febrile status epilepticus in children." | 3.78 | Lack of efficacy of phenytoin in children presenting with febrile status epilepticus. ( Carmant, L; Ismail, S; Lévy, A; Sévère, M; Tikkanen, H; Wolters, FJ, 2012) |
| "Phenytoin (PHT), valproic acid (VPA), or levetiracetam (LEV) are commonly used as second-line treatment of status epilepticus (SE), but comparative studies are not available." | 3.77 | Second-line status epilepticus treatment: comparison of phenytoin, valproate, and levetiracetam. ( Alvarez, V; Burnand, B; Januel, JM; Rossetti, AO, 2011) |
| "To evaluate the effects of high-frequency electrical stimulation (HFS) in both ventral hippocampi, alone and combined with a subeffective dose of antiepileptic drugs, during the status epilepticus (SE) induced by lithium-pilocarpine (LP)." | 3.76 | Antiepileptic drugs combined with high-frequency electrical stimulation in the ventral hippocampus modify pilocarpine-induced status epilepticus in rats. ( Alcantara-Gonzalez, D; Cuellar-Herrera, M; Neri-Bazan, L; Peña, F; Rocha, L, 2010) |
| "Cell damage and spatial localization deficits are often reported as long-term consequences of pilocarpine-induced status epilepticus." | 3.75 | Neuroprotective effects of diazepam, carbamazepine, phenytoin and ketamine after pilocarpine-induced status epilepticus. ( Cunha, AO; dos Santos, WF; Liberato, JL; Mortari, MR, 2009) |
| "In the present study we examined if rats with PB-resistant seizures are also resistant to phenytoin (PHT), using continuous EEG/video recording of spontaneous seizures." | 3.74 | Resistance to phenobarbital extends to phenytoin in a rat model of temporal lobe epilepsy. ( Bethmann, K; Brandt, C; Löscher, W, 2007) |
| " Following lysis the patient developed recurrent complex partial seizures and treatment with intravenous phenytoin was started." | 3.74 | [Subtherapeutic blood levels of phenytoin due to a medication error]. ( Burri, E; Egger, SS; Lampert, ML; Rüegg, S; Rutishauser, J, 2007) |
| "The prodrug fosphenytoin (FOS) was recently introduced as an alternative to phenytoin (PTN) and has since become a first line therapy for status epilepticus." | 3.73 | Fosphenytoin may cause hemodynamically unstable bradydysrhythmias. ( Adams, BD; Buckley, NH; Kim, JY; Tipps, LB, 2006) |
| "A 44-year-old man with treated neurosyphilis presented with subclinical status epilepticus (SE) refractory to intravenous high-dose lorazepam, phenytoin, and valproic acid over 4 days." | 3.72 | Ketamine for refractory status epilepticus: a case of possible ketamine-induced neurotoxicity. ( Lerner, AJ; Maddux, BN; Sagar, SM; Suarez, JI; Ubogu, EE; Werz, MA, 2003) |
| "Phenytoin (PHT) is a first-line drug in the treatment of status epilepticus." | 3.72 | A comparison of central brain (cerebrospinal and extracellular fluids) and peripheral blood kinetics of phenytoin after intravenous phenytoin and fosphenytoin. ( Patsalos, PN; Wang, X, 2003) |
| "We investigated the effects of valproate (VPA) on an in vivo model of status epilepticus (SE) induced by intrahippocampal application of 4-aminopyridine (4-AP)." | 3.72 | Valproate suppresses status epilepticus induced by 4-aminopyridine in CA1 hippocampus region. ( Martín, ED; Pozo, MA, 2003) |
| " Previously diagnosed with medically refractory complex partial seizures, our patient was admitted to the hospital with phenytoin toxicity." | 3.72 | Postictal laughter following absence status epilepticus. ( Boylan, LS; Devinsky, O; Kaley, TJ; Singh, A, 2003) |
| "This study evaluated the effectiveness of fosphenytoin as a single or adjunctive anticonvulsant treatment for nerve agent-induced status epilepticus." | 3.72 | Effects of fosphenytoin on nerve agent-induced status epilepticus. ( Benjamin, A; McDonough, JH; McMonagle, JD; Rowland, T; Shih, TM, 2004) |
| " This clinical policy focuses on 6 critical questions: What laboratory tests are indicated in the otherwise healthy adult patient with a new-onset seizure who has returned to a baseline normal neurologic status?Which new-onset seizure patients who have returned to a normal baseline require a head computed tomography (CT) scan in the emergency department (ED)?Which new-onset seizure patients who have returned to normal baseline need to be admitted to the hospital and/or started on an antiepileptic drug?What are effective phenytoin or fosphenytoin dosing strategies for preventing seizure recurrence in patients who present to the ED after having had a seizure with a subtherapeutic serum phenytoin level?What agent(s) should be administered to a patient in status epilepticus who continues to seize after having received benzodiazepine and phenytoin?When should electroencephalographic (EEG) testing be performed in the ED? Recommendations for patient management are provided for each 1 of these topics on the basis of strength of evidence (Level A, B, or C)." | 3.72 | Clinical policy: Critical issues in the evaluation and management of adult patients presenting to the emergency department with seizures. ( , 2004) |
| "Status epilepticus is usually initially treated with a benzodiazepine such as diazepam." | 3.71 | Characterization of pharmacoresistance to benzodiazepines in the rat Li-pilocarpine model of status epilepticus. ( Esmaeil, N; Jones, DM; Macdonald, RL; Maren, S, 2002) |
| " It was proposed that the late activity is a model for pharmacoresistant status epilepticus since it was also refractory to phenytoin, carbamazepine, phenobarbital, and midazolam." | 3.70 | Phenytoin, phenobarbital, and midazolam fail to stop status epilepticus-like activity induced by low magnesium in rat entorhinal slices, but can prevent its development. ( Dreier, JP; Heinemann, U; Zhang, CL, 1998) |
| "An animal model of self-sustaining status epilepticus (SSSE) induced in rats by brief intermittent perforant path stimulation (PPS) was examined with regard to the effects of two conventional antiepileptic drugs, diazepam and phenytoin." | 3.70 | Time-dependent decrease in the effectiveness of antiepileptic drugs during the course of self-sustaining status epilepticus. ( Baldwin, RA; Mazarati, AM; Sankar, R; Wasterlain, CG, 1998) |
| " This report describes a near-hanging episode in a patient who subsequently had status epilepticus requiring 40 mg of diazepam and 1,200 mg of phenytoin for control in the prehospital and emergency department stabilization period." | 3.70 | Hanging-induced status epilepticus. ( Pesola, GR; Westfal, RE, 1999) |
| "To examine the putative seizure-protective properties of felbamate in an animal model of self-sustaining status epilepticus (SSSE)." | 3.70 | Felbamate in experimental model of status epilepticus. ( Baldwin, RA; Mazarati, AM; Sofia, RD; Wasterain, CG, 2000) |
| " We compared seizure frequency and mean intravenous benzodiazepine dose required to control absence status epilepticus, intraindividually in subjects on carbamazepine or phenytoin before and after discontinuation of these compounds, and interindividually to subjects without treatment or receiving other drugs." | 3.70 | Refractory idiopathic absence status epilepticus: A probable paradoxical effect of phenytoin and carbamazepine. ( Osorio, I; Peltzer, JN; Reed, RC, 2000) |
| "The effect of nimodipine alone and in combination with diazepam or phenytoin was tested in the electroshock-induced mouse model of status epilepticus." | 3.70 | Anticonvulsant effect of nimodipine alone and in combination with diazepam and phenytoin in a mouse model of status epilepticus. ( Khosla, P; Pandhi, P, 2000) |
| "Six hundred and ninety-four members of the Intensive Care Society working in the UK were surveyed by postal questionnaire between May and November 1993 to determine their management of convulsive status epilepticus resistant to initial therapy with intravenous diazepam and phenytoin." | 3.69 | The intensive care treatment of convulsive status epilepticus in the UK. Results of a national survey and recommendations. ( Shorvon, SD; Smith, SJ; Walker, MC, 1995) |
| "Status epilepticus was induced in rats by injecting a combination of dibutyryl-cAMP (db-cAMP) and ethylenediaminetetraacetic acid (EDTA) into the amygdala (AM), and the effect of phenytoin (PHT), entrapped in liposomes (PHT-L) and given intravenously at 40 mg/kg, on the spiking activity of the AM epileptogenic focus was examined." | 3.69 | Liposome-entrapped phenytoin locally suppresses amygdaloid epileptogenic focus created by db-cAMP/EDTA in rats. ( Ariga, K; Iwata, Y; Kurokouchi, A; Mori, N; Osonoe, K; Saitoh, H; Suzuki, K, 1995) |
| "A 19-year-old woman presented with status epilepticus and ventricular dysrhythmias less than one hour after ingesting 5,000 mg dimenhydrinate (Dramamine)." | 3.68 | Fatality secondary to massive overdose of dimenhydrinate. ( McDonnell, KP; Winn, RE, 1993) |
| "Four-year-old, 20-kg girl, diagnosed with idiopathic tonic-clonic epilepsy, who developed AHS to phenobarbital and phenytoin and status epilepticus unresponsive to lorazepam." | 3.68 | Diazepam by continuous intravenous infusion for status epilepticus in anticonvulsant hypersensitivity syndrome. ( Bertz, RJ; Howrie, DL, 1993) |
| "The pharmacokinetic parameters controlling paraldehyde elimination were determined in nine infants infused with paraldehyde at the rate of 150 mg/kg/hr in a 5% solution in 5% dextrose for the treatment of status epilepticus." | 3.67 | Pharmacokinetics of paraldehyde disposition in the neonate. ( Boutwell, WC; Gessner, PK; Giacoia, GP; Zaleska, MM, 1984) |
| "Intravenous phenytoin, phenobarbital, and paraldehyde are effective and safe for the treatment of acute seizures such as status epilepticus." | 3.67 | Pharmacokinetics and clinical use of parenteral phenytoin, phenobarbital, and paraldehyde. ( Ramsay, RE, 1989) |
| "The drugs currently used in the emergency management of seizures are chiefly phenytoin, phenobarbital, diazepam, lorazepam, and paraldehyde." | 3.67 | Emergency management of seizures: an overview. ( Uthman, BM; Wilder, BJ, 1989) |
| "Three patients with EEG documented ictal catatonia, a nonconvulsive status epilepticus, who responded dramatically to intravenous phenytoin are described." | 3.67 | Ictal catatonia as a manifestation of nonconvulsive status epilepticus. ( Lim, J; Schraeder, P; Wheeler, S; Yagnik, P, 1986) |
| " The authors describe the case of a child with status epilepticus in whom phenytoin was administered via the intraosseous route, and seizure resolution and therapeutic serum levels were achieved." | 3.67 | Intraosseous infusion of phenytoin. ( Berens, RJ; Glaeser, PW; Losek, JD; Walsh-Kelly, CM, 1986) |
| "Twenty-two patients with partial status epilepticus were treated with phenytoin (DPH) intravenously (mean daily dose: 18,6 +/- 7,3 mg/kg)." | 3.66 | [Use of intravenous phenytoin in treatment of partial status epilepticus (author's transl)]. ( Chauplannaz, G; Courjon, J; Ferry, S; Mauguière, F, 1981) |
| "The treatment of status epilepticus can be improved by using recent developments in the pharmacokinetics and method of intravenous (IV) administration of phenytoin sodium." | 3.66 | Status epilepticus. The role of intravenous phenytoin. ( Cloyd, JC; Gumnit, RJ; McLain, LW, 1980) |
| "A 71-year-old man had status epilepticus and was treated with phenytoin (Dilantin) sodium." | 3.66 | Fatal benign phenytoin lymphadenopathy. ( Aguilar, JC; McCarthy, LJ; Ransburg, R, 1979) |
| " The treatment of status epilepticus with intravenous phenytoin is effective." | 3.66 | Epilepsy and pregnancy. ( Bruni, J; Willmore, LJ, 1979) |
| "Fifteen infants and children were treated with phenytoin for status epilepticus." | 3.65 | An effective dose schedule for phenytoin treatment of status epilepticus in infancy and childhood. ( Albani, M, 1977) |
| "Diazepam was initially administered, followed intravenously by FPHT at 22." | 3.30 | Levetiracetam versus fosphenytoin as a second-line treatment after diazepam for adult convulsive status epilepticus: a multicentre non-inferiority randomised control trial. ( Asami, M; Egawa, S; Fukuda, Y; Hoshiyama, E; Inoue, Y; Ishikawa, E; Kaneko, J; Kimura, A; Kondo, Y; Maruo, K; Marushima, A; Matsumaru, Y; Mochizuki, M; Nakamoto, H; Nakamura, K; Takahashi, Y; Uchida, M; Unemoto, K; Yamada, T; Yonekawa, C, 2023) |
| "Levetiracetam reportedly has similar efficacy and higher safety for SE; however, evidence to support its use for adult SE is lacking." | 3.01 | Levetiracetam versus fosphenytoin as a second-line treatment after diazepam for status epilepticus: study protocol for a multicenter non-inferiority designed randomized control trial. ( Asami, M; Egawa, S; Hoshiyama, E; Inoue, Y; Kaneko, J; Kimura, A; Kondo, Y; Maruo, K; Marushima, A; Nakamura, K; Takahashi, Y; Yamada, T; Yonekawa, C, 2021) |
| "IV phenytoin is an established treatment of SE, but its alkaline aqueous vehicle is associated with dermatologic irritation and systemic complications when rapidly infused." | 2.82 | A critical review of fosphenytoin sodium injection for the treatment of status epilepticus in adults and children. ( Clay, JL; Fountain, NB, 2022) |
| "Current treatment of human status epilepticus (SE) relies on drugs developed for chronic treatment of epilepsy." | 2.76 | Canine status epilepticus: a translational platform for human therapeutic trials. ( Cloyd, JC; Coles, LD; Craft, EM; Leppik, IE; Patterson, EN, 2011) |
| "Phenytoin has traditionally been considered the second-line drug of first choice after failure of first-line treatment using benzodiazepines." | 2.72 | Comparison of the efficacy and safety of levetiracetam and phenytoin in the treatment of established status epilepticus: A systematic review and meta-analysis. ( Cui, XH; Dong, XZ; Liu, JM; Liu, WN; Yang, L; Zhang, L, 2021) |
| "Midazolam was given 0." | 2.70 | Eight-year study of childhood status epilepticus: midazolam infusion in management and outcome. ( Al Riyami, K; Chacko, A; Javed, H; Koul, R, 2002) |
| "To determine the adequacy of seizure control and the adverse effects of administering an IV loading dose of phenytoin by constant infusion pump." | 2.67 | Phenytoin administration by constant intravenous infusion: selective rates of administration. ( Cline, D; Donovan, PJ, 1991) |
| "Dogs with seizure disorders have a decreased lifespan compared to the general population, and epileptic dogs with SE have a significantly abbreviated lifespan compared to epileptics that do not experience SE." | 2.55 | Status epilepticus in dogs and cats, part 2: treatment, monitoring, and prognosis. ( Blades Golubovic, S; Rossmeisl, JH, 2017) |
| "How aggressively these seizures should be treated is unclear." | 2.52 | Lacosamide in status epilepticus: Update on the TRENdS study. ( Husain, AM, 2015) |
| "Status epilepticus is defined as epileptic seizure with the duration for over 30 min or clustered seizure without complete recovery of consciousness for 30 min or more." | 2.50 | [Treatment of status epilepticus]. ( Yamanouchi, H, 2014) |
| "Diazepam gel was better than placebo gel in reducing the risk of non-cessation of seizures (RR 0." | 2.50 | Anticonvulsant therapy for status epilepticus. ( Al-Roomi, K; Krishnan, PR; Prasad, M; Sequeira, R, 2014) |
| "Refractory status epilepticus is defined as ongoing seizures failing to respond to first- and second-line anticonvulsant drug therapy and carries a high morbidity and mortality." | 2.50 | Neurocritical care: status epilepticus review. ( Al-Mufti, F; Claassen, J, 2014) |
| "Acute seizure and status epilepticus constitute one of the major medical emergencies in children." | 2.48 | Management of acute seizure and status epilepticus in pediatric emergency. ( Sasidaran, K; Singhi, P; Singhi, S, 2012) |
| "Current thinking about the acute treatment of status epilepticus (SE) emphasizes a more aggressive clinical approach to this common life-threatening neurologic emergency." | 2.45 | Emergency treatment of status epilepticus: current thinking. ( Millikan, D; Rice, B; Silbergleit, R, 2009) |
| " For each class, the dosing scheme and practical issues related to administration are described, based on evidence when available in the literature." | 2.45 | [Drugs for status epilepticus treatment]. ( Mazoit, JX; Navarro, V, 2009) |
| "Febrile seizures and epilepsies are common causes of CSE in infants and young children in Japan, followed by benign infantile convulsions (BIC), convulsions with gastroenteritis (CwG), and acute encephalitis with refractory CSE and intractable epilepsy (AECSEE), which are familiar disorders in Japan." | 2.44 | Treatment of convulsive status epilepticus in infants and young children in Japan. ( Sugai, K, 2007) |
| "Status epilepticus is a neurologic emergency associated with high mortality and long-term disability." | 2.42 | New management strategies in the treatment of status epilepticus. ( Manno, EM, 2003) |
| "Status epilepticus is a serious medical emergency that requires prompt and appropriate intervention." | 2.41 | Status epilepticus. ( Fiallos, MR; Hanhan, UA; Orlowski, JP, 2001) |
| "Nonconvulsive status epilepticus is being considered and recognized more often, including in ambulatory patients with a confusional state, after convulsive status epilepticus, and in critically ill patients." | 2.41 | The current state of treatment of status epilepticus. ( Claassen, J; Hirsch, LJ, 2002) |
| "Consequently, interventions to prevent seizures early in the course of a seizures disorder do not alter the natural history of seizure disorders with respect to whether remission will occur in the long term." | 2.40 | Do seizures beget seizures? An assessment of the clinical evidence in humans. ( Berg, AT; Shinnar, S, 1997) |
| "Seizures are commonly encountered in patients who do not have epilepsy." | 2.40 | Medical causes of seizures. ( Delanty, N; French, JA; Vaughan, CJ, 1998) |
| "Once SE is controlled, prevention of seizure recurrence should be individualized to each patient." | 2.40 | Management approaches to prolonged seizures and status epilepticus. ( Bleck, TP, 1999) |
| "Sequelae and risk for recurrence of SE are primarily related to the underlying cause." | 2.39 | Status epilepticus and acute repetitive seizures in children, adolescents, and young adults: etiology, outcome, and treatment. ( Mitchell, WG, 1996) |
| "Fosphenytoin is a water-soluble disodium phosphate ester of phenytoin that is converted in plasma to phenytoin." | 2.39 | Intravenous administration of fosphenytoin: options for the management of seizures. ( DeToledo, J; Ramsay, RE, 1996) |
| "Convulsive status epilepticus is an emergency that is associated with high morbidity and mortality." | 2.38 | Treatment of convulsive status epilepticus. Recommendations of the Epilepsy Foundation of America's Working Group on Status Epilepticus. ( , 1993) |
| " In addition to physiologic factors, such as blood pressure and cerebral blood flow, pharmacokinetic principles, including half-life, distribution, elimination, and volume of distribution (with special regard to an agent's lipid-solubility rating), should be applied." | 2.38 | The pharmacokinetics of agents used to treat status epilepticus. ( Browne, TR, 1990) |
| "Finally, seizure-like nonepileptic disorders were reviewed and differential diagnostic points highlighted." | 2.36 | Seizures and seizure-like states in the child: an approach to emergency management. ( Oppenheimer, EY; Rosman, NP, 1983) |
| "Drug treatment of status epilepticus is reviewed." | 2.36 | Drug therapy reviews: drug therapy of status epilepticus. ( Browne, TR, 1978) |
| "Midazolam has become the preferred benzodiazepine in pre- and in-hospital settings, both in children and adults." | 1.91 | Trends and Differences in Status Epilepticus Treatment of Children and Adults Over 10 Years: A Comparative Study of Medical Records (2012-2021) from a University Hospital in Germany. ( Czabanka, M; Kieslich, M; Merker, M; Purwien, L; Ronellenfitsch, MW; Rosenow, F; Schubert-Bast, S; Strzelczyk, A; Willems, LM, 2023) |
| "Midazolam was the first medication administered in 87/100 (87%) instances, mean dose of 0." | 1.72 | Status Epilepticus Australasian Registry for Children: A pilot prospective, observational, cohort study of paediatric status epilepticus. ( Babl, FE; Borland, ML; Dalziel, SR; Emeto, TI; Furyk, JS; George, S; Hearps, SJ; O'Brien, S; Phillips, N; Riney, K; Watt, K; Wilson, C, 2022) |
| "The rates of cessation of seizure and prevention of seizure recurrence for 24 h were 84% for phenytoin and 78." | 1.72 | Efficacy of intravenous levetiracetam versus phenytoin in convulsive status epilepticus and acute repetitive seizures in children. ( Akın, Y; Çağ, Y; Köle, MT; Sager, SG; Zeynel, H, 2022) |
| "Propofol was effective, exhibiting high efficacy and potency for terminating seizure activity quickly in pediatric and adult animals, suggesting it may be an effective anticonvulsant for NA-induced seizures in pediatric populations." | 1.56 | Evaluation of fosphenytoin, levetiracetam, and propofol as treatments for nerve agent-induced seizures in pediatric and adult rats. ( Ardinger, CE; Berger, KE; Dunn, EN; Haines, KM; Jackson Piercy, CE; Lee-Stubbs, RB; Matson, LM; McCarren, HS; McDonough, JH; Miller-Smith, SM; Whitten, KA, 2020) |
| "To identify factors associated with low benzodiazepine (BZD) dosing in patients with refractory status epilepticus (RSE) and to assess the impact of BZD treatment variability on seizure cessation." | 1.56 | First-line medication dosing in pediatric refractory status epilepticus. ( Abend, NS; Amengual-Gual, M; Anderson, A; Arya, R; Brenton, JN; Carpenter, JL; Chapman, K; Clark, J; Farias-Moeller, R; Gaillard, WD; Gaínza-Lein, M; Glauser, T; Goldstein, JL; Goodkin, HP; Guerriero, RM; Kapur, K; Lai, YC; Loddenkemper, T; McDonough, TL; Mikati, MA; Morgan, LA; Novotny, EJ; Ostendorf, AP; Payne, ET; Peariso, K; Piantino, J; Riviello, JJ; Sannagowdara, K; Tasker, RC; Tchapyjnikov, D; Topjian, A; Vasquez, A; Wainwright, MS; Wilfong, A; Williams, K, 2020) |
| " The objective of this study was to review the critical care management of patients with SE focusing on antiepileptic drugs (AEDs) as well as to determine the optimal dosing strategies of phenytoin (PHT) and predictors of its effectiveness." | 1.51 | Critical Care Management of Status Epilepticus at a Tertiary Care University Hospital. ( Ahmed, SN; Lindqvist, T; Mahmoud, SH; Marette, V, 2019) |
| " Criterion 2=the last drug introduced into the antiepileptic therapy within 72h before the cessation of SE and without changes in dosage or number of the co-medication." | 1.46 | The efficacy of different kinds of intravenously applied antiepileptic drugs in the treatment of status epilepticus. How can it be determined? ( Redecker, J; Rösche, J; Wittstock, M, 2017) |
| "Benzodiazepines are used as first-line treatments for status epilepticus." | 1.46 | Efficacy of levetiracetam versus fosphenytoin for the recurrence of seizures after status epilepticus. ( Daidoji, H; Doi, K; Hashimoto, H; Hiruma, T; Inokuchi, R; Morimura, N; Nakamura, K; Naraba, H; Sonoo, T; Tokunaga, K, 2017) |
| "Focal electrographic seizures in this model are resistant to several major antiepileptic drugs." | 1.42 | The AMPA receptor antagonist NBQX exerts anti-seizure but not antiepileptogenic effects in the intrahippocampal kainate mouse model of mesial temporal lobe epilepsy. ( Bankstahl, M; Klein, S; Löscher, W; Römermann, K; Twele, F, 2015) |
| " Adverse effects of fosphenytoin may include: cardiovascular events (hypotension, arrhythmias), paresthesias or pruritus or some central events - somnolence, headache, dizziness, nystagmus and ataxia." | 1.42 | The safety and efficacy of fosphenytoin for the treatment of status epilepticus. ( Borowicz, KK; Czuczwar, SJ; Popławska, M, 2015) |
| "Gum hypertrophy is a well-known and important adverse effect of phenytoin therapy in a neurosurgical patient." | 1.42 | A well known and important adverse effect of phenytoin in a neurosurgical patient. ( Goyal, K; Kumar, N; Saxena, A; Tomar, GS, 2015) |
| "Phenytoin has complex pharmacokinetics." | 1.40 | Phenytoin dosing and serum concentrations in paediatric patients requiring 20 mg/kg intravenous loading. ( Appleton, R; Hawcutt, DB; Newland, P; Piper, JD; Spinty, S; Verghese, GK, 2014) |
| " This case highlights that nutmeg, a spice, can cause serious toxic effects like status epilepticus." | 1.40 | Myristicin and phenytoin toxicity in an infant. ( David, HS; Rajavelu, KK; Sampath, S; Sivathanu, S, 2014) |
| "Phenytoin was the most prescribed second-line treatment (41%) but statistically significantly least effective (22% versus 86% seizure cessation, p<0." | 1.40 | A retrospective observational study of current treatment for generalized convulsive status epilepticus. ( Fountain, NB; Langer, JE, 2014) |
| "No change in the percentage of optimal phenytoin loading doses in the ED was observed after implementation of a combined pharmacist- and physician- dosing program." | 1.40 | Impact of a phenytoin loading dose program in the emergency department. ( Brancaccio, A; Delgado, G; Giuliano, C; McNorton, K, 2014) |
| "53." | 1.39 | Considerations in prophylaxis for tumor-associated epilepsy: prevention of status epilepticus and tolerability of newer generation AEDs. ( Buniak, L; Henry, JC; Mohile, N; Wang, H; Wychowski, T, 2013) |
| "Pentobarbital was chosen later in the therapy for all ages." | 1.39 | Treatment of status epilepticus: an international survey of experts. ( Alldredge, B; Bell, R; Bleck, TP; Brophy, GM; Claassen, J; Glauser, T; LaRoche, SM; Riviello, JJ; Shutter, L; Sperling, MR; Treiman, DM; Vespa, PM, 2013) |
| "Phenytoin was used in 56 patients (22%) with the majority (n= 43) receiving intravenous phenytoin." | 1.38 | Seizure management at Auckland City Hospital Emergency Department between July and December 2009: time for a change? ( Bergin, P; Jones, P; Rosemergy, I; Walker, E, 2012) |
| "Status epilepticus is a common neurological emergency in childhood and associated with significant morbidity and mortality." | 1.37 | Status epilepticus. ( Gulati, S; Lodha, R; Raj, D, 2011) |
| "Subacute encephalopathy with seizures in chronic alcoholism (SESA) was first described in 1981 by Niedermeyer who reported alcoholic patients presenting with confusion, seizures and focal neurological deficits and is quite distinct from patients presenting with typical alcohol withdrawal seizures." | 1.37 | Subacute encephalopathy and seizures in alcoholics (SESA) presenting with non-convulsive status epilepticus. ( LaRoche, SM; Shivdat-Nanhoe, R, 2011) |
| " Our findings strongly suggest that CoQ10 can be considered a safe and effective adjuvant to phenytoin therapy in epilepsy both to ameliorate seizure severity and to protect against seizure-induced oxidative damage by reducing the cognitive impairment and oxidative stress associated with chronic use of phenytoin." | 1.37 | Coenzyme Q10 enhances the anticonvulsant effect of phenytoin in pilocarpine-induced seizures in rats and ameliorates phenytoin-induced cognitive impairment and oxidative stress. ( Tawfik, MK, 2011) |
| "Epileptic seizures drive expression of the blood-brain barrier efflux transporter P-glycoprotein via a glutamate/cyclooxygenase-2 mediated signalling pathway." | 1.36 | COX-2 inhibition controls P-glycoprotein expression and promotes brain delivery of phenytoin in chronic epileptic rats. ( Aronica, E; Edelbroek, PM; Gorter, JA; Holtman, L; Pekcec, A; Potschka, H; Schlichtiger, J; van Vliet, EA; Zibell, G, 2010) |
| "Of patients with status epilepticus and central nervous system infection, 24." | 1.35 | Status epilepticus in central nervous system infections: an experience from a developing country. ( Kalita, J; Misra, UK; Nair, PP, 2008) |
| " Because it was known from the literature that the half-life of midazolam can increase at high dosage, the kinetics of midazolam (MDZ), 1'-hydroxymidazolam, and 4-hydroxymidazolam were assessed at steady state (dosage 1 mg/min) and after stopping treatment." | 1.35 | Pharmacokinetics of midazolam and metabolites in a patient with refractory status epilepticus treated with extraordinary doses of midazolam. ( Bodmer, M; Grignaschi, N; Haschke, M; Krähenbühl, S; Kummer, O; Link, B; Ruegg, S, 2008) |
| "Cranial MRI revealed a right frontal cavernous hemangioma." | 1.35 | Refractory status epilepticus during pregnancy secondary to cavernous angioma. ( Aladdin, Y; Gross, DW, 2008) |
| "Guillain-Barré syndrome may result in hypertensive encephalopathy that can manifest as status epilepticus before the onset of motor symptoms." | 1.34 | Status epilepticus secondary to hypertensive encephalopathy as the presenting manifestation of Guillain-Barré syndrome. ( Abend, NS; Bonnemann, CG; Licht, DJ, 2007) |
| "Diazepam was administered as the first-line drug on 157 of 177 occasions (88." | 1.33 | [Choice and administration sequence of antiepileptic agents for status epilepticus and frequent seizures in children]. ( Eto, Y; Hamano, S; Hayakawa, M; Kikuchi, K; Minamitani, M; Sugiyama, N; Tanaka, M; Yamashita, S; Yoshinari, S, 2005) |
| "The status epilepticus was resolved after antiepileptic therapy (phenytoin sodium) and treatment for hepatic encephalopathy (Branched chain amino acids)." | 1.33 | Hepatic encephalopathy with status epileptics: a case report. ( Hamagami, H; Ichinose, M; Kida, Y; Tanaka, H; Tsuji, T; Ueda, H, 2006) |
| "Generalized tonic-clonic seizure was the most common type." | 1.33 | Seizure presenting to the emergency department, Srinagarind Hospital. ( Aaauevitchayapat, N; Arunpongpaisal, S; Chaiyakum, A; Jitpimolmard, S; Paowana, W; Phunikhom, K; Phuttharak, W; Saengsuwan, J; Sawanyawisuth, K; Tiamkao, S; Vannaprasaht, S, 2006) |
| "fosphenytoin, n = 6), and were not statistically different for the three routes of administration." | 1.32 | Pharmacokinetics and clinical effects of phenytoin and fosphenytoin in children with severe malaria and status epilepticus. ( Edwards, G; Kokwaro, GO; Muchohi, SN; Newton, CR; Ogutu, BR; Otieno, GO; Watkins, WM, 2003) |
| "Phenytoin levels were assessed in relation to the type of feeding and serum albumin levels." | 1.31 | Problems with phenytoin administration in neurology/neurosurgery ITU patients receiving enteral feeding. ( Kitchen, D; Smith, D, 2001) |
| "Phenobarbital and MK-801 were superior to phenytoin in suppressing SE and in preventing chronic epilepsy." | 1.31 | Phenobarbital and MK-801, but not phenytoin, improve the long-term outcome of status epilepticus. ( Bertram, EH; Prasad, A; Williamson, JM, 2002) |
| "All children who presented in a convulsion, including convulsive status epilepticus, to the accident and emergency department over a 12-month period and who required treatment, were reviewed retrospectively to identify the effectiveness and safety of a specific treatment protocol." | 1.30 | Children presenting with convulsions (including status epilepticus) to a paediatric accident and emergency department: an audit of a treatment protocol. ( Appleton, RE; Garr, RE; Molyneux, EM; Robson, WJ, 1999) |
| "When phenytoin was discontinued, valproate levels increased, and he progressively improved." | 1.30 | Exceptionally long absence status: multifactorial etiology, drug interactions and complications. ( Andermann, F; Bastos, A; D'Agostino, MD; Dubeau, F; Fedi, M, 1999) |
| "Status epilepticus is one of the most frequent neurological emergencies in the intensive care unit." | 1.29 | Propofol in the management of refractory status epilepticus: a case report. ( Borgeat, A; Jallon, P; Suter, PM; Wilder-Smith, OH, 1994) |
| "Status epilepticus was induced in rats with actively epileptogenic cortical cobalt lesions by administration of homocysteine thiolactone." | 1.29 | Lamotrigine vs. phenytoin for treatment of status epilepticus: comparison in an experimental model. ( Hyun, B; Jaing, Q; Treiman, DM; Walton, NY, 1996) |
| "Status epilepticus was induced by injection of homocysteine thiolactone to rats with epileptogenic cortical cobalt lesions." | 1.28 | Efficacy of ACC-9653 (a phenytoin prodrug) in experimental status epilepticus in the rat. ( Treiman, DM; Walton, NY, 1990) |
| " Depending on its pharmacokinetic parameters, each drug effect has a different onset, intensity, and time course." | 1.27 | Clinical pharmacokinetics of drugs used in the treatment of status epilepticus. ( Baars, AM; van der Dries, A; van der Kleijn, E; Vree, TB, 1983) |
| "Only when the epilepsy is uncontrolled despite high plasma concentrations which cannot be raised because of side effects, a second drug should be given." | 1.27 | [Pharmacotherapy of epilepsy--current problems and controversies]. ( Schmidt, D, 1983) |
| "Status epilepticus is a medical emergency." | 1.27 | Status epilepticus. ( Hall, S, 1983) |
| "Status epilepticus is a medical emergency requiring immediate treatment." | 1.27 | Treatment of status epilepticus in adults. ( Bruni, J, 1983) |
| "Status epilepticus is a medical emergency requiring immediate treatment." | 1.27 | Treatment of status epilepticus in children. ( Camfield, PR, 1983) |
| " By means of Monte Carlo simulations an optimal dosing scheme for phenytoin loading has been calculated." | 1.27 | Intravenous phenytoin loading in patients after neurosurgery and in status epilepticus. A population pharmacokinetic study. ( Aarons, L; Gratzl, O; Landolt, H; Maitre, P; Uematsu, T; Vozeh, S, 1988) |
| "Status epilepticus is an acute, life-threatening potential complication of pregnancy in the epileptic patient." | 1.27 | Refractory status epilepticus in pregnancy. A case report. ( Field, DR; Grunert, GM, 1985) |
| "Convulsive status epilepticus is a life-threatening disorder." | 1.27 | Status epilepticus. ( Leppik, IE, 1985) |
| "Status epilepticus is a serious emergency that rarely complicates the management of the pregnant patient with seizure disorders." | 1.27 | Status epilepticus in pregnancy. A case report. ( Fougner, AC; Seltzer, VL; Wilson, SJ, 1985) |
| "Status epilepticus is a serious medical emergency requiring immediate and rational therapy." | 1.27 | Status epilepticus. ( Freeman, JM; Vining, EP, 1985) |
| "Most patients had had more than three seizures or were in status epilepticus." | 1.26 | Intravenous phenytoin in acute treatment of seizures. ( Anderson, CB; Cranford, RE; Kostick, B; Leppik, IE; Patrick, B, 1979) |
| "The possibility of treating status epilepticus by altering the orally administered therapy and leaving parenteral therapy for such cases with progressive impairment of consciousness and/or neuvoregetative disorders was indicated." | 1.26 | [Status epilepticus in Lennox-Gastaut syndrome; therapeutic aspects]. ( Lison, MP; Speciali, JG, 1977) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 90 (23.62) | 18.7374 |
| 1990's | 63 (16.54) | 18.2507 |
| 2000's | 86 (22.57) | 29.6817 |
| 2010's | 87 (22.83) | 24.3611 |
| 2020's | 55 (14.44) | 2.80 |
| Authors | Studies |
|---|---|
| Dawidowski, M | 1 |
| Wilczek, M | 1 |
| Kubica, K | 1 |
| Skolmowski, M | 1 |
| Turło, J | 1 |
| Lamie, PF | 1 |
| El-Kalaawy, AM | 1 |
| Abdel Latif, NS | 1 |
| Rashed, LA | 1 |
| Philoppes, JN | 1 |
| Clay, JL | 1 |
| Fountain, NB | 5 |
| Roberti, R | 2 |
| Rocca, M | 1 |
| Iannone, LF | 2 |
| Gasparini, S | 2 |
| Pascarella, A | 1 |
| Neri, S | 1 |
| Cianci, V | 2 |
| Bilo, L | 1 |
| Russo, E | 2 |
| Quaresima, P | 1 |
| Aguglia, U | 2 |
| Di Carlo, C | 1 |
| Ferlazzo, E | 2 |
| Furyk, JS | 1 |
| George, S | 3 |
| Phillips, N | 3 |
| Emeto, TI | 1 |
| Watt, K | 1 |
| O'Brien, S | 1 |
| Riney, K | 1 |
| Wilson, C | 1 |
| Hearps, SJ | 1 |
| Borland, ML | 2 |
| Dalziel, SR | 4 |
| Babl, FE | 5 |
| Köle, MT | 1 |
| Sager, SG | 1 |
| Zeynel, H | 1 |
| Çağ, Y | 1 |
| Akın, Y | 1 |
| Tyson, M | 1 |
| Trenear, R | 1 |
| Skellett, S | 1 |
| Maconochie, I | 1 |
| Mullen, N | 1 |
| AlMulihi, QA | 1 |
| AlMuhanna, FA | 1 |
| AlMuhanna, MA | 1 |
| AlSultan, EA | 1 |
| Coralic, Z | 1 |
| Kapur, J | 6 |
| Olson, KR | 1 |
| Chamberlain, JM | 5 |
| Overbeek, D | 1 |
| Silbergleit, R | 9 |
| Nakamura, K | 4 |
| Marushima, A | 2 |
| Takahashi, Y | 3 |
| Mochizuki, M | 1 |
| Kimura, A | 2 |
| Fukuda, Y | 1 |
| Asami, M | 2 |
| Nakamoto, H | 1 |
| Egawa, S | 2 |
| Kaneko, J | 2 |
| Unemoto, K | 1 |
| Kondo, Y | 2 |
| Yonekawa, C | 2 |
| Uchida, M | 1 |
| Hoshiyama, E | 2 |
| Yamada, T | 2 |
| Maruo, K | 2 |
| Ishikawa, E | 1 |
| Matsumaru, Y | 1 |
| Inoue, Y | 2 |
| Jain, P | 1 |
| Aneja, S | 1 |
| Cunningham, J | 1 |
| Arya, R | 2 |
| Sharma, S | 1 |
| Soto-Insuga, V | 1 |
| González-Alguacil, E | 1 |
| García-Peñas, JJ | 1 |
| Zographos, GA | 1 |
| Russ-Hall, SJ | 1 |
| Scheffer, IE | 1 |
| Rollo, E | 1 |
| Romozzi, M | 1 |
| Dono, F | 1 |
| Bernardo, D | 1 |
| Consoli, S | 1 |
| Anzellotti, F | 1 |
| Ricciardi, L | 1 |
| Paci, L | 1 |
| Sensi, SL | 1 |
| Della Marca, G | 1 |
| Servidei, S | 1 |
| Calabresi, P | 1 |
| Vollono, C | 1 |
| Iyer, AS | 1 |
| Purwien, L | 1 |
| Schubert-Bast, S | 1 |
| Kieslich, M | 1 |
| Ronellenfitsch, MW | 1 |
| Merker, M | 1 |
| Czabanka, M | 1 |
| Willems, LM | 1 |
| Rosenow, F | 2 |
| Strzelczyk, A | 1 |
| Mahmoud, SH | 1 |
| Marette, V | 1 |
| Lindqvist, T | 1 |
| Ahmed, SN | 1 |
| Hong, WP | 1 |
| Chen, TS | 1 |
| Huang, CW | 1 |
| Cook, R | 1 |
| Davidson, P | 1 |
| Martin, R | 1 |
| Elm, J | 4 |
| Barsan, W | 2 |
| Cloyd, J | 3 |
| Lowenstein, D | 3 |
| Shinnar, S | 6 |
| Conwit, R | 2 |
| Meinzer, C | 2 |
| Cock, H | 3 |
| Fountain, N | 2 |
| Connor, JT | 3 |
| Dalrymple, RA | 1 |
| Walters, E | 1 |
| Wurster Ovalle, V | 1 |
| Yin, S | 1 |
| Dribin, T | 1 |
| Le Coz, J | 1 |
| Chéron, G | 1 |
| Nabbout, R | 1 |
| Patteau, G | 1 |
| Heilbronner, C | 1 |
| Hubert, P | 1 |
| Renolleau, S | 1 |
| Oualha, M | 1 |
| Nalisetty, S | 1 |
| Kandasamy, S | 1 |
| Sridharan, B | 1 |
| Vijayakumar, V | 1 |
| Sangaralingam, T | 1 |
| Krishnamoorthi, N | 1 |
| Li, L | 1 |
| Zhang, Y | 1 |
| Jia, L | 1 |
| Jia, D | 1 |
| Faramand, A | 1 |
| Chong, W | 1 |
| Fang, Y | 1 |
| Ma, L | 1 |
| Fang, F | 1 |
| Anand, V | 1 |
| Chakrabarty, B | 1 |
| Kunju, PAM | 1 |
| Subir, HA | 1 |
| Srivastava, K | 1 |
| Bhartiya, S | 1 |
| Gavli, V | 1 |
| Patil, R | 1 |
| Rajadhyaksha, S | 1 |
| Vignesh, V | 1 |
| Rameshkumar, R | 1 |
| Mahadevan, S | 1 |
| Appleton, RE | 5 |
| Holsti, M | 1 |
| Babcock, L | 2 |
| Rogers, A | 1 |
| Bleck, TP | 5 |
| Underwood, E | 1 |
| Brigo, F | 5 |
| Del Giovane, C | 1 |
| Nardone, R | 3 |
| Trinka, E | 7 |
| Lattanzi, S | 2 |
| Dunn, EN | 1 |
| Matson, LM | 1 |
| Haines, KM | 1 |
| Whitten, KA | 1 |
| Lee-Stubbs, RB | 1 |
| Berger, KE | 1 |
| McCarren, HS | 1 |
| Ardinger, CE | 1 |
| Jackson Piercy, CE | 1 |
| Miller-Smith, SM | 1 |
| McDonough, JH | 2 |
| Lagae, L | 1 |
| Madaan, P | 1 |
| Sahu, JK | 1 |
| Sathe, AG | 2 |
| Elm, JJ | 4 |
| Cloyd, JC | 5 |
| Cock, HR | 3 |
| Lowenstein, DH | 3 |
| Conwit, RA | 1 |
| Coles, LD | 4 |
| Panda, PK | 2 |
| Sharawat, IK | 2 |
| Ohbe, H | 1 |
| Matsui, H | 1 |
| Naraba, H | 2 |
| Nakano, H | 1 |
| Fushimi, K | 1 |
| Yasunaga, H | 1 |
| Wu, K | 1 |
| Hirsch, LJ | 2 |
| Josephson, SA | 1 |
| Besli, GE | 1 |
| Yuksel Karatoprak, E | 1 |
| Yilmaz, S | 1 |
| DeMott, JM | 1 |
| Slocum, GW | 1 |
| Gottlieb, M | 2 |
| Peksa, GD | 1 |
| Roper, L | 6 |
| Lyttle, MD | 6 |
| Gamble, C | 6 |
| Humphreys, A | 6 |
| Messahel, S | 6 |
| Lee, ED | 3 |
| Noblet, J | 5 |
| Hickey, H | 6 |
| Rainford, N | 3 |
| Iyer, A | 6 |
| Appleton, R | 4 |
| Woolfall, K | 6 |
| Zimmern, V | 1 |
| Korff, C | 1 |
| Vasquez, A | 1 |
| Gaínza-Lein, M | 2 |
| Abend, NS | 2 |
| Amengual-Gual, M | 1 |
| Anderson, A | 1 |
| Brenton, JN | 1 |
| Carpenter, JL | 1 |
| Chapman, K | 1 |
| Clark, J | 1 |
| Farias-Moeller, R | 1 |
| Gaillard, WD | 1 |
| Glauser, T | 2 |
| Goldstein, JL | 1 |
| Goodkin, HP | 1 |
| Guerriero, RM | 1 |
| Kapur, K | 1 |
| Lai, YC | 1 |
| McDonough, TL | 1 |
| Mikati, MA | 1 |
| Morgan, LA | 1 |
| Novotny, EJ | 1 |
| Ostendorf, AP | 1 |
| Payne, ET | 1 |
| Peariso, K | 1 |
| Piantino, J | 1 |
| Riviello, JJ | 2 |
| Sannagowdara, K | 1 |
| Tasker, RC | 1 |
| Tchapyjnikov, D | 1 |
| Topjian, A | 1 |
| Wainwright, MS | 1 |
| Wilfong, A | 1 |
| Williams, K | 1 |
| Loddenkemper, T | 2 |
| Xue, T | 1 |
| Wei, L | 1 |
| Shen, X | 1 |
| Wang, Z | 3 |
| Chen, Z | 2 |
| Rainford, NE | 1 |
| Lee, E | 2 |
| Potter, S | 2 |
| Tate, P | 2 |
| Al Najjar, N | 1 |
| Evans, V | 2 |
| Mastroianni, G | 1 |
| Ascoli, M | 1 |
| De Sarro, G | 1 |
| Gambardella, A | 1 |
| Labate, A | 1 |
| Mishra, U | 1 |
| Ivaturi, V | 1 |
| Brundage, RC | 1 |
| Klowak, JA | 1 |
| Hewitt, M | 1 |
| Catenacci, V | 1 |
| Duffett, M | 1 |
| Rochwerg, B | 1 |
| Jones, K | 1 |
| Choong, K | 1 |
| Shi, R | 1 |
| Yin, HQ | 1 |
| Wang, ZZ | 1 |
| De Liso, A | 1 |
| Ricci, L | 1 |
| Bravi, MC | 1 |
| Pezzella, FR | 1 |
| Anticoli, S | 1 |
| Panda, P | 1 |
| Dawman, L | 1 |
| Long, B | 1 |
| Yang, L | 1 |
| Dong, XZ | 1 |
| Cui, XH | 1 |
| Liu, JM | 1 |
| Liu, WN | 1 |
| Zhang, L | 1 |
| Angurana, SK | 1 |
| Suthar, R | 1 |
| Idota, N | 1 |
| Shintani-Ishida, K | 1 |
| Ichioka, H | 1 |
| Kondou, H | 1 |
| Ikegaya, H | 1 |
| Wabl, R | 1 |
| Terman, SW | 1 |
| Kwok, M | 1 |
| Chamberlain, J | 2 |
| Hill, CE | 1 |
| Feng, Y | 1 |
| Chen, Y | 1 |
| Jia, Y | 1 |
| Wang, X | 2 |
| Jiang, L | 1 |
| Ai, C | 1 |
| Li, W | 1 |
| Liu, Y | 1 |
| Blades Golubovic, S | 1 |
| Rossmeisl, JH | 1 |
| Redecker, J | 1 |
| Wittstock, M | 1 |
| Rösche, J | 1 |
| Niquet, J | 1 |
| Baldwin, R | 1 |
| Norman, K | 1 |
| Suchomelova, L | 1 |
| Lumley, L | 1 |
| Wasterlain, CG | 3 |
| Gujjar, AR | 1 |
| Nandhagopal, R | 1 |
| Jacob, PC | 1 |
| Al-Hashim, A | 1 |
| Al-Amrani, K | 1 |
| Ganguly, SS | 1 |
| Al-Asmi, A | 1 |
| Bacon, NEA | 1 |
| Ryan, M | 1 |
| Inokuchi, R | 1 |
| Daidoji, H | 1 |
| Sonoo, T | 1 |
| Hashimoto, H | 1 |
| Tokunaga, K | 1 |
| Hiruma, T | 1 |
| Doi, K | 1 |
| Morimura, N | 1 |
| Furyk, J | 2 |
| Bonisch, M | 2 |
| Oakley, E | 2 |
| Borland, M | 1 |
| Neutze, J | 2 |
| Donath, S | 2 |
| Sharpe, C | 2 |
| Harvey, S | 1 |
| Davidson, A | 2 |
| Craig, S | 2 |
| Rao, A | 2 |
| Cheng, N | 2 |
| Zhang, M | 2 |
| Sinn, K | 1 |
| Kochar, A | 2 |
| Brabyn, C | 2 |
| Bragazzi, NL | 1 |
| Douglass, C | 1 |
| Gillinder, L | 1 |
| Lehn, A | 1 |
| Brown, H | 1 |
| Dionisio, S | 1 |
| Tchekalarova, J | 1 |
| da Conceição Machado, K | 1 |
| Gomes Júnior, AL | 1 |
| de Carvalho Melo Cavalcante, AA | 1 |
| Momchilova, A | 1 |
| Tzoneva, R | 1 |
| Zaccara, G | 1 |
| Giorgi, FS | 1 |
| Amantini, A | 1 |
| Giannasi, G | 1 |
| Campostrini, R | 1 |
| Giovannelli, F | 1 |
| Paganini, M | 1 |
| Nazerian, P | 1 |
| Amiri-Nikpour, MR | 1 |
| Nazarbaghi, S | 1 |
| Eftekhari, P | 1 |
| Mohammadi, S | 1 |
| Dindarian, S | 1 |
| Bagheri, M | 1 |
| Mohammadi, H | 1 |
| Nishiyama, M | 1 |
| Nagase, H | 1 |
| Tomioka, K | 1 |
| Tanaka, T | 2 |
| Yamaguchi, H | 1 |
| Ishida, Y | 1 |
| Toyoshima, D | 1 |
| Fujita, K | 1 |
| Maruyama, A | 1 |
| Kurosawa, H | 1 |
| Uetani, Y | 1 |
| Nozu, K | 1 |
| Taniguchi-Ikeda, M | 1 |
| Morioka, I | 1 |
| Takada, S | 1 |
| Iijima, K | 1 |
| Francis, KL | 1 |
| Harvey, AS | 1 |
| Rainford, NEA | 1 |
| Sánchez Fernández, I | 1 |
| Lamb, N | 1 |
| Tuan Huynh, NN | 1 |
| Hiroyoshi, A | 1 |
| Shozo, N | 1 |
| Takashi, T | 1 |
| Hideo, T | 1 |
| Akira, M | 1 |
| Prasad, M | 2 |
| Shenton, P | 1 |
| Dietz, S | 1 |
| Saroha, V | 1 |
| Whitehouse, WP | 1 |
| Burns, JM | 1 |
| Marino, A | 1 |
| Manno, M | 1 |
| Rhyee, S | 1 |
| Boyer, EW | 1 |
| Broglio, KR | 1 |
| Tiamkao, S | 6 |
| Sawanyawisuth, K | 3 |
| Chancharoen, A | 1 |
| Kellinghaus, C | 2 |
| Berning, S | 1 |
| Stögbauer, F | 1 |
| Husain, AM | 2 |
| Bleck, T | 1 |
| Connor, J | 1 |
| Jones, E | 1 |
| Treiman, D | 1 |
| Wychowski, T | 1 |
| Wang, H | 1 |
| Buniak, L | 1 |
| Henry, JC | 1 |
| Mohile, N | 1 |
| Piper, JD | 1 |
| Hawcutt, DB | 1 |
| Verghese, GK | 1 |
| Spinty, S | 1 |
| Newland, P | 1 |
| Une, H | 1 |
| Uehara, T | 1 |
| Tateishi, T | 1 |
| Shigetou, H | 1 |
| Oyagi, Y | 1 |
| Kira, J | 1 |
| Sivathanu, S | 1 |
| Sampath, S | 1 |
| David, HS | 1 |
| Rajavelu, KK | 1 |
| Yamanouchi, H | 1 |
| Verrotti, A | 1 |
| Sebastiani, M | 1 |
| Giordano, L | 1 |
| Striano, P | 1 |
| Belcastro, V | 1 |
| Franzoni, E | 1 |
| Parisi, P | 1 |
| Pruna, D | 1 |
| Spalice, A | 1 |
| Vignoli, A | 1 |
| Grosso, S | 1 |
| Langer, JE | 1 |
| Jain, RS | 1 |
| Nagpal, K | 1 |
| Kumar, S | 1 |
| Prakash, S | 1 |
| Handa, R | 1 |
| Krishnan, PR | 3 |
| Sequeira, R | 3 |
| Al-Roomi, K | 3 |
| Al-Mufti, F | 1 |
| Claassen, J | 3 |
| Boussadia, B | 1 |
| Ghosh, C | 1 |
| Plaud, C | 1 |
| Pascussi, JM | 1 |
| de Bock, F | 1 |
| Rousset, MC | 1 |
| Janigro, D | 1 |
| Marchi, N | 1 |
| Brancaccio, A | 1 |
| Giuliano, C | 1 |
| McNorton, K | 1 |
| Delgado, G | 1 |
| Twele, F | 1 |
| Bankstahl, M | 1 |
| Klein, S | 1 |
| Römermann, K | 1 |
| Löscher, W | 3 |
| Chakravarthi, S | 1 |
| Goyal, MK | 1 |
| Modi, M | 1 |
| Bhalla, A | 1 |
| Singh, P | 1 |
| Patterson, EE | 1 |
| Leppik, IE | 6 |
| Podell, M | 1 |
| Vite, CH | 1 |
| Bush, W | 1 |
| Mundlamuri, RC | 1 |
| Sinha, S | 1 |
| Subbakrishna, DK | 1 |
| Prathyusha, PV | 1 |
| Nagappa, M | 1 |
| Bindu, PS | 1 |
| Taly, AB | 1 |
| Umamaheswara Rao, GS | 1 |
| Satishchandra, P | 1 |
| Leclercq, K | 1 |
| Kaminski, RM | 1 |
| Popławska, M | 1 |
| Borowicz, KK | 1 |
| Czuczwar, SJ | 1 |
| Zeiler, FA | 1 |
| Zeiler, KJ | 1 |
| Teitelbaum, J | 1 |
| Gillman, LM | 1 |
| West, M | 1 |
| Kazina, CJ | 1 |
| Digby, G | 1 |
| Jalini, S | 1 |
| Taylor, S | 1 |
| Misra, UK | 3 |
| Kalita, J | 3 |
| Tomar, GS | 1 |
| Saxena, A | 1 |
| Kumar, N | 2 |
| Goyal, K | 1 |
| Lang, N | 1 |
| Rossetti, AO | 3 |
| Rüegg, S | 3 |
| Tilz, C | 1 |
| Unterberger, I | 1 |
| Uzelac, Z | 1 |
| Sonis, J | 1 |
| Borczuk, P | 1 |
| Ptak, T | 1 |
| Miller, ES | 1 |
| Bragazzi, N | 1 |
| Nair, PP | 1 |
| Bankstahl, JP | 1 |
| Gilad, R | 1 |
| Izkovitz, N | 1 |
| Dabby, R | 1 |
| Rapoport, A | 1 |
| Sadeh, M | 1 |
| Weller, B | 1 |
| Lampl, Y | 1 |
| Wanigasinghe, J | 1 |
| Liyanage, UA | 1 |
| Millikan, D | 1 |
| Rice, B | 1 |
| Navarro, V | 2 |
| Mazoit, JX | 1 |
| Miyahara, A | 1 |
| Saito, Y | 1 |
| Sugai, K | 2 |
| Nakagawa, E | 1 |
| Sakuma, H | 1 |
| Komaki, H | 1 |
| Sasaki, M | 1 |
| Sreenath, TG | 1 |
| Gupta, P | 1 |
| Sharma, KK | 1 |
| Krishnamurthy, S | 1 |
| Cunha, AO | 1 |
| Mortari, MR | 1 |
| Liberato, JL | 1 |
| dos Santos, WF | 1 |
| Wheless, JW | 1 |
| Turtzo, LC | 1 |
| Kleinman, JT | 1 |
| Llinas, RH | 1 |
| Miura, T | 1 |
| Kasai, H | 1 |
| van Vliet, EA | 2 |
| Zibell, G | 1 |
| Pekcec, A | 1 |
| Schlichtiger, J | 1 |
| Edelbroek, PM | 2 |
| Holtman, L | 1 |
| Aronica, E | 2 |
| Gorter, JA | 2 |
| Potschka, H | 1 |
| Cuellar-Herrera, M | 1 |
| Peña, F | 1 |
| Alcantara-Gonzalez, D | 1 |
| Neri-Bazan, L | 1 |
| Rocha, L | 1 |
| Baulac, M | 1 |
| Farooque, P | 1 |
| Khurana, DS | 2 |
| Melvin, JJ | 1 |
| Al-Khulaif, AH | 1 |
| Shujaa, AS | 1 |
| Miranda, M | 1 |
| Kuester, G | 1 |
| Ríos, L | 1 |
| Basaez, E | 1 |
| Hazard, S | 1 |
| Kwan, SY | 1 |
| Al-Mendalawi, MD | 1 |
| Raj, D | 1 |
| Gulati, S | 1 |
| Lodha, R | 1 |
| Seckin, M | 1 |
| Gurgor, N | 1 |
| Beckmann, YY | 1 |
| Ulukok, MD | 1 |
| Suzen, A | 1 |
| Basoglu, M | 1 |
| Al-Khamees, WA | 1 |
| Schwartz, MD | 1 |
| Alrashdi, S | 1 |
| Algren, AD | 1 |
| Morgan, BW | 1 |
| LaRoche, SM | 2 |
| Shivdat-Nanhoe, R | 1 |
| Alvarez, V | 1 |
| Januel, JM | 1 |
| Burnand, B | 1 |
| Prince, NJ | 1 |
| Hill, C | 1 |
| Pratipanawatr, T | 1 |
| Jitpimolmard, S | 3 |
| Swisher, CB | 1 |
| Doreswamy, M | 1 |
| Gingrich, KJ | 1 |
| Vredenburgh, JJ | 1 |
| Kolls, BJ | 1 |
| Patterson, EN | 1 |
| Craft, EM | 1 |
| Tawfik, MK | 1 |
| Sasidaran, K | 1 |
| Singhi, S | 2 |
| Singhi, P | 2 |
| Storti, M | 1 |
| Del Felice, A | 1 |
| Fiaschi, A | 1 |
| Bongiovanni, LG | 1 |
| Liu, X | 1 |
| Wu, Y | 1 |
| Ma, M | 1 |
| Su, L | 1 |
| Feddersen, B | 1 |
| Ismail, S | 1 |
| Lévy, A | 1 |
| Tikkanen, H | 1 |
| Sévère, M | 1 |
| Wolters, FJ | 1 |
| Carmant, L | 1 |
| Rosemergy, I | 1 |
| Bergin, P | 1 |
| Jones, P | 1 |
| Walker, E | 1 |
| Cook, AM | 1 |
| Castle, A | 1 |
| Green, A | 1 |
| Lesch, C | 1 |
| Morrison, C | 1 |
| Rhoney, D | 1 |
| Parker, D | 1 |
| Tesoro, E | 1 |
| Brophy, G | 1 |
| Goodwin, H | 1 |
| Gokun, J | 1 |
| Makii, J | 1 |
| McAllen, K | 1 |
| Bledsoe, K | 1 |
| Sangha, K | 1 |
| Weant, K | 1 |
| Liang, N | 1 |
| Murphy-Human, T | 1 |
| Rajabally, H | 1 |
| Nageshwaran, S | 1 |
| Russell, S | 1 |
| Pujar, SS | 1 |
| Scott, RC | 2 |
| Chin, RF | 1 |
| Sperling, MR | 1 |
| Alldredge, B | 1 |
| Shutter, L | 1 |
| Treiman, DM | 7 |
| Vespa, PM | 1 |
| Bell, R | 1 |
| Brophy, GM | 1 |
| Di Gennaro, G | 1 |
| Quarato, PP | 1 |
| Colazza, GB | 1 |
| Mascia, A | 1 |
| Mari, F | 1 |
| Manfredi, M | 1 |
| Jones, DM | 1 |
| Esmaeil, N | 1 |
| Maren, S | 1 |
| Macdonald, RL | 1 |
| Tsuji, S | 1 |
| Akamatsu, N | 1 |
| Sen, S | 1 |
| Ratnaraj, N | 1 |
| Davies, NA | 1 |
| Mookerjee, RP | 1 |
| Cooper, CE | 1 |
| Patsalos, PN | 2 |
| Williams, R | 1 |
| Jalan, R | 1 |
| Koul, R | 2 |
| Chacko, A | 1 |
| Javed, H | 1 |
| Al Riyami, K | 1 |
| Ubogu, EE | 1 |
| Sagar, SM | 1 |
| Lerner, AJ | 1 |
| Maddux, BN | 1 |
| Suarez, JI | 1 |
| Werz, MA | 1 |
| Manno, EM | 1 |
| Dass, R | 1 |
| Engelsen, BA | 1 |
| Karlsen, B | 1 |
| Telstad, W | 1 |
| Ogutu, BR | 1 |
| Newton, CR | 2 |
| Muchohi, SN | 1 |
| Otieno, GO | 1 |
| Edwards, G | 1 |
| Watkins, WM | 1 |
| Kokwaro, GO | 1 |
| CARTER, CH | 1 |
| JANZ, D | 1 |
| KAUTZ, G | 1 |
| RIZZUTO, VJ | 1 |
| INGLESBY, TV | 1 |
| GRACE, WJ | 1 |
| Martín, ED | 1 |
| Pozo, MA | 1 |
| Boylan, LS | 1 |
| Kaley, TJ | 1 |
| Singh, A | 1 |
| Devinsky, O | 1 |
| Benjamin, A | 1 |
| McMonagle, JD | 1 |
| Rowland, T | 1 |
| Shih, TM | 1 |
| Kwan, P | 1 |
| Brodie, MJ | 1 |
| Peters, CN | 1 |
| Pohlmann-Eden, B | 1 |
| Brevoord, JC | 1 |
| Joosten, KF | 1 |
| Arts, WF | 1 |
| van Rooij, RW | 1 |
| de Hoog, M | 1 |
| Lee, KC | 1 |
| Garcia, PA | 1 |
| Alldredge, BK | 1 |
| Hamano, S | 1 |
| Sugiyama, N | 1 |
| Tanaka, M | 1 |
| Yamashita, S | 1 |
| Yoshinari, S | 1 |
| Minamitani, M | 1 |
| Hayakawa, M | 1 |
| Kikuchi, K | 1 |
| Eto, Y | 1 |
| Walker, M | 1 |
| Redeker, S | 1 |
| Prasad, K | 2 |
| Eriksson, K | 2 |
| Metsäranta, P | 1 |
| Huhtala, H | 1 |
| Auvinen, A | 1 |
| Kuusela, AL | 2 |
| Koivikko, M | 1 |
| Malmgren, K | 1 |
| Donaire, A | 1 |
| Carreno, M | 1 |
| Gómez, B | 1 |
| Fossas, P | 1 |
| Bargalló, N | 1 |
| Agudo, R | 1 |
| Falip, M | 1 |
| Setoaín, X | 1 |
| Boget, T | 1 |
| Raspall, T | 1 |
| Obach, V | 1 |
| Rumiá, J | 1 |
| Adams, BD | 1 |
| Buckley, NH | 1 |
| Kim, JY | 1 |
| Tipps, LB | 1 |
| Lewena, S | 1 |
| Young, S | 1 |
| Chitravas, N | 1 |
| Tanaka, H | 1 |
| Ueda, H | 1 |
| Kida, Y | 1 |
| Hamagami, H | 1 |
| Tsuji, T | 1 |
| Ichinose, M | 1 |
| Kälviäinen, R | 1 |
| Autti-Rämö, I | 1 |
| Häppölä, O | 1 |
| Keränen, T | 1 |
| Kuoppala, J | 1 |
| Kurola, J | 1 |
| Mervaala, E | 1 |
| Salmi, T | 1 |
| Tallgren, M | 1 |
| Paowana, W | 1 |
| Saengsuwan, J | 1 |
| Arunpongpaisal, S | 1 |
| Chaiyakum, A | 1 |
| Phuttharak, W | 1 |
| Aaauevitchayapat, N | 1 |
| Vannaprasaht, S | 2 |
| Phunikhom, K | 1 |
| Tucker, A | 1 |
| Miyake, H | 1 |
| Tsuji, M | 1 |
| Ukita, T | 1 |
| Nishihara, K | 1 |
| Tawalee, A | 1 |
| Mayurasakorn, N | 1 |
| Yodwut, C | 1 |
| Bansong, R | 1 |
| Reungjui, S | 1 |
| Patel, R | 1 |
| Avez-Couturier, J | 1 |
| Auvin, S | 1 |
| Cuisset, JM | 1 |
| Soto-Ares, G | 1 |
| Lamblin, MD | 1 |
| Cuvellier, JC | 1 |
| Vallée, L | 1 |
| Minicucci, F | 1 |
| Muscas, G | 1 |
| Perucca, E | 1 |
| Capovilla, G | 1 |
| Vigevano, F | 1 |
| Tinuper, P | 1 |
| Bethmann, K | 1 |
| Brandt, C | 1 |
| Schulze-Bonhage, A | 1 |
| Hefft, S | 1 |
| Oehl, B | 1 |
| Burri, E | 1 |
| Rutishauser, J | 1 |
| Egger, SS | 1 |
| Lampert, ML | 1 |
| Agarwal, P | 1 |
| Chandra, R | 1 |
| Gupta, G | 1 |
| Antony, AR | 1 |
| Garg, N | 1 |
| Velioğlu, SK | 1 |
| Gazioğlu, S | 1 |
| Sinn, DI | 1 |
| Chu, K | 1 |
| Jung, KH | 1 |
| Park, KI | 1 |
| Nam, H | 1 |
| Lee, SK | 1 |
| Bonnemann, CG | 1 |
| Licht, DJ | 1 |
| Bodmer, M | 1 |
| Link, B | 1 |
| Grignaschi, N | 1 |
| Kummer, O | 1 |
| Haschke, M | 1 |
| Krähenbühl, S | 1 |
| Sadarangani, M | 1 |
| Seaton, C | 1 |
| Scott, JA | 1 |
| Ogutu, B | 1 |
| Edwards, T | 1 |
| Prins, A | 1 |
| Gatakaa, H | 1 |
| Idro, R | 1 |
| Berkley, JA | 1 |
| Peshu, N | 1 |
| Neville, BG | 2 |
| Thomas, P | 1 |
| Delima, SI | 1 |
| Walsh, LE | 1 |
| Golomb, MR | 1 |
| Deshpande, LS | 1 |
| Nagarkatti, N | 1 |
| Sombati, S | 1 |
| DeLorenzo, RJ | 2 |
| Dardis, C | 1 |
| Farid, S | 1 |
| Doherty, C | 1 |
| Aladdin, Y | 1 |
| Gross, DW | 1 |
| Oppenheimer, EY | 1 |
| Rosman, NP | 1 |
| Lockard, JS | 1 |
| Levy, RH | 1 |
| Koch, KM | 1 |
| Maris, DO | 1 |
| Friel, PN | 1 |
| van der Kleijn, E | 1 |
| Baars, AM | 1 |
| Vree, TB | 1 |
| van der Dries, A | 1 |
| Somerville, ER | 1 |
| Bruni, J | 3 |
| Schmidt, D | 1 |
| Mancall, EL | 1 |
| Covington, TR | 1 |
| Alonso, RJ | 1 |
| Mauguière, F | 2 |
| Fischer, C | 1 |
| Ferry, S | 2 |
| Courjon, J | 2 |
| Olmos-Garcia de Alba, G | 1 |
| Udaeta Mora, E | 1 |
| Malagon Valdez, J | 1 |
| Villaneuva Garcia, D | 1 |
| Valarezo Crespo, F | 1 |
| Gal, P | 1 |
| McCue, JD | 1 |
| Tate, M | 1 |
| Price, J | 1 |
| Hall, S | 1 |
| Harney, J | 1 |
| Glasberg, MR | 1 |
| Giacoia, GP | 1 |
| Gessner, PK | 1 |
| Zaleska, MM | 1 |
| Boutwell, WC | 1 |
| Koren, G | 1 |
| Brand, N | 1 |
| Halkin, H | 1 |
| Dany, S | 1 |
| Shahar, E | 1 |
| Barzilay, Z | 1 |
| Delgado-Escueta, AV | 3 |
| Bajorek, JG | 1 |
| Rothner, AD | 1 |
| Erenberg, G | 1 |
| Fröscher, W | 1 |
| Bittencourt, PR | 1 |
| Richens, A | 1 |
| Johnston, MV | 1 |
| Freeman, JM | 2 |
| Chauplannaz, G | 1 |
| Wilbur, R | 1 |
| Kulik, FA | 1 |
| Philbert, A | 1 |
| Dam, M | 1 |
| Browne, TR | 4 |
| Camfield, PR | 1 |
| Painter, MJ | 1 |
| Wilder, BJ | 4 |
| Patrick, BK | 1 |
| Cranford, RE | 2 |
| von Albert, HH | 2 |
| Albani, M | 3 |
| Enrile-Bacsal, F | 1 |
| Lovely, MP | 1 |
| Wasterlain, C | 1 |
| Porter, RJ | 1 |
| Morris, HH | 1 |
| Vijayan, N | 1 |
| Gabor, AJ | 2 |
| Racy, A | 1 |
| Osborn, MA | 1 |
| Vern, BA | 1 |
| Molinari, GF | 1 |
| Montenegro, R | 1 |
| Escobar, A | 1 |
| Gumnit, RJ | 1 |
| McLain, LW | 1 |
| Hughes, JR | 1 |
| Fuller, T | 1 |
| Walker, MC | 1 |
| Smith, SJ | 1 |
| Shorvon, SD | 1 |
| Simon, RP | 1 |
| Borgeat, A | 1 |
| Wilder-Smith, OH | 1 |
| Jallon, P | 1 |
| Suter, PM | 1 |
| Moss, W | 1 |
| Ojukwu, C | 1 |
| Chiriboga, CA | 1 |
| Handforth, A | 2 |
| Teng, E | 1 |
| Wilkins, P | 1 |
| Jones, CM | 1 |
| Dunn, HG | 1 |
| Thomas, EE | 1 |
| Cone, RW | 1 |
| Weber, JM | 1 |
| Sauter, K | 1 |
| Kaufman, HH | 1 |
| Bloomfield, SM | 1 |
| Cline, S | 1 |
| Banks, D | 1 |
| So, EL | 1 |
| Ruggles, KH | 1 |
| Cascino, GD | 3 |
| Ahmann, PA | 1 |
| Weatherford, KW | 1 |
| Munn, RI | 1 |
| Farrell, K | 1 |
| Lindow, J | 1 |
| Wijdicks, EF | 1 |
| Winn, RE | 1 |
| McDonnell, KP | 1 |
| Bertz, RJ | 1 |
| Howrie, DL | 2 |
| Ramsay, RE | 7 |
| Mitchell, WG | 1 |
| DeToledo, J | 1 |
| Mori, N | 1 |
| Kurokouchi, A | 1 |
| Osonoe, K | 1 |
| Saitoh, H | 1 |
| Ariga, K | 1 |
| Suzuki, K | 1 |
| Iwata, Y | 1 |
| Walton, NY | 4 |
| Jaing, Q | 1 |
| Hyun, B | 1 |
| George, B | 1 |
| Kulkarni, SK | 1 |
| Segeleon, JE | 1 |
| Haun, SE | 1 |
| Lukovits, TG | 1 |
| Fadul, CE | 1 |
| Pipas, JM | 1 |
| Williamson, PD | 1 |
| Sperner, J | 1 |
| Sander, B | 1 |
| Lau, S | 1 |
| Krude, H | 1 |
| Scheffner, D | 1 |
| Berg, AT | 1 |
| Kato, H | 1 |
| Kishikawa, H | 1 |
| Emura, S | 1 |
| Takashima, T | 1 |
| Ohmori, K | 1 |
| Fujita, H | 1 |
| Brown, CE | 1 |
| Smith, GD | 1 |
| Coniglione, T | 1 |
| Cadenbach, A | 1 |
| Röttger, K | 1 |
| Müller, MK | 1 |
| Comes, J | 1 |
| Stecker, MM | 1 |
| Kramer, TH | 1 |
| Raps, EC | 1 |
| O'Meeghan, R | 1 |
| Dulaney, E | 1 |
| Skaar, DJ | 1 |
| Sokol, DK | 1 |
| Dahlmann, A | 1 |
| Dunn, DW | 1 |
| Delanty, N | 1 |
| Vaughan, CJ | 1 |
| French, JA | 1 |
| Meyers, PD | 1 |
| Collins, JF | 1 |
| Colling, C | 1 |
| Rowan, AJ | 1 |
| Faught, E | 1 |
| Calabrese, VP | 1 |
| Uthman, BM | 2 |
| Mamdani, MB | 1 |
| Sagduyu, A | 1 |
| Tarlaci, S | 1 |
| Sirin, H | 1 |
| Dreier, JP | 1 |
| Zhang, CL | 1 |
| Heinemann, U | 1 |
| Mazarati, AM | 3 |
| Baldwin, RA | 3 |
| Sankar, R | 2 |
| Pesola, GR | 1 |
| Westfal, RE | 1 |
| Johnson, KH | 1 |
| Caton, H | 1 |
| Garr, RE | 1 |
| Robson, WJ | 1 |
| Molyneux, EM | 1 |
| Otero, MJ | 1 |
| Morán, D | 1 |
| Valverde, MP | 1 |
| Brown, J | 1 |
| Morris, TA | 1 |
| Jafari, N | 1 |
| Rice, AC | 1 |
| Vasconcelos, O | 1 |
| Gidal, BE | 1 |
| Seltz, JN | 1 |
| Rutecki, P | 1 |
| Sofia, RD | 1 |
| Wasterain, CG | 1 |
| Heafield, MT | 1 |
| DeToledo, JC | 2 |
| Osorio, I | 3 |
| Reed, RC | 2 |
| Peltzer, JN | 1 |
| D'Agostino, MD | 1 |
| Andermann, F | 1 |
| Dubeau, F | 1 |
| Fedi, M | 1 |
| Bastos, A | 1 |
| Touchette, DR | 1 |
| Rhoney, DH | 1 |
| Liu, H | 1 |
| Shirasaka, Y | 1 |
| Katsumori, H | 1 |
| Thompson, KW | 1 |
| Pereira de Vasconselos, A | 1 |
| Nehlig, A | 1 |
| Hesdorffer, D | 1 |
| Logroscino, G | 1 |
| Hauser, WA | 1 |
| Lowe, MR | 1 |
| Rabinstein, A | 1 |
| Villaviza, N | 1 |
| Khosla, P | 1 |
| Pandhi, P | 1 |
| Hanhan, UA | 1 |
| Fiallos, MR | 1 |
| Orlowski, JP | 1 |
| De Negri, M | 1 |
| Baglietto, MG | 1 |
| Kitchen, D | 1 |
| Smith, D | 1 |
| Spiller, HA | 1 |
| Carlisle, RD | 1 |
| Deleu, D | 1 |
| Prasad, A | 1 |
| Williamson, JM | 1 |
| Bertram, EH | 1 |
| Lockey, AS | 1 |
| McCarthy, LJ | 2 |
| Aguilar, JC | 2 |
| Barry, JE | 1 |
| Fleetham, JA | 1 |
| Ginsburg, JC | 1 |
| Nakatsu, K | 1 |
| Wigle, RD | 1 |
| Munt, PW | 1 |
| Livingston, S | 2 |
| Pruce, I | 1 |
| Pauli, LL | 1 |
| Aucamp, AK | 1 |
| Ransburg, R | 1 |
| Hawkins, JA | 1 |
| Mathewson, HS | 1 |
| Wauquier, A | 1 |
| Ashton, D | 1 |
| Melis, W | 1 |
| Willmore, LJ | 3 |
| Miyasaka, M | 1 |
| Strauss, RG | 1 |
| Patrick, B | 1 |
| Anderson, CB | 1 |
| Kostick, B | 1 |
| Passarge, C | 1 |
| Van Huffelen, AC | 1 |
| Magnus, O | 1 |
| Feussner, GF | 1 |
| Perchalski, RJ | 1 |
| Shumate, JB | 1 |
| Speciali, JG | 1 |
| Lison, MP | 1 |
| Fujita, T | 1 |
| Tanaka, S | 1 |
| Takano, K | 1 |
| Yonemasu, Y | 1 |
| Watson, C | 1 |
| Donovan, PJ | 1 |
| Cline, D | 1 |
| Mar Molinero, F | 1 |
| Sánchez Díaz, JI | 1 |
| Torres Mohedas, J | 1 |
| Conway, EE | 1 |
| Mezey, AP | 1 |
| Powers, K | 1 |
| Meessen, S | 1 |
| Riedel, RR | 1 |
| Brühl, P | 1 |
| Gordon, MF | 1 |
| Gerstenblitt, D | 1 |
| Méndez-Quijada, J | 1 |
| Mores, AF | 1 |
| Juvinao, N | 1 |
| Isenstein, D | 1 |
| Nasraway, SA | 1 |
| Cruse, RP | 1 |
| Nouailhat, F | 1 |
| Lévy-Alcover, MA | 1 |
| Goulon, M | 1 |
| Galdames, D | 1 |
| Aguilera, L | 1 |
| Castillo, S | 1 |
| Valenzuela, M | 1 |
| Leyton, S | 1 |
| Saavedra, IN | 1 |
| Roth, F | 1 |
| Keller, HP | 1 |
| Kurata, K | 1 |
| Kido, H | 1 |
| Kobayashi, K | 1 |
| Yamaguchi, N | 1 |
| Shaner, DM | 1 |
| McCurdy, SA | 1 |
| Herring, MO | 1 |
| Vozeh, S | 1 |
| Uematsu, T | 1 |
| Aarons, L | 1 |
| Maitre, P | 1 |
| Landolt, H | 1 |
| Gratzl, O | 1 |
| Sechi, GP | 1 |
| Russo, A | 1 |
| Rosati, G | 1 |
| Mutani, R | 1 |
| Monaco, F | 1 |
| Vassella, F | 1 |
| Rossi, LN | 1 |
| Filloux, F | 1 |
| Thompson, JA | 1 |
| Lim, J | 1 |
| Yagnik, P | 1 |
| Schraeder, P | 1 |
| Wheeler, S | 1 |
| Walsh-Kelly, CM | 1 |
| Berens, RJ | 1 |
| Glaeser, PW | 1 |
| Losek, JD | 1 |
| Amit, R | 1 |
| Rottem, M | 1 |
| Yatziv, S | 1 |
| Osborn, HH | 1 |
| Zisfein, J | 1 |
| Sparano, R | 1 |
| Grunert, GM | 1 |
| Field, DR | 1 |
| Crumrine, PK | 1 |
| Fougner, AC | 1 |
| Wilson, SJ | 1 |
| Seltzer, VL | 1 |
| Vining, EP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Randomized, Blinded, Comparative Effectiveness Study of Fosphenytoin, Valproic Acid, or Levetiracetam in the Emergency Department Treatment of Patients With Benzodiazepine-refractory Status Epilepticus.[NCT01960075] | Phase 3 | 478 participants (Actual) | Interventional | 2015-10-31 | Completed | ||
| Dynamics of Hemostatic Parameters in COVID-19 and Comparison of Intervention Strategies Through Adaptive Clinical Trial[NCT04466670] | Phase 2 | 379 participants (Anticipated) | Interventional | 2020-07-11 | Recruiting | ||
| A Pilot Study to Assess the Efficacy of Subanesthetic Doses of IV Ketamine in the Treatment Drug Resistant Epilepsy[NCT05019885] | Phase 2 | 6 participants (Anticipated) | Interventional | 2022-08-26 | Recruiting | ||
| Intranasal Midazolam Versus Rectal Diazepam for the Home Treatment of Seizure Activity in Pediatric Patients With Epilepsy[NCT00326612] | Phase 2 | 358 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Length of hospital stay in days (NCT01960075)
Timeframe: length of hospital stay
| Intervention | days (Median) |
|---|---|
| Fosphenytoin (FOS) | 3 |
| Valproic Acid | 3 |
| Levetiracetam | 3 |
Length of stay is determined by the number of calendar days after the day of ED arrival until hospital discharge or subject end-of-study. (NCT01960075)
Timeframe: number of calendar days after the day of ED arrival until hospital discharge or subject end-of-study
| Intervention | days (Median) |
|---|---|
| Fosphenytoin (FOS) | 1 |
| Valproic Acid | 1 |
| Levetiracetam | 1 |
The time to termination of seizures is the interval from the start of study drug infusion to cessation of clinically apparent seizure in those who meet the primary outcome. (NCT01960075)
Timeframe: start of drug infusion to seizure cessation
| Intervention | minutes (Median) |
|---|---|
| Fosphenytoin (FOS) | 11.7 |
| Valproic Acid | 7.0 |
| Levetiracetam | 10.5 |
ICU admission is recorded as occurring only if the ICU is the initial inpatient unit for the patient. (NCT01960075)
Timeframe: Admission to intensive care unit after start of study drug infusion, where the ICU is the initial inpatient unit for the patient
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 70 |
| Valproic Acid | 71 |
| Levetiracetam | 87 |
Determined by the absence of clinically apparent seizures and improving consciousness at 1 hour without other anticonvulsant medications. The Adjudicated outcomes analysis is different from Outcome measure 1 because a central clinical phenomenology core of four neurologists adjudicated from the medical records the time to seizure cessation, the time in status epilepticus before trial-drug initiation, and the cause of the seizure. For each enrollment, two neurologists from this core group conducted independent initial reviews and then determined a consensus or consulted a third adjudicator, as needed. Adjudicators were unaware of the treatment assignments and made determinations by medical record review. (NCT01960075)
Timeframe: Within 60 minutes after the start of study drug infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 57 |
| Valproic Acid | 60 |
| Levetiracetam | 67 |
Determined by the absence of clinically apparent seizures and improving consciousness at 1 hour without other anticonvulsant medications. Intention to treat (NCT01960075)
Timeframe: Within 60 minutes after the start of study drug infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 53 |
| Valproic Acid | 56 |
| Levetiracetam | 68 |
Determined by the absence of clinically apparent seizures and improving consciousness at 1 hour without other anticonvulsant medications. Per-protocol analysis (NCT01960075)
Timeframe: Within 60 minutes after the start of study drug infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 37 |
| Valproic Acid | 43 |
| Levetiracetam | 51 |
Acute anaphylaxis is defined as a clinical presentation consistent with life threatening allergic reaction occurring within 6 hours of the start of study drug infusions and manifested as urticaria in combination with either (1) a systolic blood pressure of < 90 mmHg sustained for greater than 5 minutes, or (2) objective evidence of airway obstruction, and for which the patient was treated with antihistamines and/or steroids. (NCT01960075)
Timeframe: within 6 hours of the start of study drug infusions
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 0 |
| Valproic Acid | 0 |
| Levetiracetam | 0 |
Respiratory depression is defined as impairment of ventilation or oxygenation necessitating definitive endotracheal intubation and mechanical ventilation. It is distinct from intubations performed only for airway protection in those with decreased levels of consciousness. It does not include those getting only supraglottic airways or transient bag-valve-mask support. (NCT01960075)
Timeframe: 24 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 16 |
| Valproic Acid | 10 |
| Levetiracetam | 12 |
acute seizure recurrence 60 minutes to 12 hours after start of study drug infusion (NCT01960075)
Timeframe: 60 minutes to 12 hours after start of study drug infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 14 |
| Valproic Acid | 14 |
| Levetiracetam | 16 |
Safety outcome: Death (NCT01960075)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 3 |
| Valproic Acid | 2 |
| Levetiracetam | 7 |
Endotracheal intubation within 60 minutes of start of study drug infusion (NCT01960075)
Timeframe: within 60 minutes of start of study drug infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 33 |
| Valproic Acid | 21 |
| Levetiracetam | 30 |
Safety outcome: Hepatic transaminase or ammonia elevations (NCT01960075)
Timeframe: 24 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 0 |
| Valproic Acid | 1 |
| Levetiracetam | 1 |
Life-threatening hypotension within 60 minutes of the start of study drug infusion (NCT01960075)
Timeframe: within 60 minutes of the start of study drug infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 4 |
| Valproic Acid | 2 |
| Levetiracetam | 1 |
Life-threatening cardiac arrhythmia within 60 minutes of the start of study drug infusion (NCT01960075)
Timeframe: within 60 minutes of the start of study drug infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 0 |
| Valproic Acid | 0 |
| Levetiracetam | 1 |
Purple glove syndrome is defined as the presence of all three of the findings of the objective edema: discoloration, and pain in the distal extremity in which study drug was administered, with or without known extravasation, and for which there is no other evident etiology. (NCT01960075)
Timeframe: 24 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 0 |
| Valproic Acid | 0 |
| Levetiracetam | 0 |
Number of participants with seizure cessation within 20 minutes of study drug initiation for patients with treatment success. This outcome measure was only reported in the Supplementary materials to the Primary Paper. (NCT01960075)
Timeframe: within 20 minutes
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 43 |
| Valproic Acid | 43 |
| Levetiracetam | 53 |
Length of seizure. (NCT00326612)
Timeframe: 24 hours
| Intervention | Minutes (Median) |
|---|---|
| Intranasal Midazolam | 3.0 |
| Rectal Diazepam | 4.3 |
(NCT00326612)
Timeframe: 24 hours
| Intervention | participants (Number) |
|---|---|
| Intranasal Midazolam | 21 |
| Rectal Diazepam | 17 |
(NCT00326612)
Timeframe: 24 hours
| Intervention | participants (Number) |
|---|---|
| Intranasal Midazolam | 4 |
| Rectal Diazepam | 3 |
(NCT00326612)
Timeframe: 12 hours
| Intervention | participants (Number) |
|---|---|
| Intranasal Midazolam | 1 |
| Rectal Diazepam | 1 |
(NCT00326612)
Timeframe: 24 hours
| Intervention | participants (Number) |
|---|---|
| Intranasal Midazolam | 5 |
| Rectal Diazepam | 5 |
Respiratory depression was defined as intubation at Emergency Department discharge. (NCT00326612)
Timeframe: 24 hours
| Intervention | participants (Number) |
|---|---|
| Intranasal Midazolam | 1 |
| Rectal Diazepam | 0 |
Respiratory depression was defined as requiring oxygen at discharge from the Emergency Department. (NCT00326612)
Timeframe: 24 hours
| Intervention | participants (Number) |
|---|---|
| Intranasal Midazolam | 3 |
| Rectal Diazepam | 1 |
72 reviews available for phenytoin and Absence Status
| Article | Year |
|---|---|
A critical review of fosphenytoin sodium injection for the treatment of status epilepticus in adults and children.
Topics: Adult; Anticonvulsants; Child; Humans; Levetiracetam; Phenytoin; Status Epilepticus | 2022 |
Status epilepticus in pregnancy: a literature review and a protocol proposal.
Topics: Anticonvulsants; Female; Humans; Levetiracetam; Phenytoin; Pregnancy; Review Literature as Topic; St | 2022 |
Comparison of Safety and Effectiveness between Levetiracetam and Phenytoin in the Treatment of Pediatric Status Epilepticus: A Meta- Analysis.
Topics: Anticonvulsants; Child; Humans; Levetiracetam; Phenytoin; Seizures; Status Epilepticus | 2023 |
Treatment of benzodiazepine-resistant status epilepticus: Systematic review and network meta-analyses.
Topics: Adult; Anticonvulsants; Benzodiazepines; Child; Drug Resistance; Humans; Levetiracetam; Network Meta | 2022 |
[Paediatric status epilepticus].
Topics: Adult; Anesthetics; Anticonvulsants; Benzodiazepines; Child; Epilepsy; Humans; Ketamine; Lacosamide; | 2022 |
Levetiracetam versus phenytoin for the treatment of established status epilepticus: A systematic review and meta-analysis of randomized controlled trials.
Topics: Anticonvulsants; Humans; Levetiracetam; Phenytoin; Randomized Controlled Trials as Topic; Status Epi | 2020 |
Levetiracetam vs. phenytoin as 2nd-line treatment for status epilepticus: A systematic review and meta-analysis.
Topics: Anticonvulsants; Benzodiazepines; Drug Therapy, Combination; Humans; Levetiracetam; Phenytoin; Pirac | 2020 |
Status Epilepticus in Children.
Topics: Anticonvulsants; Benzodiazepines; Child; Forecasting; Humans; Phenytoin; Status Epilepticus | 2020 |
Levetiracetam versus Phenytoin for the Pharmacotherapy of Benzodiazepine-Refractory Status Epilepticus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Topics: Anticonvulsants; Benzodiazepines; Child; Humans; Levetiracetam; Odds Ratio; Phenytoin; Randomized Co | 2020 |
Management of status epilepticus in patients with liver or kidney disease: a narrative review.
Topics: Anticonvulsants; Humans; Kidney Diseases; Liver; Phenytoin; Status Epilepticus | 2021 |
Levetiracetam Versus Phenytoin or Fosphenytoin for Second-Line Treatment of Pediatric Status Epilepticus: A Meta-Analysis.
Topics: Anticonvulsants; Child; Humans; Levetiracetam; Phenytoin; Status Epilepticus | 2021 |
[Efficacy and safety of levetiracetam versus phenytoin as second-line drugs for the treatment of children with convulsive status epilepticus: a Meta analysis].
Topics: Anticonvulsants; Child; Humans; Levetiracetam; Pharmaceutical Preparations; Phenytoin; Status Epilep | 2021 |
Efficacy of lacosamide and phenytoin in status epilepticus: A systematic review.
Topics: Anticonvulsants; Humans; Lacosamide; Phenytoin; Seizures; Status Epilepticus; Treatment Outcome | 2021 |
Comparison of the efficacy and safety of levetiracetam and phenytoin in the treatment of established status epilepticus: A systematic review and meta-analysis.
Topics: Anticonvulsants; Humans; Levetiracetam; Phenytoin; Status Epilepticus | 2021 |
Efficacy and Safety of Levetiracetam vs. Phenytoin as Second Line Antiseizure Medication for Pediatric Convulsive Status Epilepticus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Topics: Anticonvulsants; Child; Humans; Levetiracetam; Phenytoin; Randomized Controlled Trials as Topic; Sta | 2021 |
Efficacy and safety of levetiracetam versus (fos)phenytoin for second-line treatment of epilepticus: a meta-analysis of latest randomized controlled trials.
Topics: Anticonvulsants; Humans; Levetiracetam; Phenytoin; Randomized Controlled Trials as Topic; Status Epi | 2021 |
Status epilepticus in dogs and cats, part 2: treatment, monitoring, and prognosis.
Topics: Animals; Anticonvulsants; Cat Diseases; Cats; Dog Diseases; Dogs; Electroencephalography; Phenytoin; | 2017 |
A critical appraisal of randomized controlled trials on intravenous phenytoin in convulsive status epilepticus.
Topics: Administration, Intravenous; Anticonvulsants; Drug Resistance; Humans; Phenytoin; Randomized Control | 2018 |
Why we prefer levetiracetam over phenytoin for treatment of status epilepticus.
Topics: Administration, Cutaneous; Administration, Intravenous; Anticonvulsants; Exanthema; Humans; Infusion | 2018 |
Meta-analysis and cost-effectiveness of second-line antiepileptic drugs for status epilepticus.
Topics: Anticonvulsants; Benzodiazepines; Cost-Benefit Analysis; Decision Support Techniques; Humans; Lacosa | 2019 |
[Treatment of status epilepticus].
Topics: Anesthesia, General; Diazepam; Drug Administration Routes; Evidence-Based Medicine; Humans; Hypother | 2014 |
Anticonvulsant therapy for status epilepticus.
Topics: Anticonvulsants; Diazepam; Humans; Injections, Intravenous; Lorazepam; Midazolam; Phenobarbital; Phe | 2014 |
Neurocritical care: status epilepticus review.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Benzodiazepines; Critical Care; Electroencephalogra | 2014 |
Lacosamide in status epilepticus: Update on the TRENdS study.
Topics: Acetamides; Anticonvulsants; Critical Illness; Humans; Lacosamide; Phenytoin; Recurrence; Seizures; | 2015 |
Drug-induced status epilepticus.
Topics: Animals; Anti-Bacterial Agents; Anticonvulsants; gamma-Aminobutyric Acid; Humans; Nipecotic Acids; P | 2015 |
Lidocaine for Status Epilepticus in Pediatrics.
Topics: Anticonvulsants; Humans; Lidocaine; Pediatrics; Phenytoin; Prospective Studies; Seizures; Status Epi | 2015 |
Direct and indirect comparison meta-analysis of levetiracetam versus phenytoin or valproate for convulsive status epilepticus.
Topics: Anticonvulsants; Humans; Levetiracetam; Phenytoin; Piracetam; Status Epilepticus; Valproic Acid | 2016 |
Emergency treatment of status epilepticus: current thinking.
Topics: Anesthesia, General; Anticonvulsants; Benzodiazepines; Electroencephalography; Emergency Medical Ser | 2009 |
[Drugs for status epilepticus treatment].
Topics: Anticonvulsants; Barbiturates; Benzodiazepines; Fructose; Humans; Hypnotics and Sedatives; Levetirac | 2009 |
Treatment of status epilepticus in children.
Topics: Anticonvulsants; Child; Child, Preschool; Diazepam; Drug Administration Schedule; Drug Therapy, Comb | 2004 |
What is the relative value of the standard anticonvulsants: Phenytoin and fosphenytoin, phenobarbital, valproate, and levetiracetam?
Topics: Anticonvulsants; Benzodiazepines; Humans; Levetiracetam; Phenobarbital; Phenytoin; Piracetam; Prodru | 2009 |
Management of acute seizure and status epilepticus in pediatric emergency.
Topics: Anesthesia, Intravenous; Anticonvulsants; Benzodiazepines; Child; Child, Preschool; Combined Modalit | 2012 |
IV Valproate in generalized convulsive status epilepticus: a systematic review.
Topics: Administration, Intravenous; Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Female; Hu | 2012 |
A systematic review of randomized controlled trials on the theraputic effect of intravenous sodium valproate in status epilepticus.
Topics: Anticonvulsants; Diazepam; Humans; Injections, Intravenous; Levetiracetam; Phenytoin; Piracetam; Ran | 2012 |
[Treatment of status epilepticus].
Topics: Animals; Anticonvulsants; Diazepam; Disease Models, Animal; Electric Stimulation Therapy; Humans; Ma | 2001 |
New management strategies in the treatment of status epilepticus.
Topics: Anticonvulsants; Benzodiazepines; Emergency Medical Services; Humans; Phenobarbital; Phenytoin; Stat | 2003 |
Status epilepticus: emergency management.
Topics: Anticonvulsants; Benzodiazepines; Child; Clinical Protocols; Emergency Medical Services; Humans; Phe | 2003 |
Phenobarbital for the treatment of epilepsy in the 21st century: a critical review.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Cost-Benefit Analysis; Developing Countries; Drug Costs; E | 2004 |
Status epilepticus: an evidence based guide.
Topics: Anticonvulsants; Chronic Disease; Critical Care; Drug Administration Routes; Emergency Treatment; Ev | 2005 |
Anticonvulsant therapy for status epilepticus.
Topics: Anticonvulsants; Diazepam; Humans; Lorazepam; Midazolam; Phenobarbital; Phenytoin; Randomized Contro | 2005 |
[Update on current care guidelines. Prolonged epileptic attack].
Topics: Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Diazepam; Drug Therapy, Combination; El | 2006 |
Anticonvulsant therapy for status epilepticus.
Topics: Anticonvulsants; Diazepam; Humans; Lorazepam; Midazolam; Phenobarbital; Phenytoin; Randomized Contro | 2007 |
Treatment of convulsive status epilepticus in infants and young children in Japan.
Topics: Anticonvulsants; Barbiturates; Benzodiazepines; Child; Child, Preschool; Epilepsy; Humans; Infant; I | 2007 |
How urgent is the treatment of nonconvulsive status epilepticus?
Topics: Adult; Animals; Anticonvulsants; Benzodiazepines; Child; Cognition Disorders; Disease Models, Animal | 2007 |
Seizures and seizure-like states in the child: an approach to emergency management.
Topics: Anesthesia, General; Child; Child, Preschool; Diagnosis, Differential; Diazepam; Emergencies; Humans | 1983 |
Therapy for status epilepticus.
Topics: Acetazolamide; Anesthesia; Anticonvulsants; Barbiturates; Chlormethiazole; Clonazepam; Diazepam; Eth | 1983 |
Status epilepticus: mechanisms of brain damage and rational management.
Topics: Anticonvulsants; Brain Damage, Chronic; Diazepam; Electroencephalography; Humans; Phenytoin; Status | 1982 |
Anticonvulsant drugs in alcohol withdrawal: use of phenytoin, primidone, carbamazepine, valproic acid, and the sedative anticonvulsants.
Topics: Alcoholism; Anticonvulsants; Carbamazepine; Humans; Hypnotics and Sedatives; Phenytoin; Primidone; S | 1981 |
The epileptic mother and her child.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Breast Feeding; Carbamazepine; Epilepsy; Female; Fetal | 1982 |
Lidocaine in status epilepticus.
Topics: Humans; Infusions, Intravenous; Lidocaine; Phenytoin; Recurrence; Status Epilepticus | 1994 |
Treatment of convulsive status epilepticus. Recommendations of the Epilepsy Foundation of America's Working Group on Status Epilepticus.
Topics: Benzodiazepines; Humans; Morbidity; Phenobarbital; Phenytoin; Resuscitation; Spinal Puncture; Status | 1993 |
Treatment of status epilepticus.
Topics: Anticonvulsants; Benzodiazepines; Carbamazepine; Diazepam; Humans; Phenobarbital; Phenytoin; Status | 1993 |
Status epilepticus and acute repetitive seizures in children, adolescents, and young adults: etiology, outcome, and treatment.
Topics: Adolescent; Adult; Age Factors; Aged; Anticonvulsants; Benzodiazepines; Central Nervous System Disea | 1996 |
Intravenous administration of fosphenytoin: options for the management of seizures.
Topics: Anticonvulsants; Epilepsy; Humans; Infusions, Parenteral; Phenytoin; Status Epilepticus | 1996 |
Do seizures beget seizures? An assessment of the clinical evidence in humans.
Topics: Anticonvulsants; Brain Injuries; Epilepsies, Myoclonic; Humans; Phenytoin; Seizures; Seizures, Febri | 1997 |
Rational polytherapy in the treatment of status epilepticus.
Topics: Amino Acids; Animals; Anticonvulsants; Brain; Diazepam; Drug Interactions; Drug Synergism; Drug Ther | 1996 |
Medical causes of seizures.
Topics: Acute Kidney Injury; Anticonvulsants; Antitubercular Agents; Blood Pressure; Brain Diseases; Broncho | 1998 |
Management approaches to prolonged seizures and status epilepticus.
Topics: Anticonvulsants; Benzodiazepines; Diazepam; Drug Administration Schedule; Drug Therapy, Combination; | 1999 |
Fosphenytoin and phenytoin in patients with status epilepticus: improved tolerability versus increased costs.
Topics: Anticonvulsants; Humans; Phenytoin; Status Epilepticus | 2000 |
Treatment of status epilepticus.
Topics: Anticonvulsants; Benzodiazepines; Child; Humans; Patient Compliance; Phenobarbital; Phenytoin; Pract | 2000 |
Status epilepticus.
Topics: Anticonvulsants; Benzodiazepines; Child; Child, Preschool; Humans; Infant; Infant, Newborn; Midazola | 2001 |
Treatment of status epilepticus in children.
Topics: Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Child; Humans; Phenobarbital; Phenytoin; Prev | 2001 |
Emergency department drug therapy for status epilepticus in adults.
Topics: Adult; Benzodiazepines; Emergency Service, Hospital; Humans; Hypnotics and Sedatives; Lorazepam; Phe | 2002 |
The current state of treatment of status epilepticus.
Topics: Animals; Anticonvulsants; Benzodiazepines; Brain; Electroencephalography; Female; GABA Modulators; H | 2002 |
The pharmacological treatment of epilepsy.
Topics: Anticonvulsants; Carbamazepine; Child, Preschool; Clonazepam; Drug Therapy, Combination; Epilepsies, | 1979 |
Drug therapy reviews: drug therapy of status epilepticus.
Topics: Anesthesia, General; Diazepam; Epilepsies, Partial; Epilepsy, Absence; Epilepsy, Temporal Lobe; Epil | 1978 |
Status epilepticus. Clinical features, pathophysiology, and treatment.
Topics: Benzodiazepines; Clinical Protocols; Drug Therapy, Combination; Humans; Phenobarbital; Phenytoin; St | 1991 |
The pharmacokinetics of agents used to treat status epilepticus.
Topics: Anticonvulsants; Diazepam; Dose-Response Relationship, Drug; Humans; Injections, Intramuscular; Lipi | 1990 |
Treatment of status epilepticus.
Topics: Anticonvulsants; Barbiturates; Benzodiazepines; Child; Humans; Phenobarbital; Phenytoin; Status Epil | 1989 |
[Oral loading dose of phenytoin].
Topics: Adult; Aged; Epilepsy; Female; Humans; Male; Middle Aged; Phenytoin; Status Epilepticus | 1988 |
Status epilepticus.
Topics: Adult; Anticonvulsants; Barbiturates; Benzodiazepines; Carbamazepine; Humans; Infant, Newborn; Lidoc | 1986 |
[Status epilepticus in childhood].
Topics: Brain; Child; Child, Preschool; Diazepam; Female; Follow-Up Studies; Humans; Infant; Infant, Newborn | 1986 |
39 trials available for phenytoin and Absence Status
| Article | Year |
|---|---|
Treatment of Toxin-Related Status Epilepticus With Levetiracetam, Fosphenytoin, or Valproate in Patients Enrolled in the Established Status Epilepticus Treatment Trial.
Topics: Adult; Alcoholism; Analgesics, Opioid; Anticonvulsants; Benzodiazepines; Child; Cocaine; Female; Hum | 2022 |
Levetiracetam versus fosphenytoin as a second-line treatment after diazepam for adult convulsive status epilepticus: a multicentre non-inferiority randomised control trial.
Topics: Adult; Anticonvulsants; Diazepam; Humans; Levetiracetam; Phenytoin; Seizures; Status Epilepticus; Tr | 2023 |
Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus.
Topics: Adolescent; Adult; Anticonvulsants; Benzodiazepines; Child; Child, Preschool; Double-Blind Method; D | 2019 |
Clinical Effectiveness of Levetiracetam Compared to Fosphenytoin in the Treatment of Benzodiazepine Refractory Convulsive Status Epilepticus.
Topics: Anticonvulsants; Benzodiazepines; Child; Humans; Levetiracetam; Neoplasm Recurrence, Local; Phenytoi | 2020 |
Comparison of Phenytoin, Valproate and Levetiracetam in Pediatric Convulsive Status Epilepticus: A Randomized Double-blind Controlled Clinical Trial.
Topics: Anticonvulsants; Child; Child, Preschool; Double-Blind Method; Female; Humans; Infant; Intention to | 2020 |
Efficacy of levetiracetam, fosphenytoin, and valproate for established status epilepticus by age group (ESETT): a double-blind, responsive-adaptive, randomised controlled trial.
Topics: Adolescent; Adult; Age Distribution; Age Factors; Aged; Aged, 80 and over; Anticonvulsants; Child; C | 2020 |
The association of patient weight and dose of fosphenytoin, levetiracetam, and valproic acid with treatment success in status epilepticus.
Topics: Adolescent; Adult; Anticonvulsants; Body Weight; Dose-Response Relationship, Drug; Female; Humans; L | 2020 |
Levetiracetam as an alternative to phenytoin for second-line emergency treatment of children with convulsive status epilepticus: the EcLiPSE RCT.
Topics: Administration, Intravenous; Adolescent; Anticonvulsants; Child; Child, Preschool; Equivalence Trial | 2020 |
Early Exposure of Fosphenytoin, Levetiracetam, and Valproic Acid After High-Dose Intravenous Administration in Young Children With Benzodiazepine-Refractory Status Epilepticus.
Topics: Anticonvulsants; Benzodiazepines; Child; Child, Preschool; Dose-Response Relationship, Drug; Female; | 2021 |
Levetiracetam versus fosphenytoin as a second-line treatment after diazepam for status epilepticus: study protocol for a multicenter non-inferiority designed randomized control trial.
Topics: Adult; Anticonvulsants; Diazepam; Humans; Japan; Levetiracetam; Multicenter Studies as Topic; Neopla | 2021 |
Efficacy of Home Anticonvulsant Administration for Second-Line Status Epilepticus Treatment.
Topics: Adolescent; Adult; Anticonvulsants; Benzodiazepines; Child; Comparative Effectiveness Research; Doub | 2021 |
Intravenous levetiracetam vs phenytoin for status epilepticus and cluster seizures: A prospective, randomized study.
Topics: Adult; Anticonvulsants; Female; Humans; Infusions, Intravenous; Levetiracetam; Male; Phenytoin; Pira | 2017 |
Emergency treatment with levetiracetam or phenytoin in status epilepticus in children-the EcLiPSE study: study protocol for a randomised controlled trial.
Topics: Adolescent; Age Factors; Anticonvulsants; Child; Child, Preschool; Clinical Protocols; Emergencies; | 2017 |
A multicentre randomised controlled trial of levetiracetam versus phenytoin for convulsive status epilepticus in children (protocol): Convulsive Status Epilepticus Paediatric Trial (ConSEPT) - a PREDICT study.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Clinical Protocols; Emergencies; Emergency Ser | 2017 |
Sodium valproate compared to phenytoin in treatment of status epilepticus.
Topics: Adult; Aged; Anticonvulsants; Benzodiazepines; Drug Resistance; Female; Humans; Infusions, Intraveno | 2018 |
Enhancing practitioners' confidence in recruitment and consent in the EcLiPSE trial: a mixed-method evaluation of site training - a Paediatric Emergency Research in the United Kingdom and Ireland (PERUKI) study.
Topics: Emergencies; Humans; Informed Consent; Levetiracetam; Patient Selection; Phenytoin; Research Design; | 2019 |
Levetiracetam versus phenytoin for second-line treatment of convulsive status epilepticus in children (ConSEPT): an open-label, multicentre, randomised controlled trial.
Topics: Adolescent; Aged; Anticonvulsants; Australia; Child; Child, Preschool; Drug Administration Schedule; | 2019 |
Levetiracetam versus phenytoin for second-line treatment of paediatric convulsive status epilepticus (EcLiPSE): a multicentre, open-label, randomised trial.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Drug Administration Schedule; Drug Resistant E | 2019 |
Bayesian adaptive trials offer advantages in comparative effectiveness trials: an example in status epilepticus.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Bayes Theorem; Child; Child, Preschool; Comparative Effect | 2013 |
The established status epilepticus trial 2013.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Child; Child, Preschool; Double-Blind M | 2013 |
Levetiracetam versus phenytoin in management of status epilepticus.
Topics: Administration, Intravenous; Adolescent; Adult; Aged; Anticonvulsants; Disease Management; Female; H | 2015 |
Canine status epilepticus treated with fosphenytoin: A proof of principle study.
Topics: Animals; Anticonvulsants; Benzodiazepines; Dogs; Double-Blind Method; Female; Infusions, Intravenous | 2015 |
Management of generalised convulsive status epilepticus (SE): A prospective randomised controlled study of combined treatment with intravenous lorazepam with either phenytoin, sodium valproate or levetiracetam--Pilot study.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Drug Therapy, Combination; Electroencephalography; Epileps | 2015 |
A comparison of four antiepileptic drugs in status epilepticus: experience from India.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Child; Child, Preschool; Female; Humans; India; Infant; Le | 2016 |
Treatment of status epilepticus and acute repetitive seizures with i.v. valproic acid vs phenytoin.
Topics: Acute Disease; Adult; Aged; Anticonvulsants; Brain; Drug-Related Side Effects and Adverse Reactions; | 2008 |
Lorazepam versus diazepam-phenytoin combination in the treatment of convulsive status epilepticus in children: a randomized controlled trial.
Topics: Algorithms; Anticonvulsants; Child; Child, Preschool; Diazepam; Drug Therapy, Combination; Electroen | 2010 |
Canine status epilepticus: a translational platform for human therapeutic trials.
Topics: Animals; Anticonvulsants; Disease Models, Animal; Dogs; Dose-Response Relationship, Drug; Double-Bli | 2011 |
Eight-year study of childhood status epilepticus: midazolam infusion in management and outcome.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Diazepam; Dose-Response Relationship, Drug; El | 2002 |
Intravenous valproate as an innovative therapy in seizure emergency situations including status epilepticus--experience in 102 adult patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Benzodiazepines; Female; Humans; Inject | 2005 |
Status epilepticus: clinical analysis of a treatment protocol based on midazolam and phenytoin.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Drug Therapy, Combination; Female; Humans; Hyp | 2005 |
Sodium valproate vs phenytoin in status epilepticus: a pilot study.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Child; Child, Preschool; Female; Humans; India; Male; Midd | 2006 |
Randomized study of intravenous valproate and phenytoin in status epilepticus.
Topics: Adolescent; Adult; Anticonvulsants; Case-Control Studies; Child; Double-Blind Method; Female; Follow | 2007 |
Treatment of refractory status epilepticus with propofol: clinical and pharmacokinetic findings.
Topics: Adult; Aged; Barbiturates; Clinical Protocols; Drug Administration Schedule; Drug Therapy, Combinati | 1998 |
A comparison of four treatments for generalized convulsive status epilepticus. Veterans Affairs Status Epilepticus Cooperative Study Group.
Topics: Aged; Anticonvulsants; Diazepam; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Inj | 1998 |
Cost-minimization analysis of phenytoin and fosphenytoin in the emergency department.
Topics: Anticonvulsants; Cost Control; Emergency Medical Services; Humans; Models, Economic; Monte Carlo Met | 2000 |
[Treatment of status epilepticus with clonazepam].
Topics: Benzodiazepinones; Clinical Trials as Topic; Clonazepam; Diazepam; Drug Evaluation; Humans; Phenobar | 1976 |
Phenytoin administration by constant intravenous infusion: selective rates of administration.
Topics: Adult; Aged; Aged, 80 and over; Arteriosclerosis; Blood Pressure; Cardiovascular Diseases; Female; H | 1991 |
Treatment of status epilepticus: a prospective comparison of diazepam and phenytoin versus phenobarbital and optional phenytoin.
Topics: Adult; Aged; Clinical Trials as Topic; Diazepam; Drug Therapy, Combination; Female; Humans; Male; Mi | 1988 |
Single-dose oral phenytoin loading.
Topics: Administration, Oral; Adult; Aged; Capsules; Drug Administration Schedule; Epilepsy; Female; Humans; | 1987 |
270 other studies available for phenytoin and Absence Status
| Article | Year |
|---|---|
Structure-activity relationships of the aromatic site in novel anticonvulsant pyrrolo[1,2-a]pyrazine derivatives.
Topics: Animals; Anticonvulsants; Male; Mice; Pyrazines; Pyrroles; Rats; Rats, Sprague-Dawley; Status Epilep | 2013 |
Pyrazolo[3,4-d]pyrimidine-based dual EGFR T790M/HER2 inhibitors: Design, synthesis, structure-activity relationship and biological activity as potential antitumor and anticonvulsant agents.
Topics: Animals; Anticonvulsants; Antineoplastic Agents; Apoptosis; Cell Line; Cell Proliferation; Cell Surv | 2021 |
Status Epilepticus Australasian Registry for Children: A pilot prospective, observational, cohort study of paediatric status epilepticus.
Topics: Anticonvulsants; Benzodiazepines; Child; Child, Preschool; Cohort Studies; Female; Humans; Levetirac | 2022 |
Efficacy of intravenous levetiracetam versus phenytoin in convulsive status epilepticus and acute repetitive seizures in children.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Female; Humans; Infant; Infusions, Intravenous | 2022 |
Survey About Second-Line Agents for Pediatric Convulsive Status Epilepticus.
Topics: Anticonvulsants; Benzodiazepines; Child; Humans; Levetiracetam; Phenytoin; Status Epilepticus | 2023 |
Does long-term phenytoin have a place in Dravet syndrome?
Topics: Epilepsies, Myoclonic; Humans; Phenytoin; Seizures; Sodium Channels; Status Epilepticus | 2022 |
Treatment of benzodiazepine-refractory status epilepticus: A retrospective, cohort study.
Topics: Adolescent; Anticonvulsants; Benzodiazepines; Cohort Studies; Female; Humans; Lacosamide; Levetirace | 2023 |
Is Levetiracetam a Superior Anti-Seizure Medication in Pediatric Status Epilepticus?
Topics: Anticonvulsants; Child; Humans; Levetiracetam; Phenytoin; Status Epilepticus | 2023 |
Trends and Differences in Status Epilepticus Treatment of Children and Adults Over 10 Years: A Comparative Study of Medical Records (2012-2021) from a University Hospital in Germany.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Benzodiazepines; Child; Female; Hospitals, Universi | 2023 |
Critical Care Management of Status Epilepticus at a Tertiary Care University Hospital.
Topics: Aged; Anticonvulsants; Critical Care; Drug Therapy, Combination; Female; Humans; Levetiracetam; Male | 2019 |
Stimulus-induced rhythmic, periodic ictal discharges during funduscopic examination in a patient with status epilepticus.
Topics: Electroencephalography; Humans; Male; Midazolam; Phenytoin; Seizures; Status Epilepticus; Young Adul | 2019 |
Levetiracetam is a useful alternative to phenytoin for epileptic seizures in children.
Topics: Child; Epilepsy; Humans; Levetiracetam; Phenytoin; Seizures; Status Epilepticus | 2019 |
Phenytoin and levetiracetam are equally effective second-line treatments for status epilepticus.
Topics: Anticonvulsants; Child; Humans; Levetiracetam; Phenytoin; Research Design; Status Epilepticus | 2020 |
Infant with status epilepticus secondary to systemic lidocaine toxicity from topical application.
Topics: Administration, Topical; Anticonvulsants; Diagnosis, Differential; Female; Humans; Infant; Lidocaine | 2020 |
Diagnostic evaluation and management of seizures and status epilepticus in children with known epilepsy or new-onset seizures: A retrospective and comparative analysis.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Clonazepam; Diazepam; Epilepsy; Female; Hospit | 2020 |
Fosphenytoin in Status Epilepticus: The Ice Needs to be Broken.
Topics: Anticonvulsants; Child; Humans; Ice; Phenytoin; Status Epilepticus | 2020 |
Pediatric Convulsive Status Epilepticus: Act Fast, No matter With What!
Topics: Child; Double-Blind Method; Humans; Levetiracetam; Phenytoin; Status Epilepticus; Valproic Acid | 2020 |
Efficacy, Tolerability and Serum Phenytoin Levels after Intravenous Fosphenytoin Loading Dose in Children with Status Epilepticus.
Topics: Administration, Intravenous; Adolescent; Anticonvulsants; Biomarkers; Child; Child, Preschool; Dose- | 2020 |
Second-line anticonvulsants for paediatric convulsive status epilepticus.
Topics: Anticonvulsants; Child; Double-Blind Method; Humans; Levetiracetam; Phenytoin; Status Epilepticus; V | 2020 |
Second-line treatments in benzodiazepine-resistant convulsive status epilepticus: An updated network meta-analysis including the ESET Trial - What did change?
Topics: Adult; Anticonvulsants; Benzodiazepines; Humans; Network Meta-Analysis; Phenytoin; Status Epilepticu | 2020 |
Evaluation of fosphenytoin, levetiracetam, and propofol as treatments for nerve agent-induced seizures in pediatric and adult rats.
Topics: Age Factors; Animals; Anticonvulsants; Brain; Disease Models, Animal; Female; Levetiracetam; Male; O | 2020 |
Paediatric status epilepticus: finally, some evidence-based treatment guidance, but still a long way to go.
Topics: Adolescent; Anticonvulsants; Benzodiazepines; Child; Child, Preschool; Emergency Treatment; Epilepsy | 2020 |
Levetiracetam for Benzodiazepine-Refractory Status Epilepticus.
Topics: Benzodiazepines; Humans; Levetiracetam; Phenytoin; Status Epilepticus; Treatment Outcome | 2020 |
Clinical Effectiveness of Levetiracetam Compared to Fosphenytoin in the Treatment of Benzodiazepine Refractory Convulsive Status Epilepticus: Correspondence.
Topics: Benzodiazepines; Humans; Levetiracetam; Phenytoin; Status Epilepticus; Treatment Outcome | 2021 |
Phenytoin versus fosphenytoin for second-line treatment of status epilepticus: propensity score matching analysis using a nationwide inpatient database.
Topics: Adult; Anticonvulsants; Humans; Inpatients; Phenytoin; Propensity Score; Status Epilepticus | 2020 |
Choosing Anticonvulsant Medications to Manage Status Epilepticus.
Topics: Adult; Anticonvulsants; Disease Management; Drug Therapy, Combination; Epilepsy, Generalized; Female | 2020 |
Efficacy and safety profile of intravenous levetiracetam versus phenytoin in convulsive status epilepticus and acute repetitive seizures in children.
Topics: Administration, Intravenous; Adolescent; Anticonvulsants; Child; Child, Preschool; Emergency Medical | 2020 |
Seven-step framework to enhance practitioner explanations and parental understandings of research without prior consent in paediatric emergency and critical care trials.
Topics: Anticonvulsants; Child; Critical Care; Data Collection; Emergency Service, Hospital; England; Female | 2021 |
First-line medication dosing in pediatric refractory status epilepticus.
Topics: Adolescent; Age Factors; Anticonvulsants; Benzodiazepines; Child; Child, Preschool; Dose-Response Re | 2020 |
Planning for success: overcoming challenges to recruitment and conduct of an open-label emergency department-led paediatric trial.
Topics: Anticonvulsants; Child; Data Collection; Emergency Service, Hospital; England; Female; Humans; Levet | 2021 |
An uncommon case of nonconvulsive status epilepticus successfully treated with enteral Brivaracetam.
Topics: Aged, 80 and over; Electroencephalography; Female; Humans; Phenytoin; Pyrrolidinones; Status Epilept | 2021 |
Levetiracetam compared with phenytoin or fosphenytoin in benzodiazepine-refractory pediatric status epilepticus.
Topics: Anticonvulsants; Benzodiazepines; Child; Humans; Levetiracetam; Phenytoin; Status Epilepticus | 2022 |
Rapid infusion of excessive phenytoin: A newborn autopsy case.
Topics: Anticonvulsants; Autopsy; Cesarean Section; Female; Humans; Infant; Infant, Newborn; Phenytoin; Preg | 2021 |
The efficacy of different kinds of intravenously applied antiepileptic drugs in the treatment of status epilepticus. How can it be determined?
Topics: Acetamides; Administration, Intravenous; Adult; Aged; Aged, 80 and over; Anticonvulsants; Female; He | 2017 |
Simultaneous triple therapy for the treatment of status epilepticus.
Topics: Animals; Anticonvulsants; Brain Waves; Combined Modality Therapy; Disease Models, Animal; Dose-Respo | 2017 |
Efficacy of levetiracetam versus fosphenytoin for the recurrence of seizures after status epilepticus.
Topics: Administration, Intravenous; Administration, Oral; Anticonvulsants; Blood Pressure; Databases, Factu | 2017 |
Avoiding errors when administering injectable phenytoin to a child in status epilepticus.
Topics: Administration, Intravenous; Humans; Medication Errors; Patient Safety; Phenytoin; State Medicine; S | 2018 |
Treatment outcomes after the introduction of a new seizure management protocol.
Topics: Adult; Anticonvulsants; Clinical Protocols; Drug-Related Side Effects and Adverse Reactions; Emergen | 2018 |
Pharmacological characterization of the cannabinoid receptor 2 agonist, β-caryophyllene on seizure models in mice.
Topics: Animals; Anticonvulsants; Cannabinoid Receptor Agonists; Diazepam; Disease Models, Animal; Dose-Resp | 2018 |
Fosphenytoin vs. continuous midazolam for pediatric febrile status epilepticus.
Topics: Anticonvulsants; Child; Child, Preschool; Cohort Studies; Female; Humans; Infant; Male; Midazolam; O | 2018 |
Levetiracetam no better than phenytoin in children with convulsive status epilepticus.
Topics: Anticonvulsants; Child; Humans; Levetiracetam; Phenytoin; Status Epilepticus | 2019 |
Reversible focal radiological changes due to non-convulsive status epilepticus of the right parietooccipital lobe.
Topics: Anticonvulsants; Cerebral Angiography; Electroencephalography; Female; Humans; Image Processing, Com | 2013 |
What is the easier and more reliable dose calculation for iv phenytoin in children at risk of developing convulsive status epilepticus, 18 mg/kg or 20 mg/kg?
Topics: Anticonvulsants; Drug Dosage Calculations; Humans; Injections, Intravenous; Medication Errors; Pheny | 2013 |
Status epilepticus in a child secondary to ingestion of skin-lightening cream.
Topics: Anticonvulsants; Ataxia; Eating; Emergencies; Humans; Hydroquinones; Infant; Intubation, Intratrache | 2013 |
The efficacy of intravenous sodium valproate and phenytoin as the first-line treatment in status epilepticus: a comparison study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Electroencephalography; Female; Humans; | 2013 |
Intravenous lacosamide or phenytoin for treatment of refractory status epilepticus.
Topics: Acetamides; Administration, Intravenous; Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants | 2014 |
Treatment of Recurrent Electrographic Nonconvulsive Seizures (TRENdS) study.
Topics: Acetamides; Anticonvulsants; Electroencephalography; Humans; Lacosamide; Monitoring, Physiologic; Ph | 2013 |
Considerations in prophylaxis for tumor-associated epilepsy: prevention of status epilepticus and tolerability of newer generation AEDs.
Topics: Aged; Aged, 80 and over; Anticonvulsants; Brain Neoplasms; Female; Humans; Levetiracetam; Male; Midd | 2013 |
Phenytoin dosing and serum concentrations in paediatric patients requiring 20 mg/kg intravenous loading.
Topics: Administration, Intravenous; Adolescent; Anticonvulsants; Child; Child, Preschool; Drug Dosage Calcu | 2014 |
[Case of non-convulsive status epilepticus after influenza virus B infection].
Topics: Adult; Anticonvulsants; Electroencephalography; Female; Humans; Influenza B virus; Influenza, Human; | 2014 |
Myristicin and phenytoin toxicity in an infant.
Topics: Allylbenzene Derivatives; Anticonvulsants; Benzyl Compounds; Dioxolanes; Humans; Infant; Male; Myris | 2014 |
Panayiotopoulos syndrome with convulsive status epilepticus at the onset: a long-term study.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Electroencephalography; Epilepsy, Rolandic; Fe | 2014 |
A retrospective observational study of current treatment for generalized convulsive status epilepticus.
Topics: Adolescent; Adult; Age Factors; Aged; Anticonvulsants; Benzodiazepines; Child; Child, Preschool; Dru | 2014 |
Purple glove syndrome occurring after oral administration of phenytoin in therapeutic doses: mechanism still a dilemma.
Topics: Administration, Oral; Adult; Anticonvulsants; Cyanosis; Edema; Hand; Humans; Male; Phenytoin; Status | 2015 |
Effect of status epilepticus and antiepileptic drugs on CYP2E1 brain expression.
Topics: Adolescent; Adult; Animals; Anticonvulsants; Brain; Carbamazepine; Cells, Cultured; Central Nervous | 2014 |
Impact of a phenytoin loading dose program in the emergency department.
Topics: Adult; Anticonvulsants; Drug Monitoring; Emergency Medical Services; Emergency Service, Hospital; Fe | 2014 |
The AMPA receptor antagonist NBQX exerts anti-seizure but not antiepileptogenic effects in the intrahippocampal kainate mouse model of mesial temporal lobe epilepsy.
Topics: Animals; Anticonvulsants; Chronic Disease; Disease Models, Animal; Electroencephalography; Epilepsy, | 2015 |
Status epilepticus induction has prolonged effects on the efficacy of antiepileptic drugs in the 6-Hz seizure model.
Topics: Animals; Anticonvulsants; Carbamazepine; Diazepam; Disease Models, Animal; Levetiracetam; Male; Mice | 2015 |
The safety and efficacy of fosphenytoin for the treatment of status epilepticus.
Topics: Anticonvulsants; Humans; Phenytoin; Seizures; Status Epilepticus | 2015 |
Medication-induced acute dystonic reaction: the challenge of diagnosing movement disorders in the intensive care unit.
Topics: Antipsychotic Agents; Benzodiazepines; Brain; Diphenhydramine; Dyskinesia, Drug-Induced; Haloperidol | 2015 |
A well known and important adverse effect of phenytoin in a neurosurgical patient.
Topics: Accidents, Traffic; Anticonvulsants; Craniocerebral Trauma; Gingival Hypertrophy; Humans; Male; Phen | 2015 |
Making SENSE--Sustained Effort Network for treatment of Status Epilepticus as a multicenter prospective registry.
Topics: Adult; Aged; Anticonvulsants; Diazepam; Female; Humans; Lorazepam; Male; Midazolam; Middle Aged; Phe | 2015 |
Seizure and Fever.
Topics: Acyclovir; Adrenal Cortex Hormones; Anti-Bacterial Agents; Antiviral Agents; Brain Neoplasms; Ceftri | 2016 |
Status epilepticus in central nervous system infections: an experience from a developing country.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Central Nervous System Infections; Developing Countries; D | 2008 |
Resistance to antiepileptic drugs and expression of P-glycoprotein in two rat models of status epilepticus.
Topics: Amygdala; Animals; Anticonvulsants; ATP Binding Cassette Transporter, Subfamily B; Diazepam; Disease | 2008 |
Audit of treatment of convulsive status epilepticus.
Topics: Anticonvulsants; Child; Diazepam; Humans; Midazolam; Paraldehyde; Phenobarbital; Phenytoin; Practice | 2008 |
Reassessment of phenytoin for treatment of late stage progressive myoclonus epilepsy complicated with status epilepticus.
Topics: Adolescent; Adult; Age of Onset; Anticonvulsants; Child; Disease Progression; Electroencephalography | 2009 |
Neuroprotective effects of diazepam, carbamazepine, phenytoin and ketamine after pilocarpine-induced status epilepticus.
Topics: Animals; Anticonvulsants; Carbamazepine; Dentate Gyrus; Diazepam; Drug Administration Schedule; Glia | 2009 |
Capgras syndrome and unilateral spatial neglect in nonconvulsive status epilepticus.
Topics: Aged, 80 and over; Anticonvulsants; Capgras Syndrome; Functional Laterality; Humans; Male; Perceptua | 2008 |
Intestinal obstruction and phenytoin intoxication.
Topics: Anticonvulsants; Comorbidity; Epilepsy; Female; Half-Life; Humans; Intestinal Absorption; Intestinal | 2009 |
COX-2 inhibition controls P-glycoprotein expression and promotes brain delivery of phenytoin in chronic epileptic rats.
Topics: Animals; Anticonvulsants; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood-Brain Barri | 2010 |
Antiepileptic drugs combined with high-frequency electrical stimulation in the ventral hippocampus modify pilocarpine-induced status epilepticus in rats.
Topics: Amines; Animals; Anticonvulsants; Cyclohexanecarboxylic Acids; Disease Models, Animal; Electric Stim | 2010 |
Minimum requirements for approval of a drug in status epilepticus.
Topics: Anticonvulsants; Clinical Trials as Topic; Drug Approval; Europe; Humans; Phenytoin; Prodrugs; Resea | 2009 |
Persistent focal seizures after cat scratch encephalopathy.
Topics: Acyclovir; Anti-Bacterial Agents; Anticonvulsants; Antiviral Agents; Cat-Scratch Disease; Ceftriaxon | 2010 |
Phenytoin induced status epilepticus.
Topics: Adult; Anticonvulsants; Electrocardiography; Electroencephalography; Humans; Male; Phenytoin; Status | 2010 |
Refractory nonconvulsive status epilepticus responsive to music as an add-on therapy: a second case.
Topics: Aged; Anticonvulsants; Brain Neoplasms; Humans; Lung Neoplasms; Male; Music Therapy; Phenytoin; Stat | 2010 |
The role of intravenous valproate in convulsive status epilepticus in the future.
Topics: Anticonvulsants; Humans; Injections, Intravenous; Liver; Pancreatitis; Phenytoin; Practice Guideline | 2010 |
Phenytoin induced status epilepticus.
Topics: Anticonvulsants; Humans; Phenytoin; Status Epilepticus | 2010 |
Status epilepticus.
Topics: Anticonvulsants; Benzodiazepines; Child; Clinical Protocols; Fructose; GABA Modulators; Humans; Keta | 2011 |
Focal status epilepticus induced by hyperbaric oxygen therapy.
Topics: Aged, 80 and over; Anticonvulsants; Electroencephalography; Humans; Hyperbaric Oxygenation; Male; Ph | 2011 |
Status epilepticus associated with borage oil ingestion.
Topics: Acyclovir; Adult; Anticonvulsants; Borago; Diethylcarbamazine; Drug Therapy, Combination; Female; ga | 2011 |
Subacute encephalopathy and seizures in alcoholics (SESA) presenting with non-convulsive status epilepticus.
Topics: Acetamides; Alcohol Withdrawal Seizures; Alcoholism; Anticonvulsants; Brain Diseases; Confusion; Dif | 2011 |
Second-line status epilepticus treatment: comparison of phenytoin, valproate, and levetiracetam.
Topics: Aged; Analysis of Variance; Anticonvulsants; Chi-Square Distribution; Female; Humans; Levetiracetam; | 2011 |
Purple glove syndrome following intravenous phenytoin administration.
Topics: Anticonvulsants; Child; Cyanosis; Edema; Female; Hand; Humans; Infusions, Intravenous; Phenytoin; St | 2011 |
Abdominal epilepsy: an uncommon of non-convulsive status epilepticus.
Topics: Abdominal Pain; Diabetes Mellitus, Type 1; Electroencephalography; Female; Humans; Male; Middle Aged | 2011 |
Phenytoin, levetiracetam, and pregabalin in the acute management of refractory status epilepticus in patients with brain tumors.
Topics: Acute Disease; Aged; Anticonvulsants; Brain Neoplasms; Drug Therapy, Combination; Female; gamma-Amin | 2012 |
Coenzyme Q10 enhances the anticonvulsant effect of phenytoin in pilocarpine-induced seizures in rats and ameliorates phenytoin-induced cognitive impairment and oxidative stress.
Topics: Analysis of Variance; Animals; Anticonvulsants; Avoidance Learning; Catalase; Cognition Disorders; D | 2011 |
[Status epilepticus].
Topics: Anticonvulsants; Electroencephalography; Emergency Medical Services; Humans; Phenytoin; Status Epile | 2012 |
Lack of efficacy of phenytoin in children presenting with febrile status epilepticus.
Topics: Anticonvulsants; Emergency Service, Hospital; Humans; Infant; Male; Phenytoin; Retrospective Studies | 2012 |
Seizure management at Auckland City Hospital Emergency Department between July and December 2009: time for a change?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Carbamazepine; Disease Management; Emer | 2012 |
Practice variations in the management of status epilepticus.
Topics: Adult; Aged; Anticonvulsants; Benzodiazepines; Critical Care; Female; Humans; Levetiracetam; Male; M | 2012 |
An atypical case of purple glove syndrome: an avoidable adverse event.
Topics: Aged; Anticonvulsants; Compartment Syndromes; Diagnosis, Differential; Forearm; Humans; Infusions, I | 2012 |
Lack of efficacy of phenytoin in children presenting with febrile status epilepticus.
Topics: Anticonvulsants; Humans; Male; Phenytoin; Seizures, Febrile; Status Epilepticus | 2012 |
Treatment of status epilepticus: an international survey of experts.
Topics: Administration, Intravenous; Adult; Anticonvulsants; Child; Consensus; Expert Testimony; Humans; Hyp | 2013 |
Hypoglycaemia induced by phenytoin treatment for partial status epilepticus.
Topics: Adult; Anticonvulsants; Female; Humans; Hypoglycemia; Phenytoin; Status Epilepticus | 2002 |
Characterization of pharmacoresistance to benzodiazepines in the rat Li-pilocarpine model of status epilepticus.
Topics: Animals; Anticonvulsants; Benzodiazepines; Chi-Square Distribution; Diazepam; Disease Models, Animal | 2002 |
Treatment of phenytoin toxicity by the molecular adsorbents recirculating system (MARS).
Topics: Anticonvulsants; Drug Overdose; Equipment Design; Hemofiltration; Humans; Kidney Failure, Chronic; L | 2003 |
Ketamine for refractory status epilepticus: a case of possible ketamine-induced neurotoxicity.
Topics: Adult; Anticonvulsants; Atrophy; Brain; Electroencephalography; Excitatory Amino Acid Antagonists; H | 2003 |
[Status epilepticus].
Topics: Adult; Anticonvulsants; Diazepam; Humans; Phenytoin; Status Epilepticus | 2003 |
Pharmacokinetics and clinical effects of phenytoin and fosphenytoin in children with severe malaria and status epilepticus.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Female; Humans; Infant; Infusions, Intravenous | 2003 |
A comparison of central brain (cerebrospinal and extracellular fluids) and peripheral blood kinetics of phenytoin after intravenous phenytoin and fosphenytoin.
Topics: Animals; Anticonvulsants; Brain; Extracellular Space; Frontal Lobe; Hippocampus; Injections, Intrave | 2003 |
Use of parenteral diphenylhydantoin (dilantin) sodium in control of status epilepticus.
Topics: Epilepsy; Hydantoins; Ions; Phenytoin; Sodium; Sodium, Dietary; Status Epilepticus | 1958 |
[ETIOLOGY AND THERAPY OF STATUS EPILEPTICUS].
Topics: Abortion, Septic; Anticonvulsants; Birth Injuries; Brain Injuries; Brain Neoplasms; Chloral Hydrate; | 1963 |
PROBENECID (BENEMID) INTOXICATION WITH STATUS EPILEPTICUS.
Topics: Coma; Drug Therapy; Epilepsy; Gout; Phenobarbital; Phenytoin; Poisoning; Probenecid; Status Epilepti | 1965 |
Valproate suppresses status epilepticus induced by 4-aminopyridine in CA1 hippocampus region.
Topics: 4-Aminopyridine; Animals; Carbamazepine; Disease Models, Animal; Dose-Response Relationship, Drug; E | 2003 |
Postictal laughter following absence status epilepticus.
Topics: Adult; Drug Therapy, Combination; Electroencephalography; Female; Humans; Laughter; Phenytoin; Seizu | 2003 |
Effects of fosphenytoin on nerve agent-induced status epilepticus.
Topics: Animals; Anticonvulsants; Atropine; Chemical Warfare Agents; Diazepam; Disease Models, Animal; Dose- | 2004 |
Clinical policy: Critical issues in the evaluation and management of adult patients presenting to the emergency department with seizures.
Topics: Adult; Anticonvulsants; Electroencephalography; Emergency Service, Hospital; Epilepsy; Humans; Pheny | 2004 |
Clinical features of status epilepticus in patients with HIV infection.
Topics: Adult; Anti-Retroviral Agents; Anticonvulsants; Benzodiazepines; Brain Neoplasms; Central Nervous Sy | 2005 |
[Choice and administration sequence of antiepileptic agents for status epilepticus and frequent seizures in children].
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Diazepam; Drug Administration Schedule; Female | 2005 |
Expression of multidrug transporters MRP1, MRP2, and BCRP shortly after status epilepticus, during the latent period, and in chronic epileptic rats.
Topics: Animals; Anticonvulsants; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Casse | 2005 |
Treatment delay and the risk of prolonged status epilepticus.
Topics: Administration, Rectal; Anticonvulsants; Benzodiazepines; Child, Preschool; Clinical Protocols; Dise | 2005 |
[Management of status epilepticus].
Topics: Adult; Age Factors; Aged; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Child; Diazepam; Dr | 2005 |
Cortical laminar necrosis related to prolonged focal status epilepticus.
Topics: Adult; Anticonvulsants; Aphasia, Wernicke; Brain Diseases; Cerebral Cortex; Functional Laterality; H | 2006 |
Fosphenytoin may cause hemodynamically unstable bradydysrhythmias.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Anticonvulsants | 2006 |
When benzodiazepines fail: how effective is second line therapy for status epilepticus in children?
Topics: Anesthetics; Anticonvulsants; Benzodiazepines; Child; Child, Preschool; Diazepam; Dose-Response Rela | 2006 |
Appropriateness of intravenous loading dose of phenytoin treatment in Srinagarind Hospital.
Topics: Adult; Anticonvulsants; Drug Utilization Review; Female; Health Services Misuse; Hospitals, Universi | 2005 |
Hepatic encephalopathy with status epileptics: a case report.
Topics: Amino Acids, Branched-Chain; Ammonia; Brain; Electroencephalography; Hepatic Encephalopathy; Humans; | 2006 |
Seizure presenting to the emergency department, Srinagarind Hospital.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Child; Child, Preschool; Emergency Service, Hospital; Fema | 2006 |
Transient occipitotemporal subcortical diffusion-weighted magnetic resonance imaging abnormalities associated with status epilepticus. Case report.
Topics: Adult; Carbamazepine; Diazepam; Diffusion Magnetic Resonance Imaging; Drug Administration Schedule; | 2006 |
Ceftazidime overdose-related nonconvulsive status epilepticus after intraperitoneal instillation.
Topics: Aged; Anti-Bacterial Agents; Anticonvulsants; Ceftazidime; Drug Overdose; Electroencephalography; Fe | 2006 |
[Status epilepticus in a 2-month-old infant].
Topics: Anticonvulsants; Brain; Diagnosis, Differential; Electroencephalography; Humans; Infant; Injections, | 2006 |
Treatment of status epilepticus in adults: guidelines of the Italian League against Epilepsy.
Topics: Adult; Age Factors; Anesthesia, General; Anticonvulsants; Benzodiazepines; Humans; International Age | 2006 |
Resistance to phenobarbital extends to phenytoin in a rat model of temporal lobe epilepsy.
Topics: Amygdala; Animals; Anticonvulsants; Disease Models, Animal; Dose-Response Relationship, Drug; Drug R | 2007 |
Sodium valproate vs phenytoin in status epilepticus: a pilot study.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Child; Child, Preschool; Female; Humans; India; Male; Midd | 2007 |
Termination of complex partial status epilepticus by intravenous levetiracetam.
Topics: Adult; Anticonvulsants; Electroencephalography; Female; Humans; Infusions, Intravenous; Levetiraceta | 2009 |
[Subtherapeutic blood levels of phenytoin due to a medication error].
Topics: Aged; Aged, 80 and over; Anticonvulsants; Diagnosis, Differential; Drug Interactions; Drug Monitorin | 2007 |
Non-convulsive status epilepticus secondary to valproic acid-induced hyperammonemic encephalopathy.
Topics: Adult; Ammonia; Anticonvulsants; Brain; Electroencephalography; Hepatic Encephalopathy; Humans; Hype | 2007 |
Status epilepticus associated with sertindole.
Topics: Anticonvulsants; Antipsychotic Agents; Brain; Brain Chemistry; Dose-Response Relationship, Drug; Ele | 2007 |
Status epilepticus secondary to hypertensive encephalopathy as the presenting manifestation of Guillain-Barré syndrome.
Topics: Adolescent; Amines; Anticonvulsants; Antihypertensive Agents; Cyclohexanecarboxylic Acids; Diagnosis | 2007 |
Pharmacokinetics of midazolam and metabolites in a patient with refractory status epilepticus treated with extraordinary doses of midazolam.
Topics: Anticonvulsants; Carbamazepine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; | 2008 |
Incidence and outcome of convulsive status epilepticus in Kenyan children: a cohort study.
Topics: Adolescent; Analysis of Variance; Anticonvulsants; Child; Child, Preschool; Cohort Studies; Data Int | 2008 |
Simultaneous toxicities in a child on multiple anticonvulsants.
Topics: Anticonvulsants; Bone Marrow; Bone Marrow Diseases; Chemical and Drug Induced Liver Injury; Child, P | 2008 |
The novel antiepileptic drug carisbamate (RWJ 333369) is effective in inhibiting spontaneous recurrent seizure discharges and blocking sustained repetitive firing in cultured hippocampal neurons.
Topics: Animals; Anticonvulsants; Carbamates; Cells, Cultured; Data Interpretation, Statistical; Dose-Respon | 2008 |
Re: New lessons: classic treatments in convulsive status epilepticus.
Topics: Anticonvulsants; Benzodiazepines; Diazepam; Humans; Lorazepam; Phenytoin; Status Epilepticus; Valpro | 2008 |
Refractory status epilepticus during pregnancy secondary to cavernous angioma.
Topics: Abortion, Induced; Abortion, Therapeutic; Anticonvulsants; Brain Neoplasms; Female; Hemangioma, Cave | 2008 |
A monkey model for status epilepticus: carbamazepine and valproate compared to three standard anticonvulsants.
Topics: Aluminum Hydroxide; Animals; Anticonvulsants; Carbamazepine; Diazepam; Macaca mulatta; Male; Phenoba | 1983 |
Clinical pharmacokinetics of drugs used in the treatment of status epilepticus.
Topics: Animals; Anticonvulsants; Barbiturates; Benzodiazepines; Female; Humans; Kinetics; Models, Biologica | 1983 |
Tonic status epilepticus presenting as confusional state.
Topics: Adolescent; Cognition Disorders; Confusion; Diazepam; Electroencephalography; Humans; Male; Methylph | 1983 |
Drugs for epilepsy.
Topics: Anticonvulsants; Carbamazepine; Drug Interactions; Epilepsy; Humans; Phenobarbital; Phenytoin; Statu | 1983 |
[Pharmacotherapy of epilepsy--current problems and controversies].
Topics: Adolescent; Adult; Carbamazepine; Child; Child, Preschool; Epilepsies, Partial; Epilepsy; Epilepsy, | 1983 |
Pharmacologic therapy of seizures in the elderly.
Topics: Aged; Anticonvulsants; Carbamazepine; Humans; Phenobarbital; Phenytoin; Primidone; Seizures; Status | 1984 |
[Treatment of partial motor status epilepticus in adults with intravenous diphenylhydantoin (DPH). Prospective study of 50 cases].
Topics: Adult; Epilepsies, Partial; Female; Humans; Injections, Intravenous; Kinetics; Male; Middle Aged; Ph | 1984 |
Neonatal status epilepticus II: Electroencephalographic aspects.
Topics: Electroencephalography; Follow-Up Studies; Humans; Infant, Newborn; Phenobarbital; Phenytoin; Status | 1984 |
The beneficial effect of a phenytoin loading dose on seizure recurrence in patients with acute repetitive seizures: a preliminary report.
Topics: Adolescent; Humans; Phenytoin; Recurrence; Retrospective Studies; Status Epilepticus | 1984 |
Status epilepticus.
Topics: Diazepam; Humans; Phenobarbital; Phenytoin; Status Epilepticus | 1983 |
Myopathy and hypersensitivity to phenytoin.
Topics: Adult; Drug Hypersensitivity; Humans; Male; Myositis; Phenytoin; Status Epilepticus | 1983 |
Pharmacokinetics of paraldehyde disposition in the neonate.
Topics: Female; Humans; Infant, Newborn; Infusions, Parenteral; Kinetics; Male; Metabolic Clearance Rate; Pa | 1984 |
Kinetics of intravenous phenytoin in children.
Topics: Adolescent; Child; Child, Preschool; Epilepsy; Humans; Infant; Injections, Intravenous; Kinetics; Ph | 1984 |
Status epilepticus.
Topics: Anesthesia, General; Child; Child, Preschool; Diazepam; Epilepsies, Myoclonic; Epilepsies, Partial; | 1980 |
[Termination of status epilepticus with sodium valproate].
Topics: Clonazepam; Diazepam; Humans; Infant; Phenytoin; Status Epilepticus; Valproic Acid | 1980 |
Anticonvulsant-induced status epilepticus in Lennox-Gastaut syndrome.
Topics: Adolescent; Adult; Benzodiazepinones; Carbamazepine; Child; Child, Preschool; Chlormethiazole; Clona | 1981 |
Pharmacologic advances in seizure control.
Topics: Anticonvulsants; Carbamazepine; Child; Clonazepam; Humans; Kinetics; Phenytoin; Seizures; Status Epi | 1981 |
[Use of intravenous phenytoin in treatment of partial status epilepticus (author's transl)].
Topics: Adult; Epilepsies, Partial; Female; Humans; Injections, Intravenous; Male; Middle Aged; Phenytoin; S | 1981 |
Therapy of status epilepticus.
Topics: Anticonvulsants; Diazepam; Epilepsies, Partial; Epilepsy, Tonic-Clonic; Humans; Lorazepam; Paraldehy | 1982 |
Treatment of status epilepticus in adults.
Topics: Acid-Base Equilibrium; Adult; Bicarbonates; Critical Care; Diazepam; Electrocardiography; Electroenc | 1983 |
Treatment of status epilepticus in children.
Topics: Anticonvulsants; Barbiturates; Child, Preschool; Diazepam; Emergencies; Humans; Infant; Infant, Newb | 1983 |
General principles of treatment: status epilepticus in neonates.
Topics: Diagnosis, Differential; Diazepam; Humans; Infant, Newborn; Infant, Newborn, Diseases; Phenobarbital | 1983 |
Efficacy of phenytoin in treatment of status epilepticus.
Topics: Brain; Diazepam; Humans; Phenobarbital; Phenytoin; Status Epilepticus | 1983 |
Treatment of acute seizures and status epilepticus with intravenous phenytoin.
Topics: Acute Disease; Adolescent; Adult; Aged; Female; Humans; Infusions, Parenteral; Male; Middle Aged; Ph | 1983 |
A new phenytoin infusion concentrate for status epilepticus.
Topics: Adolescent; Adult; Aged; Humans; Infusions, Parenteral; Middle Aged; Phenytoin; Status Epilepticus | 1983 |
Phenytoin in infancy and childhood.
Topics: Humans; Infant; Infant, Newborn; Infant, Newborn, Diseases; Injections, Intravenous; Phenytoin; Seiz | 1983 |
Combination therapy for status epilepticus: intravenous diazepam and phenytoin.
Topics: Diazepam; Drug Therapy, Combination; Electroencephalography; Humans; Infusions, Parenteral; Injectio | 1983 |
Identification and treatment of status epilepticus.
Topics: Diazepam; Humans; Phenobarbital; Phenytoin; Status Epilepticus | 1980 |
Current concepts in neurology: management of status epilepticus.
Topics: Anticonvulsants; Diazepam; Drug Administration Schedule; Humans; Lorazepam; Phenobarbital; Phenytoin | 1982 |
Current treatment of status epilepticus.
Topics: Adult; Anticonvulsants; Child; Diagnosis, Differential; Diazepam; Humans; Hysteria; Injections, Intr | 1981 |
Therapy for status epilepticus.
Topics: Diazepam; Drug Therapy, Combination; Humans; Phenobarbital; Phenytoin; Status Epilepticus | 1980 |
Epileptic aphasia. First onset of prolonged monosymptomatic status epilepticus in adults.
Topics: Aged; Aphasia; Electroencephalography; Female; Humans; Male; Middle Aged; Phenytoin; Status Epilepti | 1980 |
[Management of the status epilepticus].
Topics: Anticonvulsants; Humans; Injections, Intravenous; Lidocaine; Phenobarbital; Phenytoin; Status Epilep | 1980 |
Status epilepticus. The role of intravenous phenytoin.
Topics: Emergencies; Humans; Injections, Intravenous; Phenytoin; Status Epilepticus | 1980 |
[Progress in clinical neurology 1970-1980. Experiences at the clinic for acute neurological diseases in Günzburg].
Topics: Cerebrovascular Disorders; Consciousness Disorders; Encephalitis; Germany, West; Hospitals, Special; | 1980 |
The use of felbamate in patients with periodic lateralized epileptiform discharges (PLEDs).
Topics: Anticonvulsants; Dominance, Cerebral; Dose-Response Relationship, Drug; Drug Therapy, Combination; E | 1995 |
The intensive care treatment of convulsive status epilepticus in the UK. Results of a national survey and recommendations.
Topics: Anesthetics, General; Anticonvulsants; Clinical Protocols; Critical Care; Diazepam; Drug Resistance; | 1995 |
Defusing status epilepticus.
Topics: Blood Gas Analysis; Body Temperature; Diazepam; Humans; Infusions, Intravenous; Lung Diseases, Obstr | 1995 |
Propofol in the management of refractory status epilepticus: a case report.
Topics: Clonazepam; Coma; Drug Therapy, Combination; Electroencephalography; Glasgow Coma Scale; Humans; Inf | 1994 |
Phenytoin-induced movement disorder. Unilateral presentation in a child and response to diphenhydramine.
Topics: Child, Preschool; Diphenhydramine; Dyskinesia, Drug-Induced; Dystonia; Facial Muscles; Female; Hemip | 1994 |
A new, non-pharmacologic model of convulsive status epilepticus induced by electrical stimulation: behavioral/electroencephalographic observations and response to phenytoin and phenobarbital.
Topics: Animals; Behavior, Animal; Disease Models, Animal; Electric Stimulation; Electroencephalography; Epi | 1994 |
Acute encephalopathy and status epilepticus associated with human herpes virus 6 infection.
Topics: Comorbidity; Electroencephalography; Encephalitis; Exanthema Subitum; Fever; Herpesviridae Infection | 1994 |
Treatment of high-dose intrathecal morphine overdose. Case report.
Topics: Drug Overdose; Female; Humans; Infusion Pumps; Injections, Spinal; Middle Aged; Morphine; Naloxone; | 1994 |
Seizure exacerbation and status epilepticus related to carbamazepine-10,11-epoxide.
Topics: Adult; Age of Onset; Carbamazepine; Female; Humans; Male; Middle Aged; Phenytoin; Seizures; Status E | 1994 |
Failure to recognize status epilepticus in a paralysed patient.
Topics: Adolescent; Diazepam; Electroencephalography; Female; Humans; Neuromuscular Blocking Agents; Nitraze | 1993 |
Phenytoin toxicity associated with hypoalbuminemia in critically ill patients.
Topics: Adult; Aged; Aged, 80 and over; Critical Illness; Epilepsy, Tonic-Clonic; Female; Humans; Male; Midd | 1994 |
Fatality secondary to massive overdose of dimenhydrinate.
Topics: Adult; Arrhythmias, Cardiac; Cardiopulmonary Resuscitation; Charcoal; Colon; Dimenhydrinate; Diphenh | 1993 |
Diazepam by continuous intravenous infusion for status epilepticus in anticonvulsant hypersensitivity syndrome.
Topics: Anticonvulsants; Child, Preschool; Diazepam; Drug Hypersensitivity; Female; Hospitals, Pediatric; Ho | 1993 |
Generalized convulsive status epilepticus.
Topics: Adolescent; Adult; Aged; Anesthetics; Anticonvulsants; Benzodiazepines; Child; Epilepsy, Generalized | 1996 |
Liposome-entrapped phenytoin locally suppresses amygdaloid epileptogenic focus created by db-cAMP/EDTA in rats.
Topics: Amygdala; Analysis of Variance; Animals; Anticonvulsants; Bucladesine; Depression, Chemical; Drug Ca | 1995 |
Lamotrigine vs. phenytoin for treatment of status epilepticus: comparison in an experimental model.
Topics: Animals; Anticonvulsants; Brain; Chromatography, High Pressure Liquid; Cobalt; Convulsants; Electrod | 1996 |
Protective effects of GABAergic drugs and other anticonvulsants in lithium-pilocarpine-induced status epilepticus.
Topics: Animals; Anticonvulsants; Baclofen; Clonazepam; Diazepam; Dizocilpine Maleate; Ethanol; GABA Agents; | 1996 |
Status epilepticus in children.
Topics: Anticonvulsants; Benzodiazepines; Child; Humans; Phenytoin; Status Epilepticus | 1996 |
Fosphenytoin injection introduced as replacement for Dilantin injection.
Topics: Administration, Oral; Anticonvulsants; Humans; Injections, Intramuscular; Injections, Intravenous; P | 1996 |
Nonconvulsive status epilepticus after intravenous contrast medium administration.
Topics: Brain Neoplasms; Contrast Media; Diatrizoate Meglumine; Electroencephalography; Glioblastoma; Humans | 1996 |
Severe transitory encephalopathy with reversible lesions of the claustrum.
Topics: Aphasia; Basal Ganglia Diseases; Blindness; Child; Deafness; Epilepsies, Myoclonic; Epilepsy; Epilep | 1996 |
Treatment of focal status epilepticus with lignocaine.
Topics: Aged; Anticonvulsants; Diazepam; Epilepsies, Partial; Epilepsy, Generalized; Humans; Lidocaine; Male | 1997 |
[Therapy of the status epilepticus].
Topics: Anticonvulsants; Barbiturates; Benzodiazepines; Diagnosis, Differential; Epilepsy; Epilepsy, Tonic-C | 1994 |
Anticonvulsant hypersensitivity: an unfortunate case of triple exposure to phenytoin.
Topics: Aged; Anticonvulsants; Continuity of Patient Care; Drug Hypersensitivity; Emergency Service, Hospita | 1997 |
["Purple glove syndrome." Severe soft tissue reaction following phenytoin infusion].
Topics: Adult; Anticonvulsants; Edema; Epilepsy, Tonic-Clonic; Female; Forearm; Humans; Inflammation; Infusi | 1998 |
Fosphenytoin in the emergency department.
Topics: Anticonvulsants; Emergency Service, Hospital; Humans; Phenytoin; Prodrugs; Seizures; Status Epilepti | 1998 |
Status epilepticus.
Topics: Adolescent; Adult; Age Factors; Anticonvulsants; Child; Humans; Infusions, Intravenous; Lorazepam; P | 1998 |
Hyaluronidase treatment for intravenous phenytoin extravasation.
Topics: Anticonvulsants; Extravasation of Diagnostic and Therapeutic Materials; Humans; Hyaluronoglucosamini | 1998 |
Generalized tonic-clonic status epilepticus: causes, treatment, complications and predictors of case fatality.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Child; Demography; Diazepam; Epilepsy, Tonic-Clonic; Femal | 1998 |
Phenytoin, phenobarbital, and midazolam fail to stop status epilepticus-like activity induced by low magnesium in rat entorhinal slices, but can prevent its development.
Topics: Animals; Anticonvulsants; Carbamazepine; Culture Techniques; Dose-Response Relationship, Drug; Drug | 1998 |
Time-dependent decrease in the effectiveness of antiepileptic drugs during the course of self-sustaining status epilepticus.
Topics: Animals; Anticonvulsants; Diazepam; Drug Evaluation, Preclinical; Male; Phenytoin; Rats; Rats, Wista | 1998 |
Hanging-induced status epilepticus.
Topics: Adult; Anticonvulsants; Diazepam; Drug Therapy, Combination; Electroencephalography; Emergency Treat | 1999 |
Initial treatment of generalized convulsive status epilepticus.
Topics: Adolescent; Adult; Anticonvulsants; Diazepam; Double-Blind Method; Electroencephalography; Emergenci | 1999 |
Children presenting with convulsions (including status epilepticus) to a paediatric accident and emergency department: an audit of a treatment protocol.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Diazepam; Emergency Service, Hospital; Female; | 1999 |
Interaction between phenytoin and ciprofloxacin.
Topics: Anti-Infective Agents; Anticonvulsants; Ciprofloxacin; Drug Interactions; Female; Humans; Middle Age | 1999 |
Fosphenytoin and status epilepticus.
Topics: Anticonvulsants; Humans; Infusions, Intravenous; Injections, Intramuscular; Phenytoin; Status Epilep | 1999 |
Pharmacological management of convulsive status epilepticus in children.
Topics: Anticonvulsants; Barbiturates; Benzodiazepines; Child; Child, Preschool; Chlormethiazole; Hospitaliz | 1999 |
Persistent increased DNA-binding and expression of serum response factor occur with epilepsy-associated long-term plasticity changes.
Topics: Animals; Brain; Cell Nucleus; Cerebellum; Cerebral Cortex; Dizocilpine Maleate; DNA-Binding Proteins | 1999 |
A 13-year-old with an acute change in mental status.
Topics: Acute Disease; Adolescent; Adrenocorticotropic Hormone; Anticonvulsants; Consciousness Disorders; Di | 1999 |
Felbamate in experimental model of status epilepticus.
Topics: Animals; Anticonvulsants; Dentate Gyrus; Diazepam; Disease Models, Animal; Dose-Response Relationshi | 2000 |
Managing status epilepticus. New drug offers real advantages.
Topics: Anticonvulsants; Emergency Treatment; Humans; Phenytoin; Status Epilepticus | 2000 |
Refractory idiopathic absence status epilepticus: A probable paradoxical effect of phenytoin and carbamazepine.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Aged; Anticonvulsants; Carbamazepine; Child; Dose-Res | 2000 |
Exceptionally long absence status: multifactorial etiology, drug interactions and complications.
Topics: Aged; Anticonvulsants; Brain Ischemia; Dementia, Vascular; Drug Interactions; Epilepsy, Generalized; | 1999 |
Self-sustaining status epilepticus: a condition maintained by potentiation of glutamate receptors and by plastic changes in substance P and other peptide neuromodulators.
Topics: Age Factors; Animals; Anticonvulsants; Diazepam; Disease Models, Animal; Electroencephalography; Ele | 2000 |
Treatment of nonfebrile status epilepticus in Rochester, Minn, from 1965 through 1984.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Anticonvulsants; Child; Child, Preschool; D | 2001 |
Cardiac arrest after fast intravenous infusion of phenytoin mistaken for fosphenytoin.
Topics: Adult; Anticonvulsants; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Costs; | 2001 |
Refractory idiopathic status epilepticus.
Topics: Anticonvulsants; Chromosome Mapping; Drug Resistance; Humans; Pharmacogenetics; Phenotype; Phenytoin | 2001 |
Anticonvulsant effect of nimodipine alone and in combination with diazepam and phenytoin in a mouse model of status epilepticus.
Topics: Animals; Anticonvulsants; Calcium Channel Blockers; Diazepam; Disease Models, Animal; Drug Therapy, | 2000 |
Problems with phenytoin administration in neurology/neurosurgery ITU patients receiving enteral feeding.
Topics: Adult; Anticonvulsants; Biological Availability; Brain Injuries; Enteral Nutrition; Female; Hospital | 2001 |
Timely antemortem and postmortem concentrations in a fatal carbamazepine overdose.
Topics: Absorption; Adult; Amobarbital; Anticonvulsants; Carbamazepine; Drug Overdose; Fatal Outcome; Female | 2001 |
Subtherapeutic free phenytoin levels following fosphenytoin therapy in status epilepticus.
Topics: Anticonvulsants; Biotransformation; Child, Preschool; Humans; Male; Phenytoin; Status Epilepticus | 2002 |
Phenobarbital and MK-801, but not phenytoin, improve the long-term outcome of status epilepticus.
Topics: Animals; Anticonvulsants; Behavior, Animal; Chronic Disease; Dizocilpine Maleate; Excitatory Amino A | 2002 |
Fatal benign phenytoin hypersensitivity.
Topics: Drug Hypersensitivity; Eosinophilia; Nephritis, Interstitial; Phenytoin; Status Epilepticus | 1977 |
Epilepsy in childhood.
Topics: Anticonvulsants; Child; Epilepsy; Epilepsy, Absence; Epilepsy, Tonic-Clonic; Humans; Infant; Infant, | 1978 |
Resin hemoperfusion as treatment for theophylline-induced seizures.
Topics: Aminophylline; Epilepsy, Tonic-Clonic; Hemoperfusion; Humans; Infusions, Parenteral; Male; Middle Ag | 1979 |
The medical treatment of epilepsy: treatment of prolonged convulsions and status epilepticus.
Topics: Adult; Anticonvulsants; Barbiturates; Child; Diazepam; Epilepsies, Myoclonic; Epilepsy, Tonic-Clonic | 1979 |
Drugs for epilepsy.
Topics: Anticonvulsants; Carbamazepine; Clonazepam; Diazepam; Epilepsy; Ethosuximide; Humans; Phenobarbital; | 1979 |
Medical treatment of epilepsy: Part II.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Calcium; Child; Drug Interactions; Epilepsy; Ep | 1978 |
Fatal benign phenytoin lymphadenopathy.
Topics: Aged; Drug Hypersensitivity; Eosinophilia; Humans; Kidney; Lymphatic Diseases; Male; Phenytoin; Skin | 1979 |
Emergency control of convulsions.
Topics: Anesthesia, General; Barbiturates; Benzodiazepines; Chlormethiazole; Emergencies; Humans; Lidocaine; | 1979 |
Behavioral analysis of amygdaloid kindling in beagle dogs and the effects of clonazepam, diazepam, phenobarbital, diphenylhydantoin, and flunarizine on seizure manifestation.
Topics: Amygdala; Animals; Anticonvulsants; Behavior, Animal; Brain; Clonazepam; Diazepam; Dogs; Electric St | 1979 |
Epilepsy and pregnancy.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Blood Coagulation Disorders; Chromosome Aberrations; C | 1979 |
Status epilepticus: discussion from experience in adult cases.
Topics: Adolescent; Adult; Clonazepam; Diazepam; Female; Humans; Phenytoin; Status Epilepticus | 1979 |
Status epilepticus in pregnancy: effect of phenytoin malabsorption on seizure control.
Topics: Administration, Oral; Adult; Female; Humans; Intestinal Absorption; Phenobarbital; Phenytoin; Postpa | 1978 |
Intravenous phenytoin in acute treatment of seizures.
Topics: Adolescent; Adult; Aged; Female; Humans; Male; Middle Aged; Phenytoin; Seizures; Status Epilepticus | 1979 |
An effective dose schedule for phenytoin treatment of status epilepticus in infancy and childhood.
Topics: Administration, Oral; Child; Child, Preschool; Drug Administration Schedule; Humans; Infant; Infant, | 1977 |
[Phenytoin dosage for the management of status epilepticus in infancy and childhood].
Topics: Age Factors; Child; Child, Preschool; Humans; Infant; Phenytoin; Status Epilepticus | 1978 |
Drug therapy of status epilepticus.
Topics: Acetazolamide; Diazepam; Humans; Lidocaine; Paraldehyde; Phenobarbital; Phenytoin; Status Epilepticu | 1978 |
[Antiepileptic emergency therapy in the adult age].
Topics: Adolescent; Adult; Age Factors; Anticonvulsants; Diazepam; Emergencies; Epilepsy; Humans; Phenobarbi | 1978 |
Efficacy of intravenous phenytoin in the treatment of status epilepticus: kinetics of central nervous system penetration.
Topics: Adult; Aged; Female; Humans; Injections, Intravenous; Male; Middle Aged; Phenytoin; Status Epileptic | 1977 |
[Status epilepticus in Lennox-Gastaut syndrome; therapeutic aspects].
Topics: Anticonvulsants; Barbiturates; Benzodiazepines; Child; Child, Preschool; Electroencephalography; Epi | 1977 |
Status epilepticus.
Topics: Adult; Amobarbital; Diazepam; Humans; Male; Phenobarbital; Phenytoin; Status Epilepticus | 1976 |
[Effect of anticonvulsants upon experimental limbic seizure status and regional cerebral blood flow in the hippocampus].
Topics: Animals; Anticonvulsants; Cats; Diazepam; Electroencephalography; Hippocampus; Isoxazoles; Phenobarb | 1992 |
Management of epilepsy.
Topics: Adult; Diazepam; Drug Administration Schedule; Female; Humans; Injections, Intravenous; Monitoring, | 1990 |
[Convulsive status].
Topics: Diazepam; Humans; Lorazepam; Paraldehyde; Phenobarbital; Phenytoin; Status Epilepticus | 1990 |
Status epilepticus following the oral ingestion of cocaine in an infant.
Topics: Cocaine; Diagnosis, Differential; Diazepam; Electroencephalography; Emergencies; Humans; Infant; Mal | 1990 |
[Status epilepticus in MVEC chemotherapy of urothelial cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Electroencephalo | 1990 |
The use of free phenytoin levels in averting phenytoin toxicity.
Topics: Adult; Female; Humans; Phenobarbital; Phenytoin; Status Epilepticus | 1990 |
Status epilepticus in pregnancy. A case report.
Topics: Adult; Female; Humans; Phenytoin; Pregnancy; Pregnancy Complications; Status Epilepticus | 1990 |
Efficacy of ACC-9653 (a phenytoin prodrug) in experimental status epilepticus in the rat.
Topics: Animals; Male; Phenytoin; Prodrugs; Rats; Rats, Inbred Strains; Status Epilepticus | 1990 |
Hypotension during slow phenytoin infusion in severe sepsis.
Topics: Acute Disease; Aged; Bacterial Infections; Critical Care; Humans; Hypotension; Male; Middle Aged; Ph | 1990 |
Pharmacokinetics and clinical use of parenteral phenytoin, phenobarbital, and paraldehyde.
Topics: Humans; Paraldehyde; Phenobarbital; Phenytoin; Status Epilepticus | 1989 |
Emergency management of seizures: an overview.
Topics: Diazepam; Emergencies; Humans; Lidocaine; Lorazepam; Phenytoin; Prodrugs; Seizures; Status Epileptic | 1989 |
[Treatment of status epilepticus in the adult. Retrospective analysis of 192 cases treated in intensive care units].
Topics: Adult; Aged; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Chlormethiazole; Drug Therapy, C | 1985 |
[Clinical treatment of grand mal epileptic status in adults].
Topics: Adult; Barbiturates; Chlormethiazole; Clonazepam; Diazepam; Emergencies; Epilepsy, Tonic-Clonic; Hum | 1986 |
Drugs for epilepsy.
Topics: Adult; Anticonvulsants; Carbamazepine; Child; Drug Interactions; Epilepsy; Humans; Phenytoin; Status | 1986 |
Long-lasting movement disorder induced by intravenous phenytoin administration for status epilepticus. A case report.
Topics: Adult; Dyskinesia, Drug-Induced; Female; Humans; Injections, Intravenous; Meningoencephalitis; Pheny | 1988 |
Intravenous phenytoin loading in patients after neurosurgery and in status epilepticus. A population pharmacokinetic study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Female; Humans; Injections, Intravenous; Male; Middle Ag | 1988 |
Phenobarbital for status epilepticus.
Topics: Drug Therapy, Combination; Humans; Phenobarbital; Phenytoin; Status Epilepticus | 1988 |
Distribution of diphenylhydantoin in the brain during experimental status epilepticus of the cat.
Topics: Animals; Blood-Brain Barrier; Brain; Cats; Female; Injections, Intraperitoneal; Male; Penicillins; P | 1987 |
Transient chorea induced by phenytoin.
Topics: Athetosis; Child, Preschool; Chorea; Emergencies; Humans; Infant; Male; Phenytoin; Status Epilepticu | 1987 |
Ictal catatonia as a manifestation of nonconvulsive status epilepticus.
Topics: Aged; Catatonia; Electroencephalography; Humans; Male; Middle Aged; Phenytoin; Status Epilepticus | 1986 |
Intraosseous infusion of phenytoin.
Topics: Child, Preschool; Drug Administration Routes; Emergencies; Humans; Male; Phenytoin; Status Epileptic | 1986 |
Termination of absence status and suppression of inter-ictal bursts with phenytoin: case report.
Topics: Child; Electroencephalography; Ethosuximide; Female; Humans; Memory Disorders; Phenytoin; Status Epi | 1986 |
Refractory status epilepticus in pregnancy. A case report.
Topics: Anticonvulsants; Diazepam; Female; Humans; Phenytoin; Pregnancy; Pregnancy Complications; Status Epi | 1985 |
Status epilepticus.
Topics: Adult; Aged; Anticonvulsants; Diazepam; Female; Humans; Male; Middle Aged; Phenobarbital; Phenytoin; | 1985 |
Phenytoin-induced movement disorder associated with intravenous administration for status epilepticus.
Topics: Child; Diagnostic Errors; Dyskinesia, Drug-Induced; Female; Humans; Infant; Male; Monitoring, Physio | 1985 |
Status epilepticus in pregnancy. A case report.
Topics: Adolescent; Diazepam; Female; Humans; Infusions, Parenteral; Phenobarbital; Phenytoin; Pregnancy; Pr | 1985 |
Status epilepticus.
Topics: Anesthesia, General; Child; Diazepam; Humans; Paraldehyde; Phenobarbital; Phenytoin; Status Epilepti | 1985 |